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Abstract 
Solid oral dosage forms such as tablets and capsules are often crushed and mixed with foods or 
fluids to aid drug delivery for those who cannot or prefer not to swallow them whole. Some 
people have a physiological problem limiting swallowing (dysphagia), and their fluids are 
thickened to ensure safe swallowing; these thickened fluids are also used to deliver crushed 
medication in replacement of water. This thesis explores the issues surrounding the swallowing 
of whole tablets and capsules, their modification by crushing and the influence of co-
administration with thickened fluids on absorption pharmacokinetics. The literature review 
(Chapter 1) examines the physiology and pathophysiology of swallowing and considers the 
particular issues surrounding swallowing tablets and capsules. It also explores the possible 
consequences of crushing the medications and mixing the powder with vehicles such as jam, 
honey, yoghurt and thickened water. 
This thesis contains two sections. In Section A (Chapter 2), the potential influence of 
psychological issues, oral sensation, sensory effect and motor ability of an individual on 
swallowing pills was investigated. It is hypothesised that swallowing tablets and capsules will 
be an issue in people with a memory of gagging on food and medication, strong gag reflex, 
heightened taste sensation, or who tend to chew their food for extended periods.  
Volunteers (153) completed a written survey and one–on-one assessments. Psychological issues 
were addressed by questions on memory of choking incidents on food or medication, and 
regularity of medication use. Sensory effects were assessed by measuring the person’s gag 
reflex, taste receptor density, size of the mouth (mallampati classification), and on food 
neophobia. Motor effects were assessed as efficiency in chewing a jelly snake. Finally, the 
volunteers were observed swallowing a capsule and the quantity of water used, and head 
position was recorded. 
In the survey, 33% of the population reported that they have had trouble swallowing medication. 
These people were more likely to have choked on medication in the past, have a smaller mouth 
cavity, and a medium or high taste receptor density. There was no relationship between trouble 
swallowing medication and gag reflex, food neophobia, chewing efficiency, quantity of water 
used to swallow, and head position. 
In Section B (Chapters 3, 4, and 5), the effect of crushing medication and mixing with water 
thickened with a commercial thickening agent on absorption pharmacokinetics was studied. 
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Paracetamol tablets were used as the model drug, and saliva samples were used to measure the 
PK profile. Chapter 3 assessed the inter- and intra-individual variability as the coefficient of 
variation of paracetamol in saliva. Volunteers took whole tablets of paracetamol (2 x 500 mg) 
on two different days separated by a week. Saliva production was stimulated using citric acid 
and paracetamol levels in the saliva were measured using high-performance liquid 
chromatography. Non-compartmental pharmacokinetic analyses were performed, and no 
significant variation (Wilcoxon signed - rank test) between the days for the total area under the 
curve (AUC(0-8 h),Saliva) and concentration maximum (Cmax) was observed. Hence, the use of 
saliva as a matrix is reproducible and reliable. 
Chapter 4, tested, the hypothesis that the rate of drug absorption will be significantly slowed, 
and the maximum drug concentration reached will be reduced when a drug is crushed and mixed 
with thickened fluid in comparison to the whole tablet, crushed tablet delivered in water, and 
crushed tablet mixed with jam. This was based on in vitro tests, in which the use of 
commercially available thickened fluids (thickness level 900) as a vehicle for delivering crushed 
tablets causes a reduction in drug dissolution in comparison to mixing with jam, water, or 
dissolution of the whole tablet. 
The effect of the delivery vehicle on paracetamol absorption was investigated in Chapter 4. In 
this randomized study, 20 healthy volunteers received paracetamol (2 x 500 mg) on four 
occasions, either as crushed tablets with water, crushed tablets with jam, crushed tablets with 
thickened fluid (level 900), or whole tablets with water. Participants used 250 ml of water to 
rinse their mouths, swallowed the rinsing, and thoroughly cleaned their teeth. Non-
compartmental PK analysis was conducted using linear trapezoidal rule method. The 90% 
confidence limits of AUC(0-8 h),Saliva for all three formulations was within the recommended 
limits (80% - 125%) and therefore could be considered to be bioequivalent for this parameter. 
However, for Cmax, only crushed tablets in jam may be regarded as bioequivalent to whole tablet, 
while Cmax, for crushed tablets with water or thickened water were not within the recommended 
limits (80% - 125%).  
In vitro and in vivo correlation (IVIVC) is often used in the process of pharmaceutical 
development. This involves using in vitro data to predict the possible in vivo concentration 
profile. In Chapter 5, IVIVC was used to predict the possible concentration time profile of 
crushed paracetamol delivered with three different levels of thickening agent. The IVIVC model 
was developed using in vitro dissolution data, and in vivo absorption data from Chapter 4, for 
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whole tablets, crushed tablets in water and crushed tablets in jam. In vitro dissolution data was 
used to predict the in vivo concentration time profile of crushed paracetamol tablets thickened 
fluid at thickness level 150, 400 and 900. The simulation was then compared with the in vivo 
data obtained in Chapter 4 using thickness level 900. The IVIVC simulation overestimated the 
reduction in rate of absorption resulting from crushing and mixing with thickened fluid at level 
900. 
In conclusion (Chapter 6), subjects who were classified as supertasters, have smaller mouth 
cavity and who have choked on medication in the past are most likely to find it difficult to 
swallow tablets and capsules as a whole. Future work could further investigate these 
relationships and consider the methods that people use to swallow their medications. In vivo 
assessment of paracetamol release from thickened water found indications for an alteration in 
the timing of the peak concentration but not in total concentration absorbed. Future research 
should be conducted with dysphagic as well as healthy subjects because of the differences in 
their swallowing functions. Finally, IVIVC indicated that a standard dissolution test is not 
predictive of drug absorption from thickened fluid and more work is required to investigate 
using a more physiologically-based model system. 
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1.1 Introduction 
The solid oral dosage form is the cheapest, most common and preferred route of administration 
for medicines. However, 10-40% of individuals find it difficult to swallow tablets and capsules 
whole. Swallowing an item the size of a nut or seed without chewing goes against our innate 
and taught reflexes, and there can be a psychological barrier to overcome. In order to swallow 
their medications, people may open capsules and crush, chew or split tablets. A variety of fluid 
and food mixers are used as vehicles to help crushed or split medications to be swallowed.  
Section A of this thesis will investigate the issues with swallowing pills in healthy subjects.  
Earlier studies reporting that people have issues swallowing medications have generally 
involved participants from community pharmacy, general practice, adolescents or from aged 
care dwellings. There has been limited research done with the general population to identify the 
extent to which they modify solid dosage forms in order to swallow them, and drivers for this 
behaviour. The specific aim (Chapter 2) is to determine the extent of medication swallowing 
issues amongst a general population, and identify the relevant issues by investigating 
psychological, oral sensory and oral motor contributions to medication swallowing issues. 
Dysphagia is a physiological problem with swallowing that results in patients being unable to 
swallow fluids without substantial risk of aspiration, so oral fluids are usually mixed with a 
thickener to create a bolus that is easier to swallow and is less likely to enter the airways. 
Thickened fluids have been used therapeutically for many years to help dysphagic patients to 
safely consume fluids, and crushed medications are often swallowed using these thickened 
fluids or other food-based mixers such as jam, honey, applesauce or yoghurt. When medications 
are modified for administration, concerns are raised about the effect on drug pharmacokinetics 
and pharmacodynamics. In vitro dissolution studies have indicated the potential for gum-based 
thickeners to retard drug release. 
Section B of this thesis will investigate if there is any change in the absorption of a modified 
drug administered with thickened fluids. Paracetamol will be used as the model drug because it 
is safe for use in the majority of the population and measurement of levels in saliva is an 
established surrogate for capillary blood. The specific aims of section B are: 
 Evaluate inter- and intra- individual variability of paracetamol absorption 
pharmacokinetics using saliva (Chapter 3). 
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 Investigate whether paracetamol absorption is delayed in vivo when crushed tablets are 
administered with thickened fluids (Chapter 4). 
 Establish whether in vitro dissolution tests accurately predict in vivo PK profile for 
crushed paracetamol tablets administered with thickened fluids (Chapter 5). 
1.2 Literature Review 
1.2.1 Physiology of Swallowing 
Swallowing is a process involving the movement of food from the mouth to the pharynx through 
the oesophagus to the stomach. Swallowing requires coordination between various muscles and 
the nervous system. In general, swallowing in healthy individuals is divided into four phases 
(Figure 1-1). These are the oral phase, oral propulsive phase, pharyngeal phase and oesophageal 
phase, which are sequentially coordinated (Dodds, 1989). 
The oral phase and oral propulsive phase are voluntary, during which the food is chewed and 
mixed with saliva to form a bolus. Then it is moved to the back of the mouth in a position so 
that the tongue transfers the food into the pharynx. Once the food enters the pharynx the 
involuntary phase of swallowing starts, this includes the pharyngeal phase and the oesophageal 
phase. During the pharyngeal phase, the food is pushed into the oesophagus and at the same 
time, the epiglottis prevents food going into the airway. The oesophageal phase involves the 
peristaltic movement of food through the oesophagus into the stomach for digestion 
(Logemann, 2007, Dodds, 1989). 
In contrast, swallowing solid oral dosage forms bypass the oral phase because these should be 
swallowed whole and not chewed. Tablets or capsules are placed on the tongue and are moved 
directly into the oral propulsive phase (Figure 1-1). 
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Figure 1-1: Schematic of anatomic structures and physiologic function of the normal swallow 
(Smith Hammond and Goldstein, 2006). 
1.2.2 Medication swallowing issues 
Many medications are available as tablets and capsules that should be swallowed whole. 
However, for some people swallowing tablets or capsules can be difficult. There have been a 
small number of studies investigating the extent of issues with swallowing whole tablets and 
capsules that have identified medication swallowing issues (Table 1-1). The studies generally 
report that 15-40% of people have difficulties swallowing whole medications. 
Table 1-1: Literature containing values for prevalence of problems swallowing solid dosage forms, 
showing the age range, number (N) and population type of participants along with % reporting a 
difficulty swallowing medications. NA – information not available. 
Study Age (y) N Population % medication 
swallowing issue 
USA 
(Kottke et al., 1990) 
 65+ 64 Community-dwelling 40% of females, 30% of 
males  
Norway 
(Andersen et al., 1995) 
0-100 6,158 Patients from general practice 26%; 32% of females, 
16% of males 
USA 
(Harris Interactive, 2004) 
18+ 679 General population 40%; 51% of females, 
27% of males 
Denmark 
(Hansen et al., 2008) 
11-20  89 Public school 36% 
UK 
(Haw and Stubbs, 2010) 
25 – 87 110 Hospital in-patients 30.9% 
New Zealand 
(Tordoff et al., 2010) 
75-85  316 Community-dwelling 14% 
Germany 
(Schiele et al., 2013) 
18-80  1051 General practice 37.4% 
Switzerland 
(Marquis et al., 2013) 
19- 96  410 Community pharmacy 
customers 
9% ongoing, 13.4% past 
Australia 
(Mercovich et al., 2014) 
NA 160 Aged care facilities (two) 18% 
UK 
(Liu et al., 2016) 
65+ 156 Community pharmacy 
customers 
7.8% 
Australia  
(Lau et al., 2015) 
25-60  369 Community pharmacy 
customers 
16.5% 
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The variation in values is often due to differences in methodology. For example, it is common 
to see more women experience discomfort swallowing pills compared with men (Table 1-1) so 
differences in the sample population can affect the overall outcome. It might be expected that 
older age groups would experience problems swallowing medications to a greater degree than 
younger people because dysphagia is more prevalent in older people (see Section 1.2.3.1) and 
polypharmacy can contribute to swallowing problems (Hajjar et al., 2007). However, when it 
comes to swallowing solid dosage forms, two studies reported that fewer elderly patients  had 
difficulty swallowing pills compared with younger people (Andersen et al., 1995) (Harris 
Interactive Inc, 2004) and a study of older community pharmacy customers indicated a low 
value of only 7.8% had difficulties with medication swallowing (Liu et al., 2016). It is common 
for older people to use tablets and capsules more often compared with the younger population, 
so one explanation may be that they are more practiced in swallowing these dosage forms 
(Llorca, 2011). 
1.2.3 Potential causes of swallowing issues 
Swallowing solid oral dosage forms (tablets and capsules) is a challenge for some people. 
Swallowing issues could either be physiological or psychological.  
1.2.3.1 Dysphagia 
Dysphagia is the medical term used to define people having difficulty with swallowing food 
and liquids and is generally accepted to mean physiological problems rather than psychological. 
Dysphagia is classified into four based on the location of the swallowing impairment: 
oropharyngeal, esophageal, esophagogastric and paraesophageal dysphagia (Schindler and 
Kelly, 2002, Wolf, 1990) (Figure 1-2, Table 1-2).  
Oropharyngeal dysphagia is due to defects of muscles and nerves of the oral cavity and pharynx 
(Abdel Jalil et al., 2015). This form of dysphagia could affect the first two phases of swallowing, 
i.e., oral and oral propulsive phases of swallowing. Multiple factors could influence 
oropharyngeal dysphagia (Ertekin and Aydogdu, 2003), including: 
 Poor retention time in the mouth 
 Neurological disorders such as stroke and Parkinson’s disease  
 Drug-induced dysphagia (Botulinum toxins, anti-psychotics) 
 Obstruction due to cancer 
 Reduced secretion of saliva (drug induced or disease-related) 
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Oesophageal dysphagia occurs either in the oesophagus, lower oesophageal sphincter or in the 
gastro-oesophageal junction, and is caused either by mechanical or neurological problems. The 
mechanical causes of dysphagia include obstruction of the oesophagus which can be internal or 
external (oesophageal carcinoma, ulcers, enlarged lymph nodes) while neurological causes 
could affect the peristaltic contraction of the oesophagus and impair sphincter movement 
(Cantarella et al., 2006, Nelson and Castell, 1988).  
 
Figure 1-2: Anatomical localization of the four types of dysphagia: Oropharyngeal dysphagia 
(Location 1); oesophageal dysphagia (Location 2); oesophagogastric dysphagia (Location 3); and 
paraesophageal dysphagia (Location 4) (Wolf, 1990) 
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Table 1-2: Aetiology of dysphagia (Wolf, 1990) 
 Motor Physical Obstruction 
Oropharyngeal Upper oesophageal sphincter 
dysfunction 
Oropharyngeal carcinoma 
 Cerebrovascular disease  
 Parkinson’s disease Congenital web 
 Peripheral neuropathy Zenker’s diverticulum 
 Myasthenia gravis  
 Myopathy  
Oesophageal Diffuse oesophageal spasm Oesophageal carcinoma 
 Achalasia Reflux esophagitis 
 Vigorous achalasia Peptic stricture 
 Scleroderma Schatski ring 
 Diabetes Mellitus  
Oesophagogastric Achalasia Gastric Carcinoma 
  Stricture 
Paraesophageal  Thyromegaly 
  Cervical spinae disease 
  Left atrial enlargement 
  Postsurgical scarring 
  Lymphadenopathy (mediastinal or 
cervical) 
1.2.3.1.1 Epidemiology of dysphagia 
The prevalence of dysphagia seen in patients living in long-term care facilities across the US 
and Europe is high, ranging from 31% – 66%. In the US, surveys conducted on inpatients 
(n=513) at the Veterans Administration Medical Centre, a long-term neuropsychiatric centre, 
found 66% of the patients had dysphagia (Layne et al., 1989). Similarly in another study in the 
US, detailed interviews with physicians, nursing staff, residents and their families determined 
that of 82 nursing home residents that were not eating well (age 60 - 102 years), 55% had 
dysphagia (Kayser-Jones and Pengilly, 1999). Prevalence of dysphagia in residential and 
nursing homes was around 31% of 361 patients (age 31 - 95 years) in the UK (Smithard et al., 
1996). 
Studies conducted in the community found that 14% - 33% of the elderly population had 
swallowing problems. A Dutch survey interviewed elderly people (n=130) aged over 87 years 
who lived at home and found that 16% complained of swallowing problems (Bloem et al., 
1990). Another survey conducted on elderly persons aged 65 and over living at home in Japan 
(n=1313) found 14% reported symptoms of dysphagia (Kawashima et al., 2004). A study that 
interviewed 117 people (age range 65 - 94 years) in the US reported that 33% of the respondents 
had swallowing issues (Roy et al., 2007). 
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Hospital admission due to dysphagia is small, but dysphagia may be associated with other 
conditions such as stroke, Parkinson's disease and multiple sclerosis (Altman et al., 2010). A 
large-scale retrospective study, "the National Hospital Discharge Survey" (NHDS) from 2005 
to 2006, involved hospitals across the US in which 77,540204 medical records were evaluated. 
Very few patients were admitted to the hospital as a result of dysphagia (0.35%), the majority 
of which were elderly people older than 75 years, but dysphagia was associated with many 
conditions (Table 1-3) (Altman et al., 2010).  
Table 1-3: Major diseases and symptoms associated with dysphagia from the national hospital 
discharge survey, 2005 – 2006 (Altman et al., 2010) 
 
 
Table 1-4: Summary of values for prevalence of dysphagia given in the literature, showing the 
underlying condition responsible for the dysphagia along with the age, number (N) and details of 
the population involved. 
Condition Age N Population Dysphagia 
Stroke 
(Falsetti et al., 1990) 
77 Males and 74 Females; 
Mean age 79.4 years  
(range 58-91), 
151 Neurorehabilitation unit patients 
with diagnosis of previous 
ischemic or hemorrhagic stroke. 
41% 
Stroke  
(Smithard et al., 
2007) 
Dysphagic 74.3 years  
(SD = 13.0)  
Non-dysphagic 69.6 years 
(SD = 14.0) 
1288 Patients with first in a life-time 
stroke (1995 – 1998) 
44% 
Stroke  
(Daniels et al., 1997) 
Mean age 66 years  
(SD 11; range 41–88 years) 
59 Patients admitted to the Veterans 
Affairs Medical Center with a 
new neurological deficit. 
75% 
Stroke 
(Lim et al., 2001) 
 
Mean age 67.5  
(SD. 11.73) years 
50 Acute stroke patients admitted to 
the stroke unit 
56% 
PD 
(Walker et al., 2011) 
 
Males 38 and 37 Females; 
Mean age was 75 years 
(range = 47–92 years, SD = 
9.68) 
75 People identified as having PD 
as part of an associated 
prevalence study 
32% 
PD 
(Barone et al., 2009) 
647 Males, the mean age of 
66.8 (SD, 9.6) years, and 
425 Females, mean age of 
68.2 (SD, 9.1) years. 
1072 Based on PRIAMO study 16% 
PD 
(Cheon et al., 2008) 
28 Males and 46 Females; 
Mean age 64.9 years  
(SD 8.6) 
74 Consecutive patients who had 
been diagnosed with PD 
31% 
Head & neck cancer 
(García-Peris et al., 
2007) 
61 Males and 26 Females; 
Mean age of 58.27  
(SD13.5) years  
(range: 16–82 years) 
87 head and neck cancer patients 
treated with surgery and 
radiotherapy or 
chemoradiotherapy. 
51% 
MS 
(Calcagno et al., 
2002) 
49 Males and 94 Females; 
Mean age 49.95 
( SD 10.87) years 
143 Primary and secondary 
progressive MS patients 
undergoing neurological 
rehabilitation. 
34% 
MS 
(Poorjavad et al., 
2010) 
20 Males and 81 Females; 
Mean age 34 (SD 9.3) 
years  
101 MS patients, who were visited at 
the MS between May 2008 and 
August 2008 
32% 
MS 
(Bergamaschi et al., 
2008) 
58 Males and 168 Females; 
Mean age was 40.5 years 
(range 21–71 years), 
226 MS patients seen for control 
visits outside relapse in one of 
four different Italian MS centers. 
35% 
MND 
(Leighton et al., 
1994) 
 
54 Males and 38 Females  
(age N/A) 
92 Consecutive patients diagnosed 
as having MND and referred for 
assessment 1986 - 1989 in ENT. 
89% 
Head injury 
(Wolf and Meiners, 
2003) 
35 Males and 16 Females; 
Mean age 43  
(range, 16 – 89) years 
51 Patients consecutively admitted 
to ICU in Germany between Oct 
1998 and July 2001. 
82% 
Abbreviations: PD = Parkinson’s diseases; MS = Multiple sclerosis; MND = Motor neuron diseases. 
 
A survey on swallowing difficulties conducted in hospitalised patients in two hospitals in the 
US found 12% - 13% of the patients in each hospital had swallowing issues. These data were 
collected from medical records in consultation with the medical nurse (Groher and Bukatman, 
1986). An Australian study found around 25% - 30% of acute hospitalised individuals (n=442) 
have dysphagia when screened by the nurse on admission across two general medical wards 
(Cichero et al., 2009). For otherwise healthy community dwelling older people in the UK 11.4% 
had symptoms of dysphagia (Holland et al., 2011)  
Stroke is the leading cause of dysphagia, with 44% - 75% of the stroke population suffering this 
condition (Falsetti et al., 1990, Smithard et al., 2007, Daniels et al., 1997, Lim et al., 2001). 
Similarly, for Parkinson’s disease 16% - 32% of patients have dysphagia (Walker et al., 2011, 
Barone et al., 2009, Cheon et al., 2008), in the case of head injury 82% have dysphagia (Wolf 
and Meiners, 2003) and in motor neuron disease suffers around 89% reported dysphagia 
(Leighton et al., 1994) (Table 1-4).  
Dysphagia is becoming an important healthcare issue around the world, as it has a significant 
impact on patients. The quality of life and work are adversely affected by dysphagia, and 
consequently, health care costs are increasing. It was observed from the NHDS study that 
dysphagia was associated with a 40% increase in the length of 4.04 days hospital stay and those 
patients undergoing rehabilitation had a greater risk of dying (13 fold) when they had dysphagia 
(Altman et al., 2010).  
1.2.3.1.2 Diagnosis of dysphagia  
Recent developments in dysphagic assessment have shown that many people have swallowing 
issues, and there is a need for a proper evaluation and understanding of this condition. 
Dysphagia increases the risk of dehydration, malnutrition and aspiration. These complications 
can be avoided with timely management and diagnosis of dysphagia. Diagnosis requires the 
consideration of patient history, physical examination (Table 1-5) and instrumental assessment 
using videofluoroscopic swallowing study (VFSS) or fiberoptic endoscopic examination of 
swallowing (FEES) (Cichero, 2006).  
 Videofluoroscopic swallowing study (VFSS): This is a radiographic study using ionized 
radiation to study the anatomy and physiology of oral, pharyngeal, and oesophageal 
stages of deglutition and to define the treatment strategies to improve swallowing safety 
or efficiency in patients with dysphagia. In this method, barium is mixed with food and 
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liquids that the patients consume while the process of is recorded (Splaingard et al., 
1988, Palmer et al., 1993).  
 Fiberoptic endoscopic examination of swallowing (FEES): This is a nasoendoscopic 
procedure that assesses the pharyngeal stage of swallowing to detect premature bolus 
loss, laryngeal penetration, tracheal aspiration, and pharyngeal residue. FEES are a non-
radioactive alternative to VFSS, and this is primarily done on patients where VFSS is 
not feasible. FEES involves the passage of a thin, flexible telescope through the nose to 
the pharynx to observe the aspiration and to determine the safety of oral feeding 
(Langmore et al., 1988). 
Table 1-5: The physical examination of dysphagia (Cichero, 2006) 
Phase  Clinical Examination 
Immediate observations  Client alertness levels and levels of client cooperation  
 Client’s fatigability  
 Can client achieve a safe swallow position independently? If 
not, how many people are required to achieve this position?  
 Note the presence of a feeding tube and/or tracheostomy  
 does the person appear to be an appropriate weight  
 Note any shortness of breath and/or respiratory rate (should be 
between 16-10 breathes per minutes at rest)  
Communication and Cognition  Is client oriented to person, place and time  
 Do they understand and hear you  
 Subjectively note voice quality (i.e., is it wet or gurgly?)  
Oropharyngeal Assessment 
 
 Inspection of oro-cavity and oropharynx  
 Note oral hygiene  
 Saliva management  
 Cranial nerve assessment (of CN VII, IX, X, XI, and XII)  
 Ability to protect the airway  
1.2.3.1.3 Feeding in dysphagia 
The goal of treating dysphagic patients is to maintain oral feeding, as long as the oral route can 
be safe. Normal feeding requires excellent muscle control and reflex in swallowing and 
controlling breathing at the same time. Dysphagic patients have difficulties in controlling the 
muscles and coordinating the reflex (Gordon et al., 1987). These patients often experience 
choking with solid food and aspiration of liquids. If proper care is not provided this could lead 
to aspiration pneumonia and other serious problems (Langmore et al., 2002). Treatment of 
dysphagic patients requires a multidisciplinary approach involving radiologists, 
gastroenterologists, dieticians, nurse, social workers, and a speech pathologist to lead the group 
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(Frank et al., 2007, Logemann, 2007). The general treatment schedule involves changes in the 
diet of patients to modify food to enhance the process of swallowing (Layne, 1990). 
If patients are unable ingest at least 50% of their caloric and protein requirement, an alternate 
route should be used i.e., use of enteral nasogastric tube (NGT), transpyloric tube (TPT), 
percutaneous endoscopic gastrostomy (Pegues) or by parenteral access (Pegues, 2006, Layne, 
1990, Luis et al., 2009). 
Globally there are different standards and terminology used to define dysphagic diets. In Table 
1-6, multiple classifications of texture-modified diets and fluid thickness are summarised. Each 
country developed standardised descriptions, however, due to inconsistency in labelling, 
defining texture, and fluid thickness, these are slightly different between the countries (Table 
1-7).  
Table 1-6 : Thickened fluid and food classification (Dieticians Association of Australia and The 
Speech Pathology Association of Australia Limited, 2007) 
Fluid name and level Description of fluid thickness 
Level 1 – Nectar Like Nectar 
Level 2 – Honey Like Honey 
Level 3 – Pudding Like Pudding 
Thin Water and all juices thinner than pineapple juice 
Thickened Liquids thickened with starch to pureed consistency 
Watery Water, tea, coffee 
Milky Milk and most fruit juices 
Single cream  Ensure plus and Enterat 
Double cream Tomato juice, thinned pureed fruit, creamed soups 
Custard  Cheese or custard sauce, smooth yoghurt 
Semi –solid  Thick set yoghurt, blancemange, mashed potato 
Food grading Description of food texture 
Liquidised/thin puree Homogenous consistency that does not hold its shape after serving 
Thick puree/soft and smooth Thickened, homogenous consistency that holds its shape after serving, and does not 
separate into liquid and solid component during swallowing that is cohesive 
Finely minced  Soft diet of cohesive, consistent textures requiring some chewing (particle size 
most often described as 0.5 x 0.5 cm) 
Modified normal  Normal foods of varied textures that require chewing avoiding particulate foods 
that pose a choking hazard (particle size most often described as 1.5 x 1.5 cm) 
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1.2.3.1.4 Medication swallowing in dysphagia 
Medication administration in people with dysphagia is understandably difficult given their 
problems with safe swallowing. People with dysphagia are more likely to have difficulty 
swallowing oral solid dosage forms compared with non-dysphagics (Liu et al., 2016). 
Medication administration is dealt with on an individual patient basis, and choice of vehicle to 
aid medication transit to the stomach will be based on their swallowing ability. For example, if 
a patient is unable to safely swallow water and needs it to be thickened, then the same thickened 
fluids or foods are likely to be used as a vehicle for medication delivery (Cichero, 2013). 
Inappropriate medication administration is likely to result in choking, or even aspiration of the 
medication into the airways (Lamaze et al., 1994, Shepherd et al., 1994).  
1.2.3.2 Psychological issues and swallowing 
The role of psychology in swallowing solid oral dosage forms is not well understood, and 
attention to this is extremely limited. Even though swallowing medication is an easy task for 
some, for others it is challenging. People who have issues swallowing medication “feared 
choking to death” or gagging, leading to anxiety when taking medication (Martino et al., 2010). 
It is common to see that patients do not report their swallowing issues as they feel it normal, or 
they feel embarrassed because they require assistance in swallowing medication. Also, some 
people who have issues swallowing do not believe that it can be resolved through professional 
help (Llorca, 2011). 
In an online survey conducted by a consulting company across the US, it was reported that 80% 
of those with issues swallowing tablets had experienced the sensation of having had a pill stuck 
in their throat. In addition, 48% disliked after taste and 32% reported gagging on their 
medication (Harris Interactive Inc, 2004). A study in England that interviewed 35 patients 
visiting their general practitioners found that most people had an aversion to taking medication. 
In this study, it was also observed that patients made their decision to discontinue their 
medication without consulting their general practitioners (Britten et al., 2004).  
Also, patient preference like taste, texture, number of medications and convenience could also 
influence patients taking their medication. In a study conducted in Netherlands at hospitals in 
Copenhagen and Herlev on 202 and 129 patients respectively, it was found that most people 
preferred taking white, small, and circular shaped tablets. In addition, most of them preferred 
capsules instead of tablets (Overgaard et al., 2001). 
  
  
14 
 
Table 1-7: Comparison between Australian, National Dysphagic Diet (US) and the UK food 
texture classification systems for food and fluids (Jukes et al., 2012) 
Australia and  
New Zealand 
Ireland UK USA 
Texture-modified foods 
Regular   Regular 
Texture A – Soft (1.5cm) Texture A - Soft Texture E – Fork 
Mashable Dysphagia diet 
(1.5cm) 
Dysphagia Advanced 
(‘bite sized’),< 2.5cm  
Texture B – Minced and 
Moist (0.5cm) 
Texture B – Minced and 
Moist 
Texture D – Pre-Mashed 
Dysphagia Diet (0.2cm) 
Dysphagia Mechanically 
altered (0.6cm) 
Texture C – Smooth pureed Texture C – Smooth 
Pureed 
Texture C – Thick Pureé 
Dysphagia Diet 
Dysphagia Puree 
 Texture D - Liquidised Texture B – Thin Pureé 
Dysphagia Diet 
 
Liquids 
Regular  Thin fluid Thin (1-50 cP) 
 Grade 1 – Very mildly 
thick  
Naturally thick fluid  
Level 150 – Mildly thick Grade 2 – Mildly thick  Thickened fluid – Stage 1 Nectar-like thick fluids 
(51-350 cP) 
Level 400 – Moderately 
thick 
Grade 3 – Moderately 
thick  
Thickened fluids – Stage 
2 
Honey-like thick fluids 
(351-1750 cP) 
Level 900 – Extremely 
thick 
Grade 4 – Extremely 
thick 
Thickened fluid – Stage 3  Spoon-thick fluids (> 
1750 cP) 
 
1.2.3.3 Medication-induced swallowing issues 
Drugs can induce swallowing difficulties or dysphagia due to their pharmacological effects. 
The drug effects can either be on the smooth muscles, salivary secretion or on other sensory 
organs that are involved in the process of swallowing (Stoschus and Allescher, 1993). Radiation 
can also cause an inability to tolerate oral medications for similar reasons. Treatment with 
certain immunosuppressant, chemotherapeutic drugs or antibiotics can affect the lining of 
mucosal membranes, which can affect swallowing (Torres et al., 2009). Oesophagitis is 
common in patients treated with these medications and can be caused by drug itself or by reflux 
of medication from the stomach. Drugs that can induce oesophageal injury, dysphagia or 
xerostomia are shown in Table 1-8 (O'Neill and Remington, 2003).  
For some patients with limited movement, it may be necessary to take medication while lying 
down which is commonly seen in nursing home patients or in the hospitals. It is hard to 
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administer medications in this position as it can be uncomfortable and may lead to oesophagitis 
(Jaspersen, 2000). 
Table 1-8: Drug that can induce oesophageal injury, dysphagia and xerostomia (Palmer et al., 
2000, O'Neill and Remington, 2003) 
Effects Drugs 
Oesophageal mucosal damage Antibiotics 
Bisphosphonates 
NSAIDs 
Potassium chloride 
Quinidine 
Aspirin 
Ferrous sulphate or succinate 
Phenylbutazone, prednisone 
Theophylline 
 
Swallowing dysfunction associated with drug-
induced parkinsonism or tardive dyskinesia 
Anti-psychotics 
Clozapine 
 
Dysphagia and disordered swallowing Botulinum toxins 
 
Xerostomia Anticholinergic drugs (atropine, n-butylscopolamine) 
Antiemetic drugs (ondansetron) 
Antihypertensive drugs (guanfacine, cloidine, terazosin, 
reserpine) 
ACE inhibitors (captopril) 
Antiarrhythmic drugs (diisopyramide, mexiletine, ipratropium 
bromide) 
Antihistaminic drugs 
Diuretics 
Opiates 
Antipsychotic drugs 
 
1.2.4 Coping with medication swallowing issues 
Patients with swallowing issues try different methods to swallow foods, liquids and medication. 
These include drinking lots of water with medications, tilting the head back, placing the pill on 
the back of the tongue or altering the medication (Llorca, 2011). Alterations involve crushing 
or splitting tablets (using spoons or glass cups) and mixing with food and liquids (honey, jam, 
fruit juice, and thickened fluid) (Nissen et al., 2009, McLachlan and Ramzan, 2010, Haw and 
Stubbs, 2010). It is not only the patients modifying their medications, but is also common to 
see drugs modified by caregivers, nursing homes and on hospital wards by health professionals 
such as nurses (Nissen et al., 2009, Rosenberg et al., 2002, Verrue et al., 2011, McLachlan and 
Ramzan, 2010, Haw and Stubbs, 2010). 
In a paper-based survey conducted in Germany on 59 general practitioners, it was reported that 
24% of tablets and capsules of medication prescribed or purchased over-the-counter were split 
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or opened (Quinzler et al., 2006). In another study conducted in the UK, a questionnaire was 
given to the nurses in a nursing home. Of 540 respondents to the survey, 61% of nursing staff 
crushed or opened medications before administration. 57% of the time the drug was hidden in 
food, and 27% of the time the drug was omitted by the nurse due to administration difficulties 
(Wright, 2002). In a survey conducted across England and Northern Ireland, a questionnaire 
was distributed to the customers that pharmacies suspected of experiencing swallowing 
difficulties. In this study, 68% (n=333) of those who answered the questionnaire modified 
capsules or crushed a tablet to swallow them (Strachan and Greener, 2005). Similarly in an 
Australian study 10.6% (n=369) of all respondents modified their dosage forms (Lau et al., 
2015). 
A coping strategy can involve training people in techniques to enable pill swallowing. Training 
was very effective in children with HIV/AIDS in the US (n=23, mean age 7.5 years). In this 
study, 22 children were successfully trained to swallow pills (Garvie et al., 2007). Children with 
attention deficient syndrome (aged 4 - 9 years, n=8) in the US were trained to swallow pills, 
and this was successful for 6 of them (Beck et al., 2005). Adolescents in Denmark (n=89, age 
11 – 20 years), who had issues swallowing tablets, developed various strategies to overcome 
the problem (Hansen et al., 2008). Pill-swallowing training is not readily available to all patients 
as it is time-consuming and can be expensive.  
1.2.5 Complications of dosage form modification 
The process of drug movement from oral intake to its site of action is described in Figure 1-4. 
Movement is complex as it is affected by multiple factors (dissolution, disintegration, diffusion, 
solubility, etc.). Dose modification is common and can have minor and major complications 
that can influence the pharmacokinetics and pharmacodynamics of the drug and various other 
factors that are described below.  
1.2.5.1 Stability 
Splitting of tablets not only causes physical loss of drug but may also affect the stability of the 
drug. It is a common practice to store split tablets in bottles that contain the same medication, 
different medication or some other substance, or in a dosage administration aid. This type of 
storage exposes the tablets to air and light that could compromise the stability of the drug. This 
issue was observed for levothyroxine sodium which is a narrow therapeutic index drug (Shah 
et al., 2010). Many oral dosage forms should not be crushed or administered through feeding 
tubes because they are designed to escape the acidic environment of the stomach or to protect 
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the stomach lining (Beckwith et al., 2004). Exposure of acid-liable or irritant drugs to the 
stomach environment can result in reduced drug efficacy (Hosny, 2016). 
1.2.5.2 Palatability 
Unpalatability is another complication of dose modification. Palatability of a drug plays a 
significant role in patient compliance. When prednisolone tablets are crushed, they have a bitter 
taste and formulation of an oral prednisolone is a better option (Lucas-Bouwman et al., 2001). 
The issue of unpalatability is often dealt with by mixing the drug (crushed) with the a vehicle, 
such as jam, beverages or with other forms of food (Nissen et al., 2009, Paradiso et al., 2002).  
1.2.5.3 Contamination and chemical interaction 
Dosage form modification can result in chemical interaction and contamination. The chemical 
interaction could occur when a drug is mixed with food or when the crushing and mixing 
involves a single set of equipment. These factors could contribute to drug-drug or drug-nutrient 
interaction, causing a loss of drug activity or interference with drug absorption. Similarly, some 
drugs when administered with enteral nutrition lose their potency. Drugs including phenytoin 
(Cacek et al., 1986), carbamazepine suspension (Clarkschmidt et al., 1990), levothyroxine 
(Manessis et al., 2008) and amiodarone tablets (Kotake et al., 2006) are known to bind with the 
feeding tube. 
The bioavailability of tetracycline is decreased when it is crushed together with iron 
supplements as it forms a complex (iron-tetracycline) (Decloedt and Maartens, 2009). 
Observational studies have noted that the equipment used to modify dosage forms was shared 
between the patients and was not cleaned between uses (Stubbs et al., 2008). For example, in 
59% of cases when medications were crushed in South Australian nursing home, the vessel was 
shared without proper cleaning (Paradiso et al., 2002). Cross contamination is a concern when 
the equipment is not cleaned after each use and could cause potential adverse events. In a case 
report, it was observed that a patient suffered from an allergic drug reaction because of failure 
to clean the container used for crushing penicillin (Cohen, 1982). 
1.2.5.4 Health and safety issue 
Drug modification may be a hazard, especially when it is known to cause skin irritation and 
other health hazards to the administrator (Gilbar and Pract, 1999, Beckwith et al., 2004). For 
example, teratogenic, carcinogenic, cytotoxic, and hormonal medications are problematic. 
Crushing these types of drugs could cause adverse effects to the administrator (Haywood and 
Glass, 2007).  
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1.2.5.5 Legal issues in drug modification 
It is a common practice to crush tablets or to open capsules for the administration of drugs to 
patients. In a study conducted in a UK nursing home, around 61% of the administered 
medications were modified by the administrating nurse or aged care workers with or without 
proper consultation (Wright, 2002). Similarly, in a South Australian study 34% of the time one 
or more medications were administered in an altered form (Paradiso et al., 2002). 
The manufacturer of a commercial dosage form is not liable for any harm caused by altering 
the original product (James, 2004, Wright, 2002). The practice of crushing and the opening of 
capsules, and mixing them with food or drinks before administration is outside the scope of the 
product licence (Morris, 2005). This places the liability on the administration staff or the 
prescriber for the unlicensed administration of a drug.  
1.2.5.6 Dissolution 
Drug dissolution is dependent on the physiochemical properties of both the active ingredient 
and the dosage. For some drugs the absorption is quick, and the rate at which the drug enters 
the systemic circulation is limited by the dissolution time (Lee et al., 2008a). Mixing drugs with 
food/mixer can have a considerable effect on drug absorption (Fleisher et al., 1999). When 
tablets were produced using pentoxifylline mixed with xanthan gum at different concentrations 
(3.5% and 29.3%), time to complete dissolution of the tablet was increased from 2.36 hrs to 
6.44 hrs resulting in slower release of the drug from the tablet (El-Gazayerly, 2003). 
Commercially available thickeners consisting of xanthan gum and maltodextrin are used to alter 
the viscosity of the liquid and food. These thickeners are used to thicken, suspend, emulsify and 
stabilise water-based system and used as an excipient for sustained release formulations 
(Dhopeshwarkar and Zatz, 1993). This can affect the dissolution rate and slow drug diffusion 
across the intestinal lumen to the absorbing membrane (Talukdar et al., 1996, Papadimitriou et 
al., 1992, Fleisher et al., 1999).  
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Figure 1-3:: (A, C, E, G) Dissolution of whole tablets or tablets that were crushed and mixed with 
water, and (B, D, F, H) tablets that were crushed and mixed with orange juice, honey, jam, 
thickened fluid or yoghurt. Tablets were immediate-release formulations of amlodipine (A, B), 
atenolol (C, D), carbamazepine (E, F) and warfarin (G, H). Dissolution is presented as the % of 
the total drug added (Manrique-Torres et al., 2014). 
The effect of crushing immediate release tablets (amlodipine, atenolol, carbamazepine and 
warfarin) and incorporating into different medias, i.e., liquid media (water, orange juice) and 
viscous media (honey, thickened fluid, yoghurt, strawberry jam) was compared with full intact 
tablets. In general, crushed tablets mixed with liquid media showed faster dissolution when 
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compared with a whole tablet. In contrast, when these crushed tablets were mixed with viscous 
media, dissolution was slowed (Manrique-Torres et al., 2014) (Figure 1-3).  
1.2.5.7 Drug absorption (Pharmacokinetics) 
Drug absorption is an extremely complex process based on both physiochemical natures of the 
drug and the physiological condition of the body (Figure 1-4). Crushing tablets and opening 
capsules can alter the drug bioavailability (rate and the extent of drug absorption) and the 
pharmacodynamic effects (concentration-effect relationship) (Martinez and Amidon, 2002, 
Fleisher et al., 1999). This can potentially affect the efficacy and the side effect profile of the 
drug. Administration of modified oral drug in the presence of a highly viscous solution or with 
thickened water could alter the drug disintegration and dissolution, and consequently has the 
potential to alter the drug absorption process. However, in some cases, modifications may not 
cause a significant problem, such as drugs possessing a wide therapeutic window and 
formulated in an immediate release preparation. 
 
Figure 1-4: Schematic diagram of the relationship between oral dosage of a drug product and its 
ultimate effect (Martinez and Amidon, 2002) 
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1.2.5.7.1 Dosage form modification  
Several studies have identified issues surrounding the modification of modified-release dosage 
forms which could lead to dose dumping and faster drug absorption (Cleary et al., 1999). While 
crushing extended-release dosage forms is well recognised to result in potentially harmful dose 
dumping and faster absorption (Martinez and Amidon, 2002, Fleisher et al., 1999, Cleary et al., 
1999, El-Gazayerly, 2003, Charatan, 2001, Schier et al., 2003) crushing immediate-release 
tablets with wide therapeutic indices is viewed as being low impact and little cause for concern 
(Burridge et al., 2011). In support of this, voriconazole tablets did not show a significant change 
in their bioavailability when crushed and administered with water (Dodds Ashley et al., 2007). 
Also, faster absorption as a result of crushing tablets can be of therapeutic advantage. Serum 
thyrotropin levels were not elevated in three hypothyroidism patients when administered with 
levothyroxine tablets. The levels were normalised after taking crushed levothyroxine tablets 
(Yamamoto, 2003). However, for medications with a low therapeutic index such as digoxin, or 
warfarin, even a minor fluctuation in bioavailability can result in sub-therapeutic or toxic drug 
levels (Penrod et al., 2001).  
Physical loss was also suggested to have occurred in other studies (Paradiso et al., 2002, Stubbs 
et al., 2008), which could lead to sub-therapeutic drug levels. Splitting tablets into smaller 
pieces is another way to facilitate swallowing. Splitting tablets has been shown to result in dose 
variations (Rosenberg et al., 2002). In a survey conducted in Germany through a general 
practice, 49% of the participants split their tablets, with an average age of 67 years and 6.3 
drugs per person (Quinzler et al., 2006). In a study conducted in a community pharmacy in The 
Netherlands, 13% of the tablets were subdivided or crushed for ease of swallowing medication 
(Rodenhuis et al., 2004), and this was similar to an Australian study where 11% split or crushed 
their medications to in order to swallow them (Lau et al., 2015). 
1.2.5.7.2 Administration with thickeners 
Modified drugs are often mixed with food, such as applesauce, jam, honey, custard and yoghurt 
(Nissen et al., 2009). Mixing with fruit juice, such as grapefruit, orange, or apple juice, is known 
to affect absorption and can result in a decrease or increase in drug bioavailability (Bailey, 2010, 
Boullata, 2004). Also, crushing and mixing with foods such as yoghurt and pudding has been 
reported to reduce the absorption of phenytoin and didanosine (Jann et al., 1986, Damle et al., 
2002) and chocolate pudding increased absorption of gabapentin (Gidal et al., 1998) in 
comparison to the whole tablet. There is also the issue of drug stability within the matrix used 
for crushed tablet delivery, with some preliminary data indicating that certain drugs may be 
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unstable over short time periods (e.g. 4 hr) in products such as jelly and peanut butter (Peloquin 
et al., 2007). 
For dysphagic patients, crushed tablets may be mixed with thickened fluids, which are given to 
patients in place of water for hydration (Cichero, 2013). According to the severity of the 
swallowing impairment, patients are prescribed with food and drinks modified to have certain 
physical attributes such as viscosity, modified texture and moistness for safe swallowing 
function. Normal ingestion relies on the manipulation and control in the oral cavity (Crary and 
Groher, 2006, Keller et al., 2012). Where there is poor oral control of propulsion of thin fluids 
and foods, these may be inadvertently transported to the airway resulting in aspiration, choking 
and suffocation. Thick fluids are the primary choice for fluid administration as they slow bolus 
transit, providing improved control of oral and pharyngeal movements (Dantas et al., 1990), 
thereby preventing further problems such as aspiration (Garcia and Chambers, 2010). Some 
thickening agents are specially formulated while others are supermarket items that may be used 
to thicken fluids and mixers (He et al., 2008). These agents are aqueous fluids containing a 
single or a combination of natural biopolymers including xanthan gum, guar gum, carob bean 
gum, tara gum, maltodextrin and modified starch (Cichero and Lam, 2014) , which hydrate and 
swell to increase the viscosity of the water.  
Viscosity of the stomach or dissolution media is known to affect drug release and dissolution. 
Dissolution and disintegration for drugs with limited permeability such as atenolol, metformin 
hydrochloride, furosemide and metoprolol tartrate was decreased significantly in viscous 
medium (Cvijic et al., 2014). Using xanthan gum or guar gum to increase the viscosity of 
dissolution media causes a reduction in benzoic acid dissolution (Sarisuta and Parrott, 1982). 
Viscous media prolongs the paracetamol disintegration and reduces the extent of absorption 
(Parojčić et al., 2008) and administration of drugs with high carbohydrate meals or meals 
supplemented with dietary fibre results in a lower maximum concentration and delayed drug 
absorption in healthy subjects (Jaffe et al., 1971, Walter-Sack et al., 1989, Paintaud et al., 1998). 
Drug dissolution was consistently reduced when tablets (amlodipine, atenolol, carbamazepine, 
warfarin) were crushed and mixed with water thickened with commercially available 
thickeners, especially those consisting primarily of xanthan gum (Figure 1-3). It should be noted 
that the reduced rate of drug dissolution was not due to generalised thickening of the dissolution 
media (Manrique-Torres et al., 2014). Therefore it may be associated with an impediment to 
dissolution of the drug particles and/or diffusion of the drug molecules out of the thickened 
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fluid and into the dissolution media. No other studies have involved delivery of medications 
with fluids thickened for use in dysphagia, but some have investigated the effect of thickeners 
in use for other reasons. Absorption of digoxin, penicillin and metformin tablets were reduced 
when taken with guar gum, used as a source of dietary fibre in diabetic patients (Huupponen et 
al., 1984, Gin et al., 1989). Administering crushed telithromycin tablets with Ensure nutrient 
drink maintained bioequivalence to whole tablet (Lippert et al., 2005), however this contains 
only very small quantities of viscosity enhancing carrageenan and cellulose gums.  
1.2.6 Pharmacokinetics  
Understanding pharmacokinetic principles is important in the selection of formulations and 
ongoing drug development. Pharmacokinetics is the term used to describe the biological 
processes affecting drug absorption, distribution, metabolism, and excretion (ADME). The net 
effect of these processes can be seen in the concentration-time profile obtained following drug 
administration. The concentration-time profile can be described mathematically by 
pharmacokinetic parameters. The two most important pharmacokinetic parameters that define 
drug disposition in the body are the systemic volume of distribution and clearance. 
Following the administration of oral medication, the extent of drug absorption is reflected in 
the fraction of an administered dose that reaches the systemic circulation. This characteristic is 
referred to as bioavailability (Riviere, 2009). Bioavailability can range between 0.0 – 1.0, with 
a bioavailability of 1 being interpreted as 100% of the administered dose reaching the systemic 
circulation (Riviere, 2009, Birkett, 2002). 
Medication can be administered through intravascular or extravascular routes. Examples of 
extravascular routes of administration include oral, subcutaneous and intramuscular. 
Understanding the nature of the route of administration is an important consideration, as 
medicines administered via extravascular routes must be absorbed from the site of 
administration into the systemic circulation before eliciting a drug response. Absorption of the 
drug is affected by drug dosage form (e.g., oral solution, suspension, capsules, tablets or 
sustained dosage formulation) and the composition of the formulation. Before the drug gets 
absorbed, the dosage form has to disintegrate, disaggregate and dissolve into the gastrointestinal 
fluid (Conrado et al., 2010). This process can be altered by multiple factors including as seen 
in Figure 1-5.  
Physiological factors such as composition, volume and hydrodynamics of the content in the gut 
lumen could affect the solubility and dissolution of the drug in the gastrointestinal tract. The 
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median fasting pH in the stomach is 1.7, and ranges between pH 1.4 – 2.1, while in the fed state 
the median is pH 5.0 with a range of pH 4.3 – 5.4 (Dressman et al., 1990). Similarly, the pH of 
small intestine varies from 4.4-8.0 in fasted and fed state (Gray and Dressman, 1996).  
 
Figure 1-5: Factors contributing to drug absorption (Conrado et al., 2010)  
Drugs that are highly soluble and rapidly dissolving immediate release formulations dissolve 
under variable conditions and are absorbed from the upper part of the gastrointestinal system. 
For poorly soluble, poorly permeable drugs or controlled release formulation, absorption may 
be delayed and can take place in a lateral part of the gastrointestinal tract (small intestine and 
colon). These drugs and products are sensitive to the physiological conditions of the 
gastrointestinal tract (Dokoumetzidis and Macheras, 2006). These physiological variabilities 
could alter the dissolution and the permeability of the drug. The Biopharmaceutics 
Classification System considers dissolution, solubility, and intestinal permeability as the major 
factors that regulate the rate and extent of drug absorption from immediate release solid oral 
dosage forms (Amidon et al., 1995). The classification states four categories as follows: 
 Class I: High solubility, high permeability: Generally well-absorbed compounds. 
 Class II: Low solubility, high permeability: Exhibit dissolution rate-limited absorption.  
 Class III: High solubility, low permeability: Exhibit permeability rate-limited absorption.  
 Class IV: Low solubility, low permeability: Exhibit very poor oral bioavailability.  
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Apart from solubility and permeability, drug stability in the gastrointestinal tract can alter the 
bioavailability. Food and liquids present in the gut can form a complex, and may affect the 
bioavailability of the drug (Bailey, 2010, Boullata, 2004). Absorption can also be affected by 
the presence of efflux transporter proteins, such as P-glycoprotein, which expel drugs back into 
the intestinal lumen following absorption (Jodoin et al., 2002). Grapefruit juice is known to 
inhibit p-glycoprotein and some cytochrome enzymes, this can have an impact on the 
pharmacokinetics of the drug whose absorption are limited with these proteins (Wang et al., 
2001). First-pass metabolism of drugs, before they reach the systemic circulation, usually 
results in drug inactivation and so for some drugs, oral administration is not feasible due to their 
high hepatic extraction ratio.  
The main site of drug absorption is the small intestine; gastric emptying rate is known to reduce 
the rate and the extent of drug absorption. Type of meal (solids or liquids), posture, and 
metabolic disorder could influence the gastric emptying. pH changes, blood flow, and 
interaction with drug or the dosage form could impact drug absorption. For successful passive 
absorption across the gastrointestinal mucosa, the drug should have appropriate physiochemical 
characteristics (lipid-soluble or water-soluble, ionised or non-ionised) (Patel and Kirkpatrick, 
2011, Riviere, 2009).  
Following the absorption of the drug into the systemic circulation, the drug is distributed to the 
organs, as well as into the organs that are responsible for the elimination of the drug. The volume 
of distribution (Vd) is a proportionality constant that relates the plasma drug concentration to 
the total amount of drug in the body. Although the volume of distribution is used to estimate 
the extent of drug distribution in the body, it does not explain the drug distribution or drug 
concentration in tissues (Patel and Kirkpatrick, 2011, Birkett, 2002).  
Clearance can be defined as the “volume of plasma cleared of drug per unit time”, indicating 
the irreversible removal of drug following administration. Clearance is an important parameter 
as it can be used to estimate the overall drug exposure and subsequently the dosage required for 
maintaining desired steady state plasma concentration (Patel and Kirkpatrick, 2011, Birkett, 
2002).  
1.2.7 Non-compartmental & compartmental pharmacokinetic analysis 
Non-compartmental pharmacokinetic analysis (NCA) is used frequently to determine the 
pharmacokinetic profile of a drug in a small group, with similar demographic and physiological 
conditions. In NCA, a standard dose is administered with intensive sampling and laboratory 
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quantification of drug concentration. In NCA, it is routine to estimate the clearance, volume of 
distribution, half-life and area under the concentration-time curve. The area under the curve 
describes the degree of systemic exposure to the drug of interest. Also calculated from the 
concentration-time curve are the maximal concentration attained (Cmax) and time that the 
maximum concentration is reached (tmax). Both concentration maximum and time to reach 
maximum concentration are suggestive of the drug absorption rate, and the mean residence time 
(MRT), indicating the average duration for the drug stay in the system following administration 
(Bulitta and Holford, 2007, Patel and Kirkpatrick, 2011).  
Compartmental analysis is a model-based approach, categorised by the number of 
compartments needed to describe the drug movement in the body. Bodies are described as one-
compartment, two-compartment or multicompartment models. The drug is either administered 
directly (e.g. IV) or indirectly (e.g. oral) into the central compartment. From the central 
compartment, the drug moves into the peripheral compartments, or is irreversibly removed from 
the body. For the purpose of this thesis, non-compartmental analysis will be used. 
1.2.8 In vitro-in vivo correlation 
Product development and optimisation of a formulation has become an integral part of dosage 
form manufacturing, as it is a time-consuming and expensive process. Alteration in formulation 
and manufacturing process including equipment are required to optimize a product. Following 
the changes to the formulation, human studies in healthy volunteers may be needed to justify 
the product as being bioequivalent or altered in bioavailability. To reduce the need of 
bioavailability tesing using humans, the FDA recommends the use of in vitro-in vivo correlation 
study. The primary objective of an in vitro-in vivo correlation can be as a substitute for an in 
vivo bioavailability testing.  
USP definition: “The establishment of a rational relationship between a biological property, 
or a parameter derived from a biological property produced by a dosage form, and a 
physicochemical property or characteristic of the same dosage form” (The United States 
Pharmacopeia and National Formulary., 2004). 
FDA definition: “IVIVC is a predictive mathematical model describing the relationship 
between an in vitro property of a dosage form and a relevant in vivo response. Generally, the 
in vivo property is the rate or extent of drug dissolution or release while the in vivo response is 
the plasma drug concentration or amount of drug absorbed ” (FDA, 1997a) 
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1.2.8.1 Levels of in vitro-in vivo correlation 
FDA has defined four levels of correlation (A, B, C and Multiple C). Each level correlates with 
different types of parameters.  
Level A correlation is the highest level of correlation, as it is a point to point relationship 
between in vitro dissolution and the in vivo absorption rate of a drug from the dosage form. 
Level A correlation is the most informative and useful from a regulatory perspective. 
Level B correlation: In Level B correlation, the mean in vivo dissolution or mean residence time 
is compared to the mean in vitro dissolution time by using statistical moment analytical 
methods. This type of correlation uses all of the in vitro and in vivo data; thus, it is not 
considered to be a point-to-point correlation. This is of limited interest and use because more 
than one kind of plasma curve can produce a similar mean residence time. 
Level C correlation: This correlation describes a relationship between the amount of drug 
dissolved (e.g. % dissolved at 1 hour) at one-time point and one pharmacokinetic parameter 
(e.g. AUC or Cmax). Level C correlation is considered the lowest correlation level as it does not 
reflect the complete shape of the plasma concentration-time curve. Similarly, a multiple Level 
C correlation relates one or more pharmacokinetic parameters of the percent drug dissolved at 
several time points of the dissolution profile and thus may be more useful.  
Level B and C correlations can be useful in early formulation development, including selecting 
the appropriate excipients, to optimize manufacturing processes, for quality control purposes, 
and to characterize the release patterns of newly formulated immediate-release and modified-
release products about the reference. For the purpose of this thesis Level A correlation will be 
described in details. 
Development of an IVIVC consists of three steps. Step I involves the calculation of the 
cumulative in vivo absorption profile of the drug for each formulation. In this step, parameters 
that describe drug input rate, drug distribution and/or elimination are determined. Model-
dependent approaches, such as Wagner-Nelson and Loo-Riegelman, or model-independent 
procedures based on numerical deconvolution, may be used (Wagner and Nelson, 1964, Loo 
and Riegelman, 1968). The Wagner-Nelson (one-compartment) method is the simplest method, 
as there is no requirement for a reference formulation. The numerical deconvolution and Loo-
Riegelman methods require administration of a reference formulation, such as intravenous 
administration or an immediate-release oral formulation. In the model-dependent approaches, 
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the distribution and elimination rate constants describe the PK after absorption. In the 
deconvolution numerical method, the drug unit impulse response function describes the 
distribution and elimination phases. In this thesis a model-independent approach, i.e., numerical 
deconvolution, will be used. 
In step 2 (IVIVC), the correlation between in vitro dissolution and in vivo drug profile is 
determined by establishing a linear or nonlinear relationship. Time-scaling may be used in some 
models as there might be some difference despite the same kinetics (FDA, 1997a). The time-
scaling factor should be the same for all the formulations if an IVIVC at level A is used. The 
difference for in vitro dissolution and in vivo absorption time scales are adjusted by using a 
time-scaling factor in the correlation model (Levy, 1964, Levy and Hollister, 1965).  
In step 3, the concentration profiles are predicted and compared with the observed (in vivo) 
concentration-time profile for each formulation. To estimate the predicted concentration, the 
input profile of the drug is predicted based on in vivo dissolution data and the in vivo-in vitro 
relationship generated in step 2. In this process, the parameter describing drug distribution 
and/or elimination phases and the predicted drug input are combined to predict the in vivo 
profile. 
To determine the validity of the model, FDA guidelines recommend two types of validation: 
internal and external. The internal validation is done by measuring predictability error (%PE) 
of data used to produce the in vitro-in vivo correlation model. For internal validation, 
formulations with three or more release rates are used to develop the model. External validation 
is used to predict the in vivo performance of a formulation with a known bioavailability that 
was not used in the model development process. This is used when two formulations with 
different release rates were employed in the model development process (Sunkara and 
Chilukuri, 2003). The prediction error can be calculated using the following equation:  
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 = (
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 − 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑉𝑎𝑙𝑢𝑒
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑉𝑎𝑙𝑢𝑒
)  𝑥 100 
The FDA criteria for prediction error should not be more than 15% and mean absolute 
prediction error should be less than 10% for each of the formulations (FDA, 1997b). 
1.2.9  Conclusion 
Studies have identified that modification of tablets and capsules is common in the general 
population. However, little attention has been given to the issue of why some individuals have 
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discomfort in swallowing tablets and why these people modify dosage forms. Therefore, the 
first aim of this thesis will be to investigate a non-dysphagic population to identify and 
understand issues relevant to swallowing difficulties that are specific to solid dose forms (i.e. 
tablets and capsules). The approach taken will be to investigate psychological, oral sensory and 
oral motor characteristics in relation to medication swallowing issues. 
To ease medication swallowing, tablets are crushed and capsule contents are removed and the 
powders are mixed with a variety of different foods and liquids (e.g. honey, jam, thickened 
fluids). This happens throughout the community, nursing homes and on hospital wards, by the 
person taking the medication and by health professionals involved in medication delivery 
(Nissen et al., 2009, Rosenberg et al., 2002, Verrue et al., 2011, Haw and Stubbs, 2010). The 
most obvious outcome from this practice is faster drug release because the disintegration step 
has been bypassed by converting the tablet or capsule to a powder. This is usually considered 
to be an issue for delayed or controlled release dosage forms but less of a problem for immediate 
release tablets and capsules. However, there is limited information to suggest that the presence 
of a food or thickener as a delivery vehicle may have the potential to delay or even reduce 
dissolution and absorption (Huupponen et al., 1984, Gin et al., 1989). Therefore, the second 
aim of this thesis will be to consider the effect of vehicles on drug absorption to investigate 
whether there is any cause for concern. Work in this laboratory has previously identified that 
water thickened with xanthan gum causes a notable delay in dissolution of five different crushed 
tablets (Manrique-Torres et al., 2014; Manrique et al., 2016). This delay was greater than the 
other viscous vehicles, jam and honey. Gum-based thickeners are most likely to be used for 
thickening drinks for people with dysphagia, and so has the potential to influence health 
outcomes for a very vulnerable population. The approach taken to address this aim will be to 
assess dissolution and absorption for a commonly crushed drug using honey, jam and thickened 
water in comparison to water. Then using dissolution and absorption results, this thesis will 
determine whether a modelling approach (IVIVC) can be used to predict pharmacokinetics of 
this drug.  
 
 Section A 
Medication swallowing difficulties in the 
general population  
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While difficulties with swallowing whole tablets and capsules is widely recognised to be a 
problem among patients who are classified as dysphagic leading to medications being modified 
(cut or crushed) and mixed with a variety of mixers, dosage form modification is also common 
in non-dysphagic subjects. Limited research has been done with otherwise healthy members of 
the population who experience difficulties swallowing whole tablets. Therefore, this section of 
the thesis investigates medication swallowing and associated issues in healthy volunteers.  
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2 Determining the prevalence and reasons for medication swallowing difficulties in 
the general population 
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2.1 Introduction 
The solid oral dosage form is the cheapest, most common and preferred route of administration 
of medicines compared to other dosage forms. However, some people find it difficult or 
impossible to swallow tablets and capsules as a whole. People diagnosed with dypshagia have 
a physiological problem with swallowing in general and often find it difficult to safely manage 
foods and liquids (Schindler and Kelly, 2002). Oral medication delivery is also difficult due to 
the risk of penetration and/or aspiration into the airway (Carnaby-Mann and Crary, 2005). 
Dysphagia has been estimated to occur in 16% of the Australian population (Eslick and Talley, 
2008), primarily amongst the elderly and those with certain medical conditions such as stroke, 
Parkinson’s Disease and multiple sclerosis (Altman et al., 2010). Tablets are regularly crushed, 
and capsules are opened and mixed with a variety of vehicles such as jam, honey, food items 
and thickened fluids (Nissen et al., 2009, McLean et al., 2001, Carnaby-Mann and Crary, 2005).  
People in the general community without dysphagia can also experience difficulty swallowing 
tablets and capsules in whole. Although the difficulty in swallowing solid dose medication has 
been documented in nursing home residents and people with dysphagia (Paradiso et al., 2002, 
Wright, 2002, Chisaka et al., 2006, Kottke et al., 1990), much less information is available 
regarding non-dysphagic individuals. A survey of the general population in Norway (n=6,158) 
reported that 26% of the population had issues swallowing medications (Andersen et al., 1995), 
though another study found only 6% (16/268) of pain centre patients refused to take part in their 
study because of difficulties with medication swallowing (Overgaard et al., 2001). A smaller 
study in Denmark with 89 adolescents aged between 11 and 20 found that over one-third of 
participants had difficulties taking oral medications particularly in tablets forms (Hansen et al., 
2008). Amongst 369 community pharmacy consumers in Australia, 16.5% of people reported 
having difficulties swallowing tablets and 10.6% regularly modified their medicines to make 
them easier to swallow (Lau et al., 2015). The first aim of the present study was to gather more 
information on the prevalence of medication swallowing difficulties amongst the general, non-
dysphagic population. 
Research into the reasons why people find it difficult to swallow whole solid medications has 
primarily focussed on physical dosage form factors, such as shape, colour and texture. The main 
barriers identified amongst Danish adolescents were the size, taste and, discomfort while taking 
the tablet, a sensation indicationg that the tablet was stuck in the throat and general dislike for 
tablets (Hansen et al., 2008). Patients at another Danish pain centre preferred to swallow 
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capsules and coated tablets over uncoated tablets, smaller than bigger tablets, and arched rather 
than flat tablets though medium or large tablets were preferred when they were oblong or oval 
but small tablets were preferred to be circular (Overgaard et al., 2001). In Norway, the majority 
of the population complained about the size, followed by surface texture, form and taste of 
tablets (Andersen et al., 1995). Tablet and capsule colour can also be important, with white 
being preferred for both capsules/tablets while purple tablets and brown capsules were the most 
disliked (Overgaard et al., 2001). Colour can also influence patient perception of effect and 
efficacy (De Craen et al., 1996). None of this previous work has investigated whether there is a 
difference in perception of tablet and capsule characteristics between people who find it difficult 
to swallow whole medications in comparison to those who do not find it difficult. Therefore, 
this study also aims to investigate whether there is a relationship between medication 
swallowing issues and perception of dosage form characteristics. 
Prior episodes of choking on tablets/capsules have been reported as one of the reasons for 
avoiding medications (Harris Interactive Inc, 2004, Macdonald et al., 2001). Danish adolescents 
reported that discomfort while taking the tablet and a sensation that the tablet was stuck in the 
throat were associated with a dislike of swallowing whole medications (Hansen et al., 2008). A 
previous experience of a medication scratching the oesophagus or leaving an unpleasant odour 
and taste (Wamberg, 1988) or tissue damage to the oesophagus by retention of capsules/tablets 
causing irritation and pain (Hey et al., 1983) could lead to subsequent fear of swallowing whole 
medications. The present study includes the aim to investigate whether there is a relationship 
between a memory of choking on food or medications and the presence of difficulties 
swallowing whole medications. 
To easily swallow a tablet or capsule, two anthropological reflexes must be over-ridden; the 
reflex to chew solid food in order that the medication be swallowed whole, and the gag reflex. 
The gag reflex is a primitive reflex designed to protect the airway by not allowing a bolus that 
would constitute a choking risk to enter the pharynx (e.g. a very large or poorly chewed bolus). 
A study on healthy people found that 37% had no gag reflex (Davies et al., 1995), and it is 
possible that there is a link between the presence of a gag reflex and difficulty swallowing 
medications. However, there is no literature to support or refute this hypothesis. Additionally, 
the size of the oral cavity is commonly classified to determine whether intubation is possible 
(Samsoon and Young, 1987), but there is no information on how oral cavity size might affect 
the ability to swallow a large, unchewed bolus such as a tablets or capsule. Therefore, this study 
provides an opportunity to investigate whether those people reporting difficulties swallowing 
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whole tablets and capsules are more likely to have a strong gag reflex and/or a smaller mouth 
size than those who do not have trouble swallowing whole medications. 
The first point of contact for the capsule/tablet is the tongue. The fungiform papillae, which are 
mushroom shaped projections on the tongue, contain the taste buds (Frank et al., 1992). The 
anterior part of the tongue has more fungiform papillae than its posterior (Zhang et al., 2009, 
Arvidson and Friberg, 1980). The number of fungiform papillae is often used as a measure of 
taste bud density, and there is an association between higher density of taste buds 
(‘supertasters’) and rejection of certain type of foods (Lee et al., 2008b). Successful oral 
processing relies on an intact motor and sensory system. While chewing food, the sensory 
system provides continuous feedback to the brain to determine the need for further chewing 
resulting in particle size reduction to make the bolus swallow-safe. Individuals with a high 
density of taste buds have an increased sensory awareness of material in their mouth. A higher 
sensory awareness may also trigger oral rejection that the solid dose medication bolus is 
improperly formed for safe swallowing. The present study aims to investigate whether people 
with a higher density of taste buds, acting as a pseudo-marker for increased sensory awareness, 
are more affected by the taste of oral medications and difficulty swallowing tablets/capsules 
than those with lower taste bud densities. 
People who are food neophobic avoid certain foods and are less likely to try new foods often 
due to, a heightened sensory awareness of food (Veeck, 2010). The acceptance of new products 
is not well understood (Van Kleef et al., 2002) but the decision to try a new food is influenced 
by the texture of the product, its appearance, taste, smell and texture are associated with the 
liking or disliking of food (Weaver and Brittin, 2001). For many individuals, the dislike of food 
is more related to its appearance and texture than with the taste (Veeck, 2010). Tablets and 
capsules are designed to be swallowed whole and may present a textural challenge to those with 
food neophobia. The potential for a relationship between food neophobia and the presence or 
absence of difficulties swallowing capsules/tablets has not previously been investigated. This 
study aims to determine whether people who are classified as food neophobic or those who have 
preferences for certain food textures are more likely to present with a medication swallowing 
issue. 
Texture, odour and flavour play a vital role in the perception of food and heps in deciding 
whether to continue with the mastication and swallowing process, or to eject the item from the 
mouth (Biswas et al., 2014). Placing the medication on the tongue also stimulates saliva 
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secretion and initiates the processes of mastication and swallowing. As noted above, processing 
tablets and capsules without chewing goes against our innate and taught reflexes. Food is 
routinely chewed into smaller particles for safe swallowing and to avoid choking (Mishellany 
et al., 2006). The present study aims to investigate whether those people who swallow their 
food at larger particle sizes (i.e. with less chewing) are more likely to be comfortable to swallow 
whole tablets and capsules. 
Oral dosage forms are designed to be swallowed without chewing, which is different to normal 
swallowing of a solid bolus. Posture and head position affect ease of tablet and capsule 
swallowing and their transit time to the stomach (Kasashi et al., 2011). For example, being in 
an upright position allows gravity to help with bolus transport through the oesophagus (Channer 
and Virjee, 1982). Similarly it is easier to swallow with the head in neutral or chin forward 
position than with head tilted upwards (head extension). During head extension the airway is 
opened, as used in cardiopulmonary resuscitation, providing a direct and dangerous trajectory 
for the medication to enter the airway if swallowed in this position. Additionally, a liquid such 
as water is advised to be used because it can both mask the presence of the tablet in the mouth 
to make swallowing easier and aid transfer of the medication to the stomach (Osmanoglou et 
al., 2004). A minimum of 20 mL or 30 mL of water has been used in studies investigating tablet 
swallowing (Kasashi et al., 2011, Overgaard et al., 2001) though 50 - 60 mL has been 
recommended based on monitoring efficiency of capsule transit time (Channer and Virjee, 
1982, Osmanoglou et al., 2004). This study aims to investigate whether there is a relationship 
between head position and/or quantity of water used to swallow medications and difficulties 
with tablet swallowing. 
Despite the fact that some people find it difficult to swallow tablets/capsules, the reason for this 
difficulty is not often considered and is little understood. Swallowing a solid dose (tablet or 
capsule) in whole requires the individual to override sensory cues from taste receptors, and the 
gag reflex, and motor cues from the chewing reflex. For example, people with heightened taste 
sensation, or those who tend to chew their food for extended periods resulting in finely chewed 
particles, or those who have a strong gag reflex may be more likely to have difficulties 
swallowing whole solid medications. Therefore, this study will investigate a non-dysphagic 
population to determine firstly the extent of medication swallowing issues in the general 
population, and then secondly identify relevant issues by investigating psychological, oral 
sensory and oral motor contributions to medication swallowing issues.  
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2.2 Materials and Methods 
2.2.1 Population 
An email was sent to staff and students within the School of Pharmacy, University of 
Queensland, Australia and staff of the Health and Food Sciences Precinct, Queensland, 
Australia with an invitation to participate in the study. Volunteers were provided with an 
information sheet about the project and asked to sign an informed consent form before 
participating. This study was approved by the University of Queensland; Medical Research 
Ethics Committee (Approval number: 2011/111).  
2.3 Study Design 
The study was subdivided into four parts.  
 Phase 1 – Psychological contributions to medication swallowing issues  
 Phase 2 – Oral sensory contributions to medication swallowing issues 
 Phase 3 – Oral motor contributions to medication swallowing issues 
 Phase 4 – Observation of medication swallowing 
2.3.1 Phase 1 – Psychological contribution to medication swallowing issues 
To investigate potential psychological effects associated with tablet-swallowing, participants 
were asked to complete a questionnaire on tablet/capsule swallowing. The questionnaire 
consisted of a combination of closed multi-response questions and open-ended questions to 
elicit the participant’s perception of issues with swallowing tablets or capsules, and memory of 
choking incidents on food and medication. Questions were also asked to identify coping 
strategies used by volunteers. All survey questions were piloted on a group of pharmacy 
practitioners for understanding.  
Participants were provided with a range of different sized capsules and tablets that were selected 
based on their size, shape and availability (Table 2-1). After visually inspecting the size of the 
capsules/tablets they were asked to score their perception of their comfort level if asked to 
swallow the different sized medicines (Appendix I).  
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Table 2-1: Products used to represent various oral formulations (sourced from the School of 
Pharmacy) 
Type of Formulation No: Product used 
Capsule 1 Dothep 25mg – Alphapharma Pty Limited 
2 Dilantin 100 mg - Pfizer 
3 Hard gelatin capsule filled with lactose monohydrate - PCCA 
4 Minocycline 100 mg – Sigma Pharmaceuticals 
5 Hard gelatin capsule filled with lactose monohydrate - PCCA 
6 Dizole 200 mg – Alpharma 
7 Amoxil 500 mg – Aspen 
Caplet 1 Champix 0.5 mg – Pfizer 
2 Gliclazide 30 mg – GenRx 
3 Avapro 150mg - Sanofi-aventis 
4 Acetaminophen 500 mg (product from the USA) 
5 Paracetamol 500 mg – GSK 
6 Augmentin Duo Forte (875/125mg) – GSK 
7 Atrovastatin 80 mg – Generic Health 
Tablet 1 Azathioprine 250 mcg – Sandoz 
2 Lanoxin 250 mcg – Aspen 
3 Placebo – manufactured in the University lab 
4 Carbamazepine 200mg – Sandoz 
5 Acetaminophen 325 mg - McNeil Consumer health care 
6 Paracetamol 500 mg - Sanofi-Aventis 
7 Gaviscon tablet – Pfizer 
Other Shape 1 Placebo – manufactured in the University lab 
2 Norvasc 5 mg – Pfizer 
3 Amlodipine 10 mg – Sandoz 
4 Anginine 600 mcg - Arrow 
5 Dilantin 50 mg – Pfizer 
6 Nurofen liquid capsule 200 mg – Reckitt Benckiser 
7 Fish oil 1g – Nature's Own 
 
2.3.2 Phase 2 – Oral sensory contributions to medication swallowing issues  
The relationship between oral sensation and swallowing medication was investigated by 
measuring the gag reflex, classifying oral structures using a modified mallampati system, 
measuring taste receptor density, and completing a questionnaire on the perception of food 
texture (Appendix II).  
2.3.2.1 Gag reflex 
In a comfortable seated upright position, the subjects were asked to open their mouth. The 
examiner (a speech pathologist with 23 years of clinical experience) firmly touched the right 
side of the tongue with a wooden spatula, starting at the front dorsum, and gradually walked the 
tongue depressor backwards until the participant responded to the stimulation (Figure 2-1). The 
gag reflex was defined as constriction of the pharynx in response to the stimulus. As soon as a 
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response was observed on the right side of the mouth, the examiner moved to test the left side 
starting again from the front dorsum. If no response was observed from the sides of the tongue 
and the faucial pillars (identified as ‘beyond tongue’ in Figure 2-1), the tongue depressor was 
gently pushed against the midline of the pharyngeal wall at the back of the throat to attempt to 
elicit a response.  The speech pathologist also assessed the participant for signs of dysphagia 
through this process (Appendix II). 
 
Figure 2-1: The image used by the examiner to assess the areas that exhibit a gag reflex. 
2.3.2.2 Modified Mallampati classification 
The Modified Mallampati classification is used in anaesthesia to predict the ease of intubation, 
by examining the visibility of oropharyngeal structures when the subjects are in a seated 
position with their mouth fully opened. The higher mallampati scores (class 3 & 4) are 
associated with difficult intubation (Samsoon and Young, 1987, Mallampati et al., 1985). All 
subjects were requested to sit in a comfortable position and asked to open their mouth as widely 
as possible with tongue protruding. The examiner sat on the opposite side, and inspected the 
pharyngeal structures using a torch. The airway was classified into one of the following four 
categories (Figure 2-2):  
 Class I: Soft palate, fauces, uvula and pillars are visible 
 Class II: Soft palate, fauces, is visible but less of the uvula visible 
 Class III: Soft palate and only the top of uvula are visible 
 Class IV: Soft palate not visible at all 
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Figure 2-2: Modified Mallampati classification of oropharyngeal visualization (Samsoon and 
Young, 1987) 
2.3.2.3 Taste bud receptor density  
The method for counting taste bud receptor density was similar to Shabake et al (Shahbake et 
al., 2005). Participants were asked not to eat or drink for 1 hour before the test and were asked 
not to smoke for 2 hours prior to the test. Following the rinsing of the mouth with water, 
petroleum jelly (Vaseline®) was applied to the lower lip to reduce staining of extra-oral tissues. 
0.5% methylene blue food colouring (Queen Fine Foods, Alderley, QLD) was applied to the 
tongue with a sterile cotton tip applicator and participants were asked to swallow once. A 
disposable plastic slide, pre-labelled with reference number, was then placed on the tongue so 
that the midline of the tongue bisected the 1 cm2 window. A tongue depressor was placed on to 
the tip of the tongue, to reduce the movements. Digital images were taken using a Nikon D60 
digital camera (Nikon Corp, Japan), for each participant, and the clearest image was selected 
for counting (Figure 2-3a). Both the fungiform and filiform papillae stain light blue with 
methylene blue, while the fungiform papillae that contain the taste buds, (Arvidson and Friberg, 
1980) were distinguished from filiform papillae by their larger size and mushroom-shape. The 
digital image was loaded into a computer, and the fungiform papillae were independently 
counted by two researchers (Figure 2-3b).using Adobe Photoshop CS 6.5 (Adobe Systems 
Incorporated, San Joes, CA, USA). 
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Figure 2-3: Digital image of the human tongue tip a) stained with methylene blue to visualise 
fungiform papillae (large light blue ovals) and filiform papillae (small light blue ovals), and b) 
showing the count of the fungiform papillae 
2.3.2.4 Food neophobia and food texture  
A questionnaire about willingness to try 22 different foods based on texture was administered 
with a five point hedonic scale (Scale: 1 = dislike extremely, 2 = dislike moderately, 3 = neither 
like nor dislike, 4 = like moderately, 5 = like extremely). This was modified from the previous 
9–point scale (Weaver and Brittin, 2001). A separate survey provided the participants with an 
option of two responses (True and False) to determine whether or not the participant was food 
neophobic. A person was classified as neophobic if ‘True’ was selected for 6 or more questions 
(Pliner and Hobden, 1992). Please refer to Appendix I for details of the questionnaires used. 
2.3.3 Phase 3 – Oral motor contributions to medication swallowing issues 
To understand the effect of oral motor capabilities on medication swallowing issues, a task was 
devised to examine chewing efficiency and particle size reduction (Appendix III). The 
participant was provided with a piece of confectionary jelly snake that was 5 cm in length, and 
was asked to “chew it as they usually chew their food”. When they felt a readiness for 
swallowing they were asked to spit the jelly into a plastic bag provided. The participant was 
also provided with a glass of water just in case they wanted to rinse their mouth. The plastic 
bag of chewed jelly snake was visually inspected to determine the size of the particles. The 
chewed particles were measured with a ruler, and a note was made as to whether the bolus was 
cohesive (stuck together like a ball). Digital images were taken using Nikon D60 digital camera 
for visual analysis. 4 mm was chosen as an ideal particle size based on the previous study on 
healthy young people with good oral health (Woda et al., 2010). Sizes of the particles were 
classified into five different categories: 
a b 
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 All particles are very small (< 4mm) 
 Most particles are very small (< 4mm) 
 Roughly equal numbers of small and large particles 
 Most particles are large (> 4mm) 
 All particles are large (> 4 mm) 
2.3.4 Phase 4 – Observation of medication swallowing 
Participants were assessed for their ability to swallow capsules. Size 00 gelatine capsule 
(PCCA, Matraville, NSW, Australia) were filled with 100’s and 1000’s confectionary particles 
(Dollar Sweets Company, VIC, Australia) to provide weight to the capsule. A disposable plastic 
cup (200 mL) and a jug of water were provided, but attention was neither drawn to these items, 
nor was it insisted that they are used. The participant was then asked to “swallow the capsule 
as they normally would.” Subsequently, it was noted whether the participant had completed the 
task and if so whether it was completed in single attempt. In addition, the approximate quantity 
of water used was assessed based on visual inspection of the contents in the cup (full, half, 
quarter, less than a quarter, none), whether the capsule was placed at the front, middle or back 
of the mouth and if their head position had deviated from neutral (Appendix IV).  
2.4 Statistical analysis 
The data are adenoted in percentages for continuous and categorical variables. The results were 
analysed using Pearson’s Chi-squared test for count data; all data were dichotomised for 
analysis and statistical significance was accepted at p<0.05. Chi-square tests were performed 
using R Foundation for Statistical Computing, [R version 2.15.0 (2012-03-30)], using Rcmdr-
package (version 1.9-6). A non-parametric Mann-Whitney t-test was used to test for any 
difference in food preferences between participant categories (e.g. gender, current medication 
swallowing issue) using XLSTAT Version 2015.4.01.20231 (Addinsoft, NY, USA). 
2.5 Results 
153 volunteers from two different sites took part in the study. One subject was excluded from 
the study, as the participant did not complete the demographic section of the questionnaire. The 
median age of participants was similar between males and females (36 years), with the 
distribution showing more female (64%) than male (36%) participants (Table 2-2).  
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Table 2-2: Demographic characteristics of respondents 
 Percentage of population Age Range Median Age 
Total Population  152 19-66 36 
Males 55 19-62 36 
Females 97 20-66 36 
 
2.5.1 Phase 1-Psychological contributions to medication swallowing issues  
Of the 152 participants, 32% (n=49) indicated that they currently have difficulties swallowing 
medications (Table 2-3), and 58% had experienced difficulties swallowing medications at some 
time in their life. 66% of the individuals reported taking medication on a regular basis (Table 
2-3), reporting that their medications were mostly oval (60%) or round (37%) with no 
association with medication swallowing difficulties.  
One-third of the participants (n = 49/152) reported that they have crushed a medication before 
swallowing, and 48% reported that someone, such as a parent, had at some time helped them to 
crush medication to make it easier to swallow (Table 2-4) but only 18% (n = 28/152) thought 
that they had trouble learning to swallow tablets or capsules. Of the participants reporting 
medication swallowing difficulties, about half of them (26/49; 53%) have also crushed tablets 
to aid swallowing, a significant relationship (p = 0.0001) in comparison to the 22% (23/103) 
who have crushed at some time but do not currently have a problem swallowing tablets whole. 
Of these 23 participants who have crushed tablets at some time to make swallowing easier, 14 
indicated that they have experienced difficulties swallowing medications at an earlier time in 
their life while 9 appear to modify medications without need. 
Table 2-3: General distribution of medication swallowing issue (n=152) 
Questions for the participants Yes No 
Do you take any tablets/capsules on a regular basis 100 (66%) 52 (34%) 
Have you ever had trouble swallowing a tablet or 
capsule or other medication 
88 (58%) 64 (42%) 
Do you currently have trouble swallowing tablets 
or capsules 
49 (32%) 103 (68%) 
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Table 2-4: Response (%) to different questions related to medication modification and swallowing 
Questions for the participants Yes No N/A 
Have you ever cut or crushed a medication to make it 
easier to swallow? 
49 102 1 
Has anyone else (e.g. a parent), ever crushed a 
medication for you, to make it easier to swallow? 
71 80 1 
Did you have trouble learning to swallow tablets or 
capsules? 
28 123 1 
The following items or manoeuvres help me to swallow tablet/capsules: 
Placing the tablet/capsule at the very back of my mouth 62 85 5 
Tipping my head back as I swallow the tablet/capsule 76 73 3 
Swallowing the tablet/capsule with a liquid (e.g. water) 148 4 0 
Swallowing the tablet/capsule with food 126 22 4 
Swallowing the tablet/capsule by itself 44 105 3 
 
When questioned on the vehicles used to swallow medication, 97% (n = 148/152) used water, 
83% (n = 126/152) used food and 28% (n = 44/152) reported that they can swallow the dry 
capsules/tablets without any vehicle. This shows that people often employ multiple methods to 
swallow their medicines, with 13% (n=21/152) reporting both water and food, and 28% (n = 
42/152) using either water or no vehicle at all. To aid in the swallowing process 41% (n = 
62/152) reported that they placed the capsule at the very back of the mouth, and 50% (n = 
76/152) reported that they tipped their head back to swallow the medication (Table 2-4). Some 
other approaches were also reported by different individuals to help swallow tablets and 
capsules whole (Table 2-5). Most of the participants reported that they use large quantity of 
water to swallow medications.  
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Table 2-5: Methods used for swallowing tablets/capsules by the 14 participants that provided some 
additional information in response to the question. 
 All small tab with water | Big tab next with water | all groups of tab must be at front of tongue, 
so water hits them and washes them down 
 Best method - swallow with water 
 Drink lot of water, I ask myself what would Mary Poppins do 
 I often make the tablet float around in my mouth with some water for a couple of seconds 
before swallowing 
 Orientating an oval tablet/capsule so that it points forward/back and not sideways. 
 Place the tablet on my tongue, wait second for the saliva to accumulate, voila!  
 Placing tablet on tongue and swallowing with liquid 
 Break it in half taking a drink to wet throat before taking tablet 
 Chewing movements to generate saliva to make tablets easier to swallow. 
 I sometimes hum or dance to take my mind off swallowing a pill/tablet. 
 Grimaced and concentrated when swallowing. 
 Head forward then backward Sip water first then placed capsule and swallowed on 2nd 
attempt felt it 'caught' needed extra water though it might be too hard. 
 Placed "fat" side down, so it does not "scractch" on the way down the throat. 
 Sipped water first to make it slippery. Then positioned the capsule so that it pointed vertically 
downwards towards the throat, as opposed to horizontally across the mouth. 
 
The question regarding participant memory of choking on medications (tablets or capsules) was 
answered by 68% (n = 103/152) of the participants, with 43% of those (n = 44/103) responding 
that they did remember choking on a tablet or capsule some time. There was a significant 
correlation (p = 0.0015) between the memory of choking on medication and having a current 
issue with swallowing medications, with 60% (n = 28/47) of those with a current issue with 
swallowing medications having a memory of choking on medication (Figure 2-4a). However, 
this question was designed to be answered only by those reporting problems swallowing 
medication, which explains the low response rate, and so the data is incomplete and the 
correlation should be considered with this in mind. Most of the participants (149/152) answered 
the question about having a memory of choking on food, and 26% of them (n = 38/149) reported 
that they had choked on food. There was no correlation between having a memory of choking 
on food (p = 0.27) with current issues swallowing medications (Figure 2-4b). 
When the participants viewed the samples of different sizes and shapes of tablets and capsules, 
all the participants believed that certain dosage forms appeared easier to swallow than others. 
Gelatine capsules were most preferred followed by caplets and compressed tablets (Table 2-6). 
Greater than 90% of the participants were comfortable with swallowing up to 17.1 - 17.5 mm 
long caplets and hard gelatin capsules, but as the length increased above this participants were 
more comfortable with hard gelatin capsules than caplets. For the largest size, 64% of the 
participants indicated they would swallow the largest hard gelatine capsules (23.3 cm), 44% 
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were happy to swallow even larger softgel (26.2 cm) but only 23% were comfortable with the 
largest caplet (21.1 cm). For circular tablets, greater than 90% of participants were happy to 
swallow sizes up to 8.5 cm diameter, but discomfort with tablet size worsened as diameter 
increased above 9.6 cm and only 20% would swallow the largest size (15.6 cm). Responses 
regarding tablets with non-standard shapes were generally reflective of circular tablets or 
capsules/caplets of a similar size. 
 
Figure 2-4: Recollection of an episode of a) choking on medication (n = 103) or b) choking on food 
(n = 149) for participants that reported having a current issue with swallowing medications in 
comparison to those with no current issue with swallowing medications. The number of 
participants is shown within each bar. There was a significant correlation between memory of 
choking on medication (p = 0.0015) but not food (p=0.27) and a current issue with swallowing 
medications. 
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Table 2-6: Dosage forms - perception and preferences for swallowing medications of various sizes, 
types and shapes (n= 152) 
Capsule  
 
No Yes No Yes No Yes No Yes No Yes No Yes No Yes 
% response 0 100 4 96 5 95 6 94 14 86 23 77 36 64 
Body length 
(mm) 
14.3 
 
15.6 
 
15.6 17.5 19.4 21.2 23.3 
Capsule size 4 3 2 1 0 00 000 
Capsule No: 1 2 3 4 5 6 7 
Caplet  
 
No Yes No Yes No Yes No Yes No Yes No Yes No Yes 
% response 0 100 3 97 5 95 9 91 14 86 54 46 77 23 
Body length 
(mm) 
7.72 9.37 12.02 17.08 16.63 21.54 22.12 
Caplet No: 1 2 3 4 5 6 7 
Tablets  
 
No Yes No Yes No Yes No Yes No Yes No Yes No Yes 
% response 1 99 3 97 4 96 7 93 13 88 30 70 80 20 
Body length 
(mm) 
5.96 6.65 7.52 8.53 9.57 12.26 15.87 
Tablet No: 1 2 3 4 5 6 7 
Other  
 
No Yes No Yes No Yes No Yes No Yes No Yes No Yes 
% response 13 87 7 93 12 88 6 94 24 76 9 91 56 44 
Body length 
(mm) 
8.05 8.72 9.02 7.0 10.9 14.8 26.2 
Other No: 1 2 3 4 5 6 7 
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78% of the volunteers aged between 50 – 66 years were comfortable with swallowing the largest 
capsule while 57% of 30 – 49 yr olds and 59% of 19 – 28 yr olds were comfortable, and a 
similar pattern was observed for tablets and caplets. Differences between ages were not 
statistically significant. Reasons for the preferences stated are described in Appendix V. 
2.5.2 Phase 2 – Oral sensory contributions to medication swallowing issues  
2.5.2.1 Gag reflex 
No gag reflex was exhibited by 42% (n = 64/152) of the participants, i.e. they did not respond 
to the pressure of the tongue depressor at any of the locations in the oral cavity. (Table 2-7) and 
(Table 2-8) describe the distribution of the gag reflex in the study population. As anticipated, 
when the gag reflex was present it was mostly triggered from the rear of the oral cavity. There 
was no correlation between age or gender with presence or absence of the gag reflex, and there 
was no significant relationship with medication swallowing issues (p = 0.73).  
Table 2-7: Presence of gag reflex at different side and location of the mouth. The gag reflex was 
tested on the right side first and as soon as a reflex was found the test moved to start again at the 
front of the left side. If no response was found on either side, then the pharyngeal wall was tested. 
Right side Left side Pharyngeal 
wall - 
midline 
No 
response 
Front 
dorsum 
Back 
dorsum 
Faucial 
pillar 
Front 
dorsum 
Back 
dorsum 
Faucial 
pillar 
11 38 35 7 36 36 1 64 
 
Table 2-8: Location of gag reflex at different locations in the mouth. The gag reflex was tested on 
the right side first and as soon as a reflex was found the test moved to start again at the front of 
the left side. If no response was found on either side, then the pharyngeal wall was tested. 
Bilateral Right Left Front 
dorsum 
Back 
dorsum 
Faucial 
pillars 
Pharyngeal 
wall - 
midline 
No 
response 
75 84 79 12 43 43 1 64 
 
2.5.2.2 Modified Mallampatti classification 
The size of the mouth cavity was classified into four groups using the Modified Mallampatti 
classification. There were no statistical differences between I and II and between III and IV, so 
they were regrouped into two categories - ‘Large mouth cavity’ (class I and II) and ‘Small 
mouth cavity’ (Class III and IV). 46% of the population demonstrated a good view of the mouth 
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cavity and were classified as having a large mouth cavity while 54% of the population 
demonstrated a poor view or had a small mouth cavity size. For those who reported current 
issues with medication swallowing, 29% (n=14) of the population were classified as large 
mouth cavity and 71% (n = 35) had a small mouth cavity. A significant (p = 0.003) correlation 
between medication swallowing issues and mouth cavity size indicated that people with a small 
mouth cavity were more likely to present with medication swallowing issues (Figure 2-5). Age, 
sex, taste bud count and presence or absence of the gag reflex did not show any correlation with 
the mouth cavity size. 
 
 
Figure 2-5: Mallampati classification of the oral cavity for participants who indicated that they 
are currently having issues swallowing tablets and capsules (n = 49) and those currently having 
no issues swallowing medications (n = 103). The number of participants are shown above each bar. 
There was a significant correlation between mouth cavity size and a current issue with swallowing 
medications (p=0.003). 
2.5.2.3 Taste receptor density 
Counts of fungiform papillae were used to classify participants into three groups, low or non-
tasters (less than 15 per cm2), medium tasters (15 to 24 per cm2) and supertasters (more than 25 
per cm2). Four subjects did not participate in this part of the study, and poor image quality 
prevented the use of a further 10 participants. The mean (± SD) number of fungiform papillae 
per 1 cm2 for 138 subjects was 14.2 ± 9.4, with a range between 0 – 41 papillae, leading to 15% 
being classified as supertasters, 34% as medium tasters and 51% as non-tasters. A greater 
proportion of participants who were classified as super and medium tasters reported having 
current problems with swallowing medications than not. In contrast, low or non-tasters mostly 
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did not have issues swallowing medications (Figure 2-6). There was a significant relationship 
between current medication swallowing issues and taste bud count between the medium taster 
and non-taster groups (p = 0.042), and also between super taster and non-taster groups (p = 
0.028). 
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Figure 2-6: Percentage of fungiform papillae on the supertaster, medium taster and non-taster 
compared with current swallowing issue and no swallowing issue. The number of participants is 
shown above each bar. * indicates a significant difference (P<0.05) between groups in terms of the 
proportion reporting current medication swallowing issues. 
2.5.2.4 Food neophobia and food texture  
According to the food neophobia questionnaire, 46% of the participants exhibited food 
neophobia i.e. indicated a positive response to six or more of the ten questions. The food 
neophobia questionnaire did not show any relationship (p = 0.60) with current issues 
swallowing tablets/capsules, as 14% of the population who reported having medication 
swallowing issues were neophobic, while 18% of people with neophobia did not report 
medication swallowing issues.  
For most of the food items listed in the questionnaire there was no correlation between current 
problems with medication swallowing and food texture preferences (Table 2-9). Only three of 
the food items viz., muesli/granola bar, potato chips (crisps) and popcorn showed a significant 
association with current problems with medication swallowing, with those reporting problems 
with medication swallowing having a significantly lower preference score for those food items  
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Table 2-9: Preferences given by participants (n=152) for food items differing in texture, required 
chewing ability and choking risk (Weaver and Brittin, 2001, Pliner and Hobden, 1992). 
Preferences are displayed as mean ± standard deviation of ratings given on a 5 point scale (1 = 
dislike extremely, 2 = dislike moderately, 3 = neither like nor dislike, 4 = like moderately, 5 = like 
extremely) for those who reported currently having an issue with swallowing medicines and those 
who did not. A Mann-Whitney t-test was used to test for the significance of any difference in means 
and P values are shown with significant values in bold (* p >0.05). 
Food Item Chewing 
ability 
required 
Choking risk Current medication 
swallowing issue 
P value 
No (n=103) Yes (n=49) 
Muesli or granola bar Advanced Young & elderly 3.97 ± 0.86 3.57 ± 1.08 0.02* 
Soup with whole 
pieces of vegetables 
or meat 
Advanced Young & elderly 4.20 ± 0.83 4.08 ± 1.04 0.47 
Cereal with milk Advanced Young & elderly 4.15 ± 1.06 3.40 ± 1.12 0.20 
Yoghurt or mousse Beginner No risk 4.44 ± 0.89 4.34 ± 0.86 0.55 
Oysters Intermediate Young 2.69 ± 1.61 3.12 ± 1.59 0.12 
Grapes Intermediate Young & elderly 4.50 ± 0.79 4.47 ± 0.84 0.81 
Pease Intermediate Young & elderly 4.15 ± 0.88 4.20 ± 0.89 0.70 
Corn Intermediate Young & elderly 4.32 ± 0.84 4.16 ± 0.97  0.33 
Potato chips (crisps) Transitional No risk 4.49 ± 0.67 4.14 ± 0.94 0.02* 
Ice cream wafers Transitional No risk 4.05 ± 0.92 3.86 ± 0.91 0.23 
Mashed potato Beginner No risk 4.39 ± 0.88 4.43 ± 1.00 0.81 
Marshmallow Beginner Young & elderly 4.02 ± 1.08 4.08 ± 1.09 0.74 
Bran or shredded 
wheat 
Advanced Young & elderly 3.47 ± 1.11 3.25 ± 1.05 0.24 
Lettuce Intermediate Young 4.19 ± 0.73 4.31 ± 0.87 0.44 
Apple with skin on Advanced Young & elderly 4.07 ± 0.98  3.98 ± 1.01 0.61 
Nuts Advanced Young & elderly 4.15 ± 1.01 4.04 ± 1.06  0.56 
Cooked chicken Intermediate Middle-aged & 
elderly 
4.45 ± 0.92 4.25 ± 0.90  0.20 
Cooked red meat  
(e.g. steak) 
Advanced Young, Middle-
aged & elderly 
4.09 ± 1.23 4.14 ± 0.87  0.75 
Bread Intermediate Middle-aged & 
elderly 
4.41 ± 0.73 4.29 ± 0.84  0.38 
Popcorn Advanced Young & elderly 4.02 ± 0.98 3.55 ± 1.14 0.013* 
Green string beans Advanced Young & elderly 3.92 ± 1.01 3.65 ± 1.07 0.14 
Scrambled eggs Beginner No risk 4.15 ± 0.95  4.29 ± 1.02 0.42 
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2.5.3 Phase 3 - Oral motor contributions to medication swallowing issues  
(Table 2-8). Advanced chewing ability is required for muesli/granola bar and popcorn and these 
pose a high choking risk for young and elderly, however other foods items being classified in 
the same way (e.g. cereal with milk and green string beans) did not exhibit a significant 
association with a current issue swallowing whole medications. Food texture (hard, dry, low 
moisture content, particulate easily) rather than chewing ability are the commonality for potato 
chips, popcorn and muesli bars (Table 2-9). 
Chewing efficiency of subjects was assessed using a confectionary jelly snake (Figure 2-7). 
Half (52%) of the participants chewed their jelly snake to particle sizes greater than 4 mm at 
the point of being ready to swallow, and this was similar whether they reported having issues 
swallowing whole medications (49%) or not (53%). Of the remainder, 32% chewed to particle 
sizes less than 4 mm and 16% chewed to roughly equal quantities of large and small pieces 
(Figure 2-8). A greater proportion of participants that chewed to a roughly equal number of 
large and small pieces reported having current medication swallowing issues than not, and 
conversely a lower proportion of participants who chewed the jelly snake to mostly small 
particles reported having current medication swallowing issues (Figure 2-8). This lead to a 
significant difference between chewing to an equal number of large and small particles in 
comparison to mostly large particles (p = 0.008), or mostly small particles (p = 0.0008).  
 
Figure 2-7: Particle size reduction on chewing of a 5 cm piece of jelly snake. Examples shown are 
for all/most small (ID 151), mixed (ID 135) and large (ID 129) particle size. 
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Figure 2-8: Relationship between particle size of bolus fragments after chewing a piece of jelly 
snake (n = 152) with reported issues swallowing whole medications. The number of participants is 
shown above each bar. * indicates a significant difference (P<0.05) between groups in terms of the 
proportion reporting current medication swallowing issues. 
2.5.4 Phase 4 - Observation of medication swallowing 
When participants were observed swallowing a capsule, 3% (n=4/152) of them could not 
complete the task. One participant made an effort to swallow the capsule but could not proceed 
after two further attempts due to a choking sensation. Two participants attempted to swallow 
but then refused because they needed food to swallow the pills, and the fourth declined to 
swallow as the participant was scared and felt like vomiting. All four participants had reported 
having a current problem with swallowing medications. Most of the participants took the option 
of using water to swallow the capsule. The cups had a nominal volume of 200 mL but were 
considered to be ‘full’ with approximately 150 mL and half full with approximately 90 mL; 
25% of participants used quantities of water (ranging between 90 mL and 150 mL) (Figure 2-9). 
The volume of a quarter of a cup was approximately 40 mL, which was used by 12% (n=19/152) 
of the participants while 60% (n=91/152) used less than a quarter of a cup or no water to help 
swallow the capsule. There was no significant correlation between trouble swallowing capsules 
and the amount of water used (Figure 2-9). 
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Figure 2-9: Quantity of water used to swallow a capsule (size 00) based on visual assessment of the 
200 mL disposable plastic cup. The number of participants is shown above each bar (Quarter to 
full cup = 40 mL – 150 mL; Less than quarter cup = <40 mL). 
Most (83%; n=125/151) of the participants exhibited a neutral/forward posture when 
swallowing the capsules, and this was similar whether they reported having a current issue with 
swallowing medications (79%) or not (84%) (Table 2-10). The majority of participants (81%) 
were observed to place the capsule on their tongue at the front of the mouth (Table 2-11). Very 
few participants placed the capsules either at middle or at the back of the dorsum and this was 
not associated with current issues with swallowing medications (p > 0.05). 
Table 2-10: Number of participants displaying each head position while placing the capsule before 
swallowing (n=151). 
Current swallowing issue Neutral/forward 
posture 
Extended/backward 
posture 
No 87 16 
Yes 38 10 
 
Table 2-11: Number of participants placing the capsule at each location on the tongue before 
swallowing (n=151). 
Current swallowing issue Front 
dorsum 
Middle 
dorsum 
Back 
dorsum 
No 82 13 8 
Yes 41 2 4 
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2.6 Discussion  
The prevalence of current medication swallowing issues in the 152 adult participants in this 
study, none of whom have dysphagia (as assessed by a speech pathologist), was 32%. This 
value is higher than the Australian population demographic of community pharmacy customers 
in the same city (16.5%) (Lau et al., 2015) or patients taking three or more different solid oral 
dose forms (22.5%) (Marquis et al., 2013). However it is similar to the 26% of the general 
population reported in Norwegian population (Andersen et al., 1995, Chisaka et al., 2006, 
Wright, 2002, Kottke et al., 1990) and 32% of adolescents in Denmark (Hansen et al., 2008).  
Two-thirds of participants (32%) reported crushing tablets at some time in order to make 
swallowing easier. This was more likely to have occurred for those reporting that they have 
difficulties swallowing whole tablets (53%) but was also performed by some who do not 
currently have a problem swallowing tablets whole but have had at some time in the past (14%), 
and by a small proportion (9%) of people with no history of any problems swallowing tablets. 
Reports of the prevalence of tablet crushing and splitting are variable, as they are dependent on 
the population surveyed. For example, 49% of the participants recruited through general 
practices in Germany split their tablets, but their average age was 67 and was taking an average 
of 6.3 drugs per person (Quinzler et al., 2006). For community pharmacy customers, 13% of 
tablets were subdivided or crushed for ease of swallowing in The Netherlands (Rodenhuis et 
al., 2004) and 11% of customers reported this type of modification in Australia (Lau et al., 
2015). Medications that are designed to release the drug slowly (extended release, sustained 
release, controlled release), when modified could alter drug absorption and may lead to adverse 
events or even death (Karch and Karch, 2000). Crushing and splitting immediate release tablets 
can result in dose variation that has the potential to have clinical implications (Hill et al., 2009, 
McDevitt et al., 1998, Verrue et al., 2011).  
The reporting of current medication-swallowing difficulties was significantly associated with 
having a memory of choking on whole tablets or capsules, but not a memory of choking on food 
or the presence of a gag reflex. However, when given the task of physically swallowing a 
capsule, all but four of the participants (97%) completed the task, and only one of these would 
be considered to have a medication-swallowing phobia (Macdonald et al., 2001) as the 
participant declined to swallow because of fear and vomiting sensation. Stimulation of the 
autonomic nervous system associated with anxiety results in muscle tension and inhibition of 
saliva flow, which thereby affects the swallowing process (Pluess et al., 2009). Indeed, 
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anticholinergic medications that result in oral dryness as a side effect have been responsible for 
swallowing difficulties (Stoschus and Allescher, 1993). Anxiety or fear of swallowing 
medications may arise from gagging on medication (Schiele et al., 2013, Evans and Pechtel, 
2011). Some medications, such as antibiotics, bisphosphonates, NSAID’s, quinidine, and 
aspirin can cause tissue damage when they come in contact with the oesophagus (O'Neill and 
Remington, 2003) which can leave a negative memory that may leads to avoidance of 
swallowing medications (Greenberg et al., 1988). There are also situations in which no specific 
incident can be identified as precipitating the anxiety over medication swallowing (McNally, 
1994, Macdonald et al., 2001). The fact that a significant correlation resulted from the memory 
of choking on medication but not foods indicates that swallowing of food and medications is 
conceptualised differently. 
The size of the mouth cavity was significantly associated with medication-swallowing issues. 
Participants who had larger mouth cavities (Mallimpati Class I & II) were less likely to report 
any current difficulties swallowing whole solid oral medications. Notably, the four participants 
who did not complete the capsule-swallowing task were all identified to have a small mouth 
cavity (Mallampati Class III & IV). The modified Mallampati classification is used by 
anaesthesiologists to assess the difficulty of endotracheal intubation with different oral cavity 
sizes (Lee et al., 2006, Glick et al., 2012). To our knowledge, this is the first study to investigate 
the relationship between mouth cavity size and medication swallowing issues. It is possible that 
a larger mouth cavity may support easy swallowing through less exposure to areas of high 
sensation in the mouth such as the tongue and taste buds. There are however, some limitations 
to this study. Firstly, assessments were performed by one investigator (speech pathologist) and 
addition of another different observer may give rise to alternative classifications. Secondly the 
modified Mallampati classification may be influenced by obesity and ethnicity (Lee et al., 2006) 
which were not considered in this study.  
Greater taste bud density at the front of the tongue was significantly associated with reports of 
medication-swallowing issues suggesting that subjects with increased sensory awareness could 
be sensitive to the taste of capsules/tablets. Overall, 15% of the participants were classified as 
supertasters, which was similar to the 16% of adults in a study in southern Italy (Negri et al., 
2012). Fungiform papillae density varies across the tongue (Shahbake et al., 2005, Jung et al., 
2004), but as 81% of participants placed the test capsule on the front of their tongue this was 
the most appropriate location to assess. Texture can be as important as taste in the sensory 
perception of food, and for some individuals, texture can be the reason for not liking a particular 
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type of food (Szczesniak, 1990). A positive correlation was identified for current medication 
swallowing issues with a lower preference score for potato crisps, popcorn and granola bars, 
which are hard, dry, have low moisture content and are particulate in texture. Further 
investigation into the relationship between medication swallowing issues with taste and texture 
preferences is recommended.  
It was hypothesised that people who swallow food as large particle sizes may find swallowing 
tablets easier than those who reduce food to very small particle sizes. The hypothesis was 
partially supported in that a lower proportion of participants who chewed the jelly snake to 
mostly small particles reported having current medication swallowing issues than not. However, 
50% of participants would have swallowed their snake after very little chewing and at large 
particle sizes, and there was no difference in reporting of medication swallowing issues amongst 
this group. Of more interest is that 60% of participants who produced mixed particle sizes (large 
and small) reported difficulty swallowing medications. This suggests that the homogeneity of 
the final bolus is more important than the actual particle size (small or large) generated in 
predicting tablet swallowing issues. The jelly snake was chosen as it is commercially 
manufactured, which minimises differences such as those can be observed in fresh products 
(e.g. fruit or vegetables), the chewy texture required chewing effort, and the sample did not 
disintegrate with saliva or become stuck to the teeth while resulting in a bolus that could be 
assessed easily for particle size once expectorated. However, a single product may not reflect 
an individual’s efficiency in chewing different food products, as particle size distribution is 
highly dependent on the type of food presented while inter-individual variation for particle 
reduction of a particular food type is relatively minor (Peyron et al., 2004). Furthermore, the 
choice of 4 mm was based on the upper limit of median particle size for swallowing carrots 
(Woda et al., 2010), which contrasts in taste, texture and consistency. Also, many of the 
participants reported that they felt “awkward and embarrassed” while being watched whilst they 
were chewing and spitting food into a bag which many have hindered the process of chewing 
and could have affected the data.  
The majority of the participants who believed that they found it difficult to swallow whole solid 
oral medications were able to physically swallow a size 00 capsule, as only four participants 
failed the task. This suggests that while people may choose not to swallow or to split/crush 
before swallowing as a preference, they may actually be able to swallow their medications 
whole. In this case, it is possible that the presence of the speech pathologist at the swallowing 
task provided an expectation that they should perform in a certain way, and this helped them to 
  
58 
 
overcome their psychological barrier to swallowing the large capsule. Additionally, the 
perception of ability to swallow a medication was based purely on obeservation through a 
plastic container, and did not allow participants to touch or hold each item, which may have 
reduced their anxiety around swallowing it. Participants described coping strategies used to help 
swallow tablets and capsules (Table 2-11), and indeed three of the four participants only failed 
because their preferred swallow-aid, such as a particular food item, was not available. Size, 
shape and type of oral dosage form are important determinants in the level of comfort that 
participants felt with swallowing. In the present study participants were unsurprisingly more 
comfortable to swallow small tablets/capsules compared to larger forms. More people reported 
that they would swallow the largest capsules (size 00 and 000) than the largest tablets or caplets. 
Indeed, capsules are often preferred to tablets and oesophageal transit is superior to plain oval 
or round tablets of a similar size (Channer and Virjee, 1985). The perception of colour was not 
investigated as there were previous studies reported on the relationship between colour and 
swallowing preception (Overgaard et al., 2001, Liu et al., 2016), however it is noted that a 
limitation of this study is the use of example medications that varied in colour as well as size 
and shape. The survey questions did not clearly ask for only size and shape to be considered, 
and so although none of the comments regarding reasons for thinking they would or would not 
be able to swallow a particular medication mentioned colour the possiblity exists that colour 
may have swayed their opinion. 
As the physical ability to swallow was assessed using a capsule, the number of people 
experiencing medication swallowing issues may have been different if tablets had been used 
for the test, or a capsule/tablet of different size/shape/texture or even colour (De Craen et al., 
1996). Training is an important and effective way to improve medication swallowing, 
demonstrating that it is primarily a psychological barrier, with specific training programs for 
young adults (Garvie et al., 2007) and children (Blount et al., 1984, Walco, 1986, Beck et al., 
2005, Cruz-Arrieta, 2008, Ghuman et al., 2004, Meltzer et al., 2006, Reitman and Passeri, 2008) 
having very high success ranging between 75 – 90% that is retained several months later.  
Water is an important component for medication swallowing. The volume of liquid used for 
swallowing is influenced by the size of the capsule/tablets being swallowed (Fuchs, 2009). The 
minimum recommended volume for swallowing the tablets/capsules to ensure safe transport 
through the oesophagus has been given as 50 mL based on following magnetically marked 
capsules (Channer and Virjee, 1982) and 60 mL based on videofluorscopic observation of a 
barium tablet (Channer and Virjee 1982). However 30 mL has been indicated to be the smallest 
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volume required due to observation of capsules adhering to the oesophageal membrane with 
lower volumes (Kasashi et al., 2011). Therefore, in the present study, participants using a 
quarter of the cup of water (40 mL) or more were considered to have used an adequate quantity 
of water. In this case, 62% of the participants who completed the capsule swallowing task 
(n=92/148) were considered to have used far less than that is recommended for medication 
swallowing but this was not associated with reporting of medication swallowing issues.  
In contrast to the use of water, the majority of the participants (83%) held appropriate head 
positioning during swallowing. An upright posture, (Kasashi et al., 2011, Osmanoglou et al., 
2004) and neutral head position are critical to safe medication swallowing. Swallowing with 
the head in extension can result in medication entering the lungs during swallowing; this has 
been observed in patients swallowing endoscopic capsules (Choi et al., 2010) whilst the chin-
down position promotes faster oesophageal transit time (Kasashi et al., 2011, Schiele et al., 
2014). 
2.7 Conclusion 
In conclusion, this study has determined that a third of healthy non-dysphagic adults find it 
difficult to swallow whole tablets and capsules, and a similar proportion had at some time 
crushed or split tablets/capsules in order to help swallow them. A relationship was observed 
between reported medication swallowing issues with a memory of having choked on 
medication, a greater number of taste buds and small anatomical size of the oral cavity. The 
presence or absence of the gag reflex, memory of a choking episode on food, food neophobia, 
quantity of water used to swallow medications and head posture when swallowing a capsule 
were not statistically associated with medication swallowing difficulties. In addition, there was 
no correlation between medication swallowing issues and perceptions of tablet/capsule size and 
shape, actual tablet swallowing difficulty (when asked to swallow capsules) and volume of 
water used to complete the capsule swallowing task. This study has addressed a number of 
potential reasons behind medication swallowing issues and signals that valuable insights may 
be provided by further research. 
 
  
Section B 
 
Delivering crushed medications in 
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Many people have difficulties with swallowing whole tablets and capsules. This is more likely 
to be a problem for children and elderly people. While some simply dislike swallowing solid 
dosage forms (see Chapter 2), some people suffer from dysphagia, often associated with 
conditions such as stroke, Parkinson’s, multiple sclerosis and dementia, which causes problems 
with swallowing food and liquid and so therefore oral medications.  
People having issues swallowing their medications may crush it and mix with food or drinks 
(Nissen et al., 2009, Lee et al., 1996, Gidal et al., 1998, McLean et al., 2001). For dysphagic 
patients, oral fluids are usually mixed with a thickener, which creates a bolus that is easier to 
swallow and is less likely to accidently enter the airways. Thickened fluids are an essential tool 
for safe swallowing and have been used therapeutically for many years (Cichero, 2013). In an 
in vitro study in our laboratory, drug dissolution was consistently reduced when tablets 
(amlodipine, atenolol, carbamazepine, warfarin) were crushed and mixed with commercially 
available thickened fluids, and this was a particular problem with products consisting primarily 
of xanthan gum (Manrique-Torres et al., 2014). It was observed that mixing crushed tablets 
with thickened fluids caused prolonged dissolution time compared to other mixers (water, jam, 
yogurt, honey and juice) and compared to dissolution of the whole tablet.  
Section B of this thesis describes the first study conducted to investigate the effect of thickened 
water on drug absorption. Based on the in vitro data, we hypothesise that the rate of drug 
absorption will be significantly slowed, and the maximum drug concentration reached will be 
reduced when a drug is crushed and mixed with the thickened fluid in comparison to the whole 
tablet, crushed tablet delivered in water, and crushed tablet mixed with jam.  
Paracetamol is used as the model drug because it is widely used and considered to be very safe 
at standard doses. Paracetamol absorption pharmacokinetics are assessed by quantifying 
paracetamol levels in saliva; earlier studies have established that good correlation exists 
between paracetamol in saliva and venous blood (Adithan and Thangam, 1982, Wade et al., 
2008, Sanaka et al., 2000), and quantification of paracetamol in saliva is well established 
(Schaiquevich et al., 2002). Additionally, saliva presents a low risk and economical approach 
that does not require trained personnel for collection (Mullangi et al., 2009).  
Intra-individual variation has been shown to be insignificant using blood samples (Paintaud et 
al., 1998) but there are no studies available to describe intra-individual variation using saliva. 
Therefore Chapter 3 describes the assessment of the inter- and intra-individual variability as 
coefficient of variation (CV) in salivary paracetamol concentrations in healthy individuals. In 
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Chapter 4 the rate of drug absorption in healthy individuals is assessed using salivary 
paracetamol when tablets are crushed and delivered with water, crushed and delivered with jam, 
or crushed and delivered with thickened water. Subsequently, in Chapter 5, an approach usually 
used to compare bioavailability of different dosage forms, in vitro–in vivo correlation (IVIVC), 
is used to assess whether in vitro data can be used as a good predictor of in vivo performance 
of paracetamol when tablets are crushed and mixed with thickened fluids. 
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3 Intraindividual variability of salivary paracetamol pharmacokinetics in healthy 
volunteers 
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3.1 Introduction 
Ideally, non-invasive methods such as saliva sampling would be used to determine drug levels 
in the blood to avoid venepuncture. Patient discomfort, skin irritation and risk of infections can 
be avoided, skilled medical staffs are not required for the collection, and collection and 
processing are less costly. Although the use of saliva seems to possess a number of advantages 
over other biological matrices for monitoring drug levels, there are also some potential issues. 
Some factors that could affect the quantity of saliva are changes in salivary pH, contamination 
due to smoking, snorting drugs, oral ingestion of food and chewing habits (Kaufman and 
Lamster, 2002, Hofman, 2001, Mullangi et al., 2009). Hence, the use of saliva as an alternate 
to plasma is being extensively studied (Greenaway et al., 2011, Lins et al., 2007, Ibarra et al., 
2010).  
Paracetamol is a suitable drug for saliva analysis. It has a weak base (pKa = 9.5), low molecular 
weight, and negligible protein binding (Forrest et al., 1982). Saliva can be used to quantify 
paracetamol levels; however, the metabolites cannot be detected (Rittau and McLachlan, 2012). 
Paracetamol is a popular medication used for treating fever, headaches, and mild pain in adults 
and children as well as having uses in post-operative and orthopaedic pain management (Toms 
et al., 2008). 
The pharmacokinetics (PK) of paracetamol has been measured using a number of biological 
matrices including blood plasma, urine, and saliva (Jensen et al., 2004, Rittau and McLachlan, 
2012). Distribution of paracetamol between plasma and saliva via the salivary glands is very 
well established, with several studies showing a significant correlation between plasma and 
saliva levels (Adithan and Thangam, 1982, Wade et al., 2008, Sanaka et al., 2000, Schaiquevich 
et al., 2002). In addition, studies have shown higher levels during the first 50 minutes after the 
administration of paracetamol followed by constant levels during the elimination phase for both 
saliva and plasma (Adithan and Thangam, 1982, Kamali et al., 1987b). 
Although there are several studies comparing the levels of paracetamol between saliva and other 
biological matrices (Rittau and McLachlan, 2012), no studies have compared the inter- and 
intra-individual variability of paracetamol in saliva till date. Therefore, the aim of this study 
was to evaluate inter- and intra-individual variability of paracetamol PK using saliva. 
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3.2 Methods 
3.2.1 Subjects 
An email invitation to join the trial was sent to all staff and postgraduate students within the 
School of Pharmacy, University of Queensland, Australia. Volunteers were asked to sign an 
informed consent form before commencing screening. This study was approved by the 
University of Queensland Medical Research Ethics Committee (Approval No: 2012001319). 
Demographic information including current medical conditions, allergies, and any pre-existing 
medical conditions were collected. Volunteers who were smokers, pregnant or had known 
allergies to paracetamol were excluded from the trial. All the participants were healthy, had no 
contraindicating medical condition and were not on any other medication during the study 
period. Healthy volunteers (n=20), of whom 10 were male and 10 were female, were recruited. 
The average age of the subjects was 31.03 ± 5.1 (mean ±SD; range 24 – 45) years, body weight 
67.50 ± 11.6 (range 50 – 95) kg and height 169.40 ± 7.8 (156 – 183) cm. All subjects were 
asked not to consume paracetamol during the 24 hours prior to the study, refrain from drinking 
coffee or tea in the morning and asked to fast 2 hours before the trial. 
3.2.2 Trial design 
All participants received paracetamol (2 x 500 mg Panadol, GlaxoSmithKline, NSW, Australia) 
as whole tablets with 250 mL of water on two occasions separated by a washout period of 
between 3 and 7 days. Following swallowing, participants brushed their teeth with an electronic 
toothbrush for 4 minutes. Participants were then confined to a room for 2 hours to restrict 
activity to reduce Intra- and inter-individual variability in paracetamol levels. At 2 2-hours 
marks, a snack voucher was provided, and participants commenced their normal level of activity 
and diet. Saliva samples were collected at the intervals 10 min, 15 min, 20 min, 30 min, 40 min, 
50 min, 1 hour, 1 hour 20 min, 1 hour 40 min, and 2, 3, 4, 6, and 8 hours.  
3.2.3 Saliva collection 
The Salivette® (Sarstedt AG & Co, Nümbrecht, Germany) citric acid-treated saliva collection 
device was used to collect saliva samples (Figure 3-1). The citric-acid treated absorbent cotton 
pad was placed inside the participant’s mouth and chewed for 45 sec, and the pad was replaced 
into the polypropylene tube to be centrifuged (2 min at 500 x g) according to the manufacturer’s 
protocol. The recoverable saliva after centrifuge ranged between 0.8 mL – 1.4 mL (as 
recommended by the manufacturer). Samples were stored at -80ºC for subsequent analysis. 
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Figure 3-1: Salivette® saliva collection device 
3.2.4 Paracetamol assay 
Paracetamol levels in saliva were measured using a high-performance liquid chromatography 
(HPLC) method (Borin and Ayres, 1989). Samples (225 µL) were mixed with 230 µL of 80 
µg/mL 2-acetamidophenol as the internal standard (Sigma-Aldrich Co, MO 63103, USA). 
Salivary proteins were precipitated by adding 45 µL of 70% perchloric acid and centrifuging 
the mixture at 1000 G. The supernatant was injected through a guard column into an Alltima® 
(Grace Materials Technologies, Vic, Australia) HP C18 column (250 x 4.6 mm, 5 µm) and 
absorbance was measured at a wavelength of 254 nm. The mobile phase was 25% methanol in 
distilled water at 1 mL/min. Calibration standards with 8 points were run for each batch of 
samples and were linear between 0 µg/mL and 20 µg/mL, with a limit of detection of 0.5 µg/mL. 
Coefficient of variation (CV) between three different days for the standard curve was 4% and 
9% at 20 µg/mL and 5 µg/mL respectively. 
3.2.5 Data analysis 
Pharmacokinetic parameters were estimated using the salivary concentration–time profile, and 
a standard model-independent approach was used. Total area under the curve to the time at 
which the last sample was taken (AUC(0-8 h),Saliva), maximum salivary concentration (Cmax), time 
maximum for the peak (tmax) and elimination half – life (t1/2) were calculated using the linear 
trapezoidal rule method. Non-compartmental pharmacokinetic analysis was conducted using 
Phoenix® WinNonlin® (Build 6.3.0.395). 
Intra- and inter-individual variation in these parameters were estimated using one-way analysis 
of variance (one-way ANOVA, Microsoft Excel 2010, USA). Intra- and inter-individual 
variability in these parameters were expressed as coefficient of variation (CV). Coefficient of 
variation for intra-individual variation (CVW) and inter-individual variation (CVB) were 
calculated as:  
𝐶𝑉𝑊 =  
√𝑀𝑆𝑊
?̅?
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𝐶𝑉𝐵 =  
√(𝑀𝑆𝐵 −  𝑀𝑆𝑊)/𝑛0
?̅?
 
where MSW is the mean sum of squares within subjects, MSB is the mean sum of squared 
between subjects, ?̅? is the overall mean for all observation and n0 is the number of replicates 
per subject (in this case, two); absolute values were used for this analysis (Sjovall et al., 1986). 
Non-parametric Wilcoxon’s signed-rank test (XLSTAT Version 2015.2.01.17149, Addinsoft 
NY10001, USA) was used to look for any significance between intra-individual difference 
between days 1 and 2.  
3.3 Results 
The mean time course of saliva concentration of the 20 participants was similar between the 
days (Figure 3-2). Calculation of PK parameters for each individual’s paracetamol absorption 
produced concentration maximum (Cmax) values that ranged between 4.08 - 12.26 µg/mL on 
day 1 and 4.03 - 15.38 µg/mL on day 2 (Figure 3-3a), resulting in mean values of 7.48 µg/mL 
and 7.95 µg/mL for day 1 and day 2, respectively (Table 3-1). The time at which these maxima 
were obtained (tmax) varied widely, ranging from 0.25 to 2 hr on day 1 and from 0.25 to 1.67 hr 
on day 2 (Table 3-2, Figure 3-3b), leading to similar average values of 0.80 and 0.65 hr on day 
1 and 2 respectively (Table 3-1). Intra-individual CV was very high for Cmax (37%) and tmax 
(67%) whereas inter-individual CV was lower (Table 3-1).  
The area under the peak, calculated to the time at which the last saliva sample was taken (AUC(0-
8 h),Saliva) were very similar between the two days, ranging from 9.67 – 27.33 and 8.99 -29.34 
µg*h/mL (Figure 3-4), and both having a mean of 16 µg*h/mL (Table 3-1). As seen with Cmax 
and tmax, AUC(0-8 h),Saliva was associated with higher coefficient of variation between days (intra-
individual at 31%) than between people (inter-individual at 21%). However, for all of these PK 
parameters (Cmax, tmax, and AUC(0-8 h),Saliva), there were no statistically significant differences 
between day 1 and day 2 when compared using Wilcoxon’s signed-rank test. 
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Figure 3-2: Saliva paracetamol concentration (Mean ± SD) following the oral administration of 2 
x 500 mg paracetamol on two different occasions separated by at least 3 days in 20 healthy 
volunteers. 
 
Table 3-1: Pharmacokinetic parameters for salivary paracetamol following oral dosing of 2 x 500 
mg whole tablets on two different occasions separated by at least 3 days in 20 healthy volunteers. 
Parameters shown are the coefficient of variation (CV), time to peak plasma concentration (tmax), 
peak plasma concentration (Cmax), area under the curve to the last sample taken (AUC(0-8 h),Saliva) 
and half-life (t1/2). 
PK parameters Day 1 Day 2 Intra-individual  
% CVW 
Inter-individual  
% CVB 
Cmax (µg/mL) 7.48 ± 2.88 7.95 ± 2.76 37 25 
AUC(0-8 h),Saliva 
(µg*hr/mL) 
16.29 ± 4.72 16.05 ± 5.13 31 21 
tmax (hr) 0.80 ± 0.60 0.65 ± 0.40 67 11 
t1/2 (hr) 2.13 ± 0.477 2.19 ± 0.63 43 31 
  
 
 
Time (hr)
0 2 4 6 8
P
a
ra
c
e
ta
m
o
l 
c
o
n
c
e
n
tr
a
ti
o
n
 (
g
/m
l)
0
1
2
3
4
5
6
7
Day 1 
Day 2 
  
69 
 
Table 3-2: The median and range for the pharmacokinetic parameter tmax (n=20), measured in 
hours, following single-dose administration of paracetamol tablets 2 x 500 g (whole tablets) on Day 
1 and Day 2 
Parameters Whole tablets 
Day 1 
Whole tablets 
Day 2 
median 0.67 0.50 
range 0.33 – 2 0.25 – 1.67 
 
 
Figure 3-3: Individual values of (a) maximum plasma concentration reached (Cmax) and (b) time 
at which the maximum concentration was reached (tmax) on two different days of paracetamol (1 
g) oral administration. Data for each individual are connected by a line. 
 
 
Figure 3-4: Individual values of the area under the curve until the last saliva sample was taken 
(AUC(0-8 h),Saliva) on to two different days of paracetamol (1 g) oral administration. Data for each 
individual are connected by a line. 
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3.4 Discussion 
The current study looked at the intra- and inter-individual variation in salivary PK of 
paracetamol oral immediate release tablets in healthy subjects. In this study, we compared three 
PK parameters: total exposure (AUC), peak exposure (Cmax), and time to reach maximum 
concentration (tmax).  
The total exposure of the drug (AUC) is dependent on clearance, dose and bioavailability (F) 
such that AUC = F x Dose/Clearance. Intra- and inter-individual variability (as coefficient of 
variation, CV) for AUC was less than 30%, which classifies it as a less variable drug according 
to the FDA (FDA, 2006). Variability in AUC may have been influenced by age, sex, weight 
and ethnicity, all of which varied between participants in this study, and yet AUC using saliva 
had low variability. Plasma protein binding can influence drug saliva levels by altering 
distribution into saliva, body tissues and fluids (Liu and Delgado, 1999), however at therapeutic 
concentrations paracetamol does not bind to plasma proteins and only 15-20% is bound with 
overdose (Forrest et al., 1982).  
The peak paracetamol concentration measured in saliva (Cmax) for the present study (4.0 – 15.4 
µg/mL) was in agreement with salivary paracetamol concentrations in other studies (5 – 18.5 
µg/mL) (Sanaka et al., 2000, Schaiquevich et al., 2002). Cmax and tmax are dependent on the 
extent and the rate of drug absorption, and measurement of these is influenced by the number 
of samples collected for analysis. In this study, measurements were made over an 8 hr period 
with frequent sampling for the first 50 minutes, which is more frequent than that used in other 
studies measuring salivary paracetamol (Kamali et al., 1987a, Rittau and McLachlan, 2012, 
Sanaka et al., 2002).  
Absorption of paracetamol is affected by various factors. First-pass metabolism, distribution in 
the body fluids, gastric emptying cycle, food, diurnal variation, posture and drug interaction 
could influence paracetamol levels (Medhus et al., 2001, Willems et al., 2001). Also, it has been 
reported that the absorption of paracetamol is reduced in vegetarians (Prescott et al., 1993). 
While posture does not influence the AUC, it can influence the absorption phase of the drug 
(Queckenberg and Fuhr, 2009). In this study CV for Cmax was slightly higher (37%) than the 
30% recommended for less variable drugs (FDA, 2006). A strict protocol was followed and the 
subjects were requested to be seated for the first 2 hrs of the study, but some subjects were 
observed to move around, which could have influenced the Cmax variability.  
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Time to reach maximum concentration (tmax) is known to have high variability, being between 
0.25 hr – 3 hrs in the fasted state when different brands of paracetamol were administered on 
healthy volunteers and plasma concentrations were measured (Sevilla-Tirado et al., 2003). A 
similarly large range (0.44 – 2.0 hrs) for tmax has been observed when saliva was used for 
measuring paracetamol levels (Sanaka et al., 2002) hence the values of 0.25 – 2 hrs seen in the 
present study is not totally unexpected. Consequently, tmax is not used often as a comparator in 
bioequivalent studies (Qiu et al., 2009).  
Studies have shown a good correlation between saliva, capillary and serum plasma levels for 
paracetamol (Rittau and McLachlan, 2012). However, paracetamol levels could be influenced 
by the method of saliva collection, pH of saliva, flow rate, existing pathophysiology of the oral 
cavity, and the physiochemical properties of the drug (Kaufman and Lamster, 2002, Liu and 
Delgado, 1999). Also, studies have shown that stress and hydration may influence the flow rate 
of saliva (Kaufman and Lamster, 2002, Ship and Fischer, 1997), and intra-individual variation 
in saliva production when stimulated using citric acid ranges between 17% and 23%, which 
may also influence the drug concentration measured in saliva (Burlage et al., 2005, Blomgren 
and Hasseus, 2009).  
3.5 Conclusion 
In conclusion, no significant differences in PK parameters were found in healthy volunteers 
who received an oral dose of 1 g paracetamol as whole tablets on two different days. Hence 
measurement of saliva concentrations is a suitable method to evaluate paracetamol PK.  
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4 Delivering crushed paracetamol tablets using thickened fluids: does it alter the 
pharmacokinetics? 
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4.1 Introduction 
For people who find it difficult to swallow whole tablets and capsules, finding an alternate 
dosage form, or alternative medication that is available in a different dosage form, can be 
challenging. Consequently tablets and capsules are often crushed by patients, caregivers, and 
medical staff to enable the medication to be swallowed. While crushing extended-release 
dosage forms is well recognised to result in potentially harmful dose dumping and faster 
absorption (Martinez and Amidon, 2002, Fleisher et al., 1999, Cleary et al., 1999, El-Gazayerly, 
2003, Charatan, 2001, Schier et al., 2003), crushing immediate-release tablets with wide 
therapeutic indices is generally viewed as being low impact and little cause for concern 
(Burridge et al., 2011). In support of this, voriconazole tablets did not show a significant change 
in their bioavailability when crushed and administered with water (Dodds Ashley et al., 2007). 
However, for medications with a low therapeutic index such as digoxin, or warfarin, even a 
minor fluctuation in bioavailability can result in sub-therapeutic or toxic drug levels (Penrod et 
al., 2001).  
Modified drugs are often mixed with food, such as applesauce, jam, honey, custard and yoghurt 
(Nissen et al., 2009). Mixing with fruit juice, such as grapefruit, orange, or apple juice, is known 
to affect absorption and can result in a decrease or increase in drug bioavailability (Bailey, 2010, 
Boullata, 2004). In addition, crushing and mixing with foods such as yoghurt and pudding has 
been reported to reduce the absorption of phenytoin and didanosine (Jann et al., 1986, Damle 
et al., 2002) and chocolate pudding increased absorption of gabapentin (Gidal et al., 1998) in 
comparison to whole tablets. There is also the issue of drug stability within the matrix used for 
crushed tablet delivery, with some preliminary data indicating that certain drugs may be 
unstable over short time periods (e.g. 4 h) in products such as jelly and peanut butter (Peloquin 
et al., 2007). 
For dysphagic patients, crushed tablets may be mixed with thickened fluids, which are given to 
patients in place of water for hydration (Cichero, 2013). The effect of mixing crushed tablets 
with thickened fluids on drug absorption has not been studied. Administering crushed 
telithromycin tablets with Ensure nutrient drink, which contains small quantities of viscosity 
enhancing carageenan and cellulose gums, maintained bioequivalence to the whole tablet 
(Lippert et al., 2005). However, absorption of digoxin, penicillin and metformin tablets were 
reduced when taken with guar gum, used as a source of dietary fibre in diabetic patients (Gin et 
al., 1989, Huupponen et al., 1984). 
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In in vitro tests, drug dissolution was consistently reduced when tablets (amlodipine, atenolol, 
carbamazepine, warfarin) were crushed and mixed with water thickened with commercially 
available thickeners, especially those consisting primarily of xanthan gum (Manrique-Torres et 
al., 2014). It was observed that mixing crushed tablets with water thickened to the thickest level 
prescribed for dysphagia in Australia (level 900) prolonged dissolution time compared to other 
mixers (water, jam, yogurt, honey and juice) and compared to dissolution of the whole tablet. 
Similar results were observed for crushed paracetamol mixed with water thickened with a 
xanthan gum thickener (Easythick Advanced, Flavour creations, Tennyson, QLD, Australia), 
whereby only 36% of drug was released from the thickener in the first 30 mins of the dissolution 
test and the maximum achieved in 3 hours was 80% (Chapter 5).  
The aim of this study was to investigate whether altered dissolution measured in vitro translates 
into an alteration in drug absorption in vivo. Based on the in vitro data, we hypothesised that 
the rate of drug absorption will be slowed, and the peak concentration and overall systemic 
exposure will be reduced when a drug is crushed and mixed with thickened water for 
swallowing. This is the first study conducted to investigate the effect of thickened water on the 
pharmacokinetic profile (i.e. rate and extent of drug absorption). Paracetamol was chosen as a 
model drug because it is widely used and considered to be very safe at standard doses, and 
concentrations in saliva can be used as a surrogate for blood levels (Adithan and Thangam, 
1982).  
4.2 Methods 
4.2.1 Subjects 
This study was approved by the University of Queensland Medical Research Ethics Committee. 
An email invitation to join the trial was sent to all the staff and postgraduate students from the 
School of Pharmacy, University of Queensland, Australia. Volunteers were asked to sign an 
informed consent form before commencement of screening. Demographic information 
including current medical condition, allergies, and pre-existing medical conditions were 
collected. Volunteers who were smokers, pregnant or had known allergies to paracetamol were 
excluded from the trial. A total of 20 healthy volunteers, both male and female, were recruited. 
All the participants were healthy, had no contraindicating medical condition during the study 
period.  
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4.2.2 Trial design 
Participants attended the study on four occasions for the cross-over trial, with each visit spaced 
at least three days apart. Participants were asked not to consume paracetamol during the 24 
hours before the study, refrain from drinking coffee or tea in the morning and asked to fast 2 
hours before the trial. Participants received one of the following four treatments at each visit, 
each involving immediate release paracetamol tablets (2 x 500 mg, Panadol, GlaxoSmithKline, 
NSW Australia) (FDA, 2014). The order in which they received the treatments was randomized. 
 Treatment 1 (Whole tablets): Whole tablets, swallowed whole with 250 mL of water. 
 Treatment 2 (Crushed tablets with water): Tablets that were crushed and mixed with 100 
mL of water, followed by 150 mL water used to rinse the mouth before swallowing. 
 Treatment 3 (Crushed tablets in thickened water): Tablets that were crushed and mixed with 
15 g water thickened to level 900, with EasyThick Advanced, followed by 250 mL water 
used to rinse the mouth before swallowing. 
 Treatment 4 (Crushed tablets in jam): Tablets that were crushed and mixed with strawberry 
jam (15 g), followed by 250 mL of water used to rinse the mouth before swallowing. 
Table 4-1 describes the physicochemical characteristics and rheological attributes of the vehicle 
used in this study. 
Table 4-1: Physicochemical characteristics and rheological attributes of the vehicles used in this 
study (Manrique-Torres et al., 2014) 
Vehicle Brand 
 
Composition Thickness pH Density Viscosity 
(cP) 
Easythick 
Advanced 
Flavour 
Creations 
maltodextrin, 
xanthan gum, 
vitamin C,  
calcium chloride 
Level 900 4.4 1.01 1250 
Level 400 4.8 1.00 414 
Level 150 4.8 1.00 176 
Jam 
 
Golden 
Circle 
strawberries, 
pectin, food acids, 
natural colour, 
sugar 
 3.0 1.32 3120 
 
The 250 ml water was provided for each treatment to enable extensive rinsing (with swallowing) 
to remove paracetamol powder from the oral mucosa. In addition, immediately after treatment 
administration participants cleaned their teeth using an electronic toothbrush for 4 minutes. 
Participants were then confined to a room for 2 hours to restrict activity in order to reduce intra- 
and inter-individual variability in paracetamol levels (Vance et al., 1992; Renwick et al., 1992). 
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After two hours, a snack voucher was provided, and participants commenced normal activity 
and diet. Saliva samples were collected before swallowing the paracetamol and at 5 min, 10 
min, 15 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1 hour 20 min, 1 hour 40 min, 2, 3, 4, 6, 
and 8 hours after treatment administration. Where sample time varied from this schedule the 
actual time of collection was used. 
4.2.3 Saliva collection 
The Salivette® citric acid-treated saliva collection device was used to collect saliva samples 
(Figure 3-1). The citric acid treated absorbent cotton pad was placed inside the participant’s 
mouth and chewed for 45 sec, and the pad replaced into the polypropylene tube for centrifuging 
(2 min at 500 x g) according to manufacturer’s protocol. Samples were stored at -80ºC for 
subsequent analysis. 
4.2.4 Paracetamol assay 
Paracetamol levels in saliva were measured using a high-performance liquid chromatography 
(HPLC) method (Borin and Ayres, 1989). Samples (225 µL) were mixed with 230 µL of 80 
µg/mL 2-acetamidophenol as the internal standard (Sigma-Aldrich Co, MO 63103, USA). 
Salivary proteins were precipitated by adding 45 µL 70% perchloric acid and centrifuging at 
1000 G. The supernatant was injected through a guard column into an Alltima® HP C18 column 
(250 x 4.6 mm, 5 µm) and absorbance measured at a wavelength of 254 nm. The mobile phase 
was 25% methanol in distilled water at 1 mL/min. Calibration standards were run for each batch 
of samples and were linear between 0 µg/mL and 20 µg/mL, with a limit of detection of 0.5 
µg/mL. The coefficient of variation (CV) between days for the standard curve was 2% and 4% 
at 20 µg/mL and 5 µg/mL respectively. 
4.2.5 Data analysis 
Pharmacokinetic parameters were estimated using the salivary concentration–time profile, and 
a standard model-independent approach was used. Total area under the curve to the time at 
which the last sample was taken (AUC(0-8 h),Saliva), maximum salivary concentration (Cmax), time 
maximum for the peak (tmax) and elimination half – life (t1/2) were calculated using the linear 
trapezoidal rule method. The non-compartmental pharmacokinetic analysis was conducted 
using Phoenix® WinNonlin® (Build 6.3.0.395).  
Bioequivalence in paracetamol exposure (Cmax and AUC(0-8 h),Saliva) between the reference 
(whole tablet) and various test treatments (crushed tablet with water, crushed tablet in jam, and 
crushed tablet in thickened water) was tested by determining if the 90% confidence interval 
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(CI) for the point estimate of the geometric mean ratio between of the test and reference were 
within the range of 80% – 125% (FDA, 2001). An ANOVA was used to test the significance of 
the treatment and period effects. Significant differences in tmax were assessed using a non-
parametric approach using a Kruskal-Wallis rank sum test with Dunn’s pairwise comparisons 
with a significance level of 0.05 (XLSTAT Version 2015.2.01.17149, Addinsoft NY10001, 
USA). 
4.3 Results 
The 20 healthy adults who took part in this study (Table 4-2) were aged between 24 and 45 
years, with 10 males (27-39 years, mean age of 30 years) and 10 females (23-44 years, mean 
age of 32 years). The males had an average weight of 73 kg and height of 172 cm, and the 
females averaged at 63 kg and 164 cm. 
Table 4-2: Demographics of the trial participants. 
Demographic Variable (Unit) Mean ± std dev Range Median 
Age (y) 31.5 ± 5.5 24-45 20 
 Height (cm) 168.1 ± 7.4 156-183 170 
Body Weight (kg) 68.0 ± 12.1 50-95 67.5 
BMI (kg/m2) 24.1 ± 4.3 16-33 22.9 
 
Following administration of all treatments, paracetamol was rapidly absorbed with maximum 
concentrations achieved within 1 hr of dosing, as shown by the concentration-time profile 
plotted as an average of the 20 participants (Figure 4-1). 
The mean peak concentration (Cmax) of paracetamol ranged between 5.62 – 8.00 µg/mL (Table 
4-2) and this was reached (tmax) in a mean time of between 28 mins to 1 hr and a median of 20 
mins to 45 min (Table 4-2). The highest Cmax and shortest tmax were associated with crushed 
tablets administered with water while the lowest Cmax and longest tmax were associated with the 
delivery of crushed tablets in thickened water. 
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Table 4-3: Pharmacokinetic parameters of salivary paracetamol following single-dose 
administration of reference paracetamol tablets 2 x 500 g (whole tablets) and test formulations of 
paracetamol tablets 2 x 500 g crushed and mixed with water, thickened water or jam. Data for 
Cmax, AUC(0-8 h),Saliva and t1/2 show mean ± standard deviation of 20 healthy subjects, data for tmax 
show mean with median in brackets. 
 Whole tablets Crushed tablets 
 Water Thickened 
water 
Jam 
Cmax (µg/mL) 6.95 ± 2.89 8.00 ± 3.15 5.62 ± 2.12 6.93 ± 2.32 
AUC(0-8h),Saliva 
(µg/mL*hr) 
16.11 ± 4.90 16.75 ± 5.84 15.61 ± 4.09 15.07 ± 4.21 
t1/2 2.32 ± 0.45 2.33 ± 0.60 2.74 ± 0.77 2.32 ± 0.68 
tmax (hr) 0.95 (0.75) 0.56 (0.33) 1(0.67) 0.46 (0.33) 
 
 
Figure 4-1: Salivary plasma concentration-time profile (mean of 20 healthy subjects) of 
paracetamol following a single dose of 1 g taken as whole tablets (2 x 500 g), or crushed and 
delivered with water, jam or thickened water. 
The statistical analysis of treatment comparisons for Cmax and AUC(0-8 h),Saliva between the whole 
paracetamol tablets, used as a reference formulation, and the three test formulations, crushed 
tablets with water, crushed tablets in jam and crushed tablets in thickened water, is shown in 
Table 4-3. For the pharmacokinetic parameter AUC(0-8 h),Saliva, the 90% confidence limits for the 
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mean ratios of the three test formulations relative to the whole tablet, were all within the limits 
of 80% – 125% indicating that they are bioequivalent. For Cmax, the 90% confidence limits for 
crushed tablets in jam may be regarded as bioequivalent to whole tablet, but crushed 
paracetamol with water had an upper range that exceeded the recommended limit of 125%, and 
the crushed tablets with thickened water had a lower value that was below the recommended 
limit of 80%, so these two formulations were not bioequivalent to the whole tablet. 
Table 4-4: Summary statistics for paracetamol pharmacokinetic parameters Cmax and AUC(0-8 
h),Saliva following single-dose administration of reference paracetamol tablets 2 x 500 g (whole 
tablets) and test formulations of paracetamol tablets 2 x 500 g crushed and mixed with water, 
thickened water or jam. 
Parameter Geometric Least Square Means  (T/R) 
Ratio 
(%) 
90% CI limits Power 
(%) 
Reference Test 
Cmax 
Whole 7.08 Crushed + water 7.87 111.21 93.70 – 132.00 69 
Whole 7.08 Crushed + 
thickened water 
5.24 73.99 61.95 – 88.37 67 
Whole 7.08 Crushed + jam 6.66 94.16 79.64 – 111.33 71 
        
AUC(0-8 
h),Saliva 
Whole 16.61 Crushed + water 16.92 101.89 93.66 – 110.84 100 
Whole 16.61 Crushed + 
thickened water 
15.98 96.21 88.17 – 104.99 99 
Whole 16.61 Crushed + jam 15.47 93.11 85.75 – 101.10 100 
 
Non-parametric analysis of tmax indicated a significant difference amongst the comparison 
treatments, which was associated with crushed tablet with jam or with water being different to 
the crushed tablet with thickened water and the whole tablet (Table 4-4). Significant difference 
was observed between the crushed tablet delivered with thickened water in comparison to 
crushed tablet with water (p = 0.002) or with jam (p = 0.005). Similarly, there was a significant 
difference between tmax for whole tablets with crushed tablet with water (p = 0.001) and with 
jam (p = 0.003). 
4.4 Discussion 
This study tried to investigate the pharmacokinetic effects of crushing paracetamol tablets and 
mixing with thickened water for oral delivery. In vitro studies have demonstrated the drug 
dissolution is restricted when mixed with thickened water, and we suspected that this could 
translate into an alteration in drug absorption in vivo.  
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Table 4-5: The median and range for the pharmacokinetic parameter tmax (n=20) following single-
dose administration of reference paracetamol tablets 2 x 500 g (whole tablets) and test 
formulations of paracetamol tablets 2 x 500 g crushed and mixed with water, thickened water or 
jam. Values with different superscript letters were significantly different according to multiple 
pairwise comparisons using Dunn’s procedure (P<0.05). 
Parameters Whole tablets Crushed tablets 
  Water Thickened water Jam 
tmax (hr) 
(median) 
0.75a 0.33b 0.67a 0.33b 
tmax (hr) 
(range) 
0.25 - 2 0.08 – 3 0.25 – 3 0.08 – 1.33 
 
Crushing paracetamol and mixing with water or thickened water resulted in a formulation that 
was not bioequivalent to the whole tablet. Crushed tablets taken with water had a higher Cmax 
than whole tablets, and reached that maximum in a shorter time (tmax). Crushed tablets with 
thickened water had a lower Cmax, though tmax was similar to whole tablets. Delivering crushed 
tablets with jam had a similar Cmax but a shorter tmax than the whole tablet. No significant 
difference in the total quantity of paracetamol absorbed (AUC(0-8 h),Saliva) was detected during 
the 8 hr study. 
Water was administered with whole tablets and with crushed tablets. Absorption of paracetamol 
predominantly occurs in the small intestine rather than the stomach (Forrest et al., 1982). Gastric 
emptying of liquids is 10 to 40 mL/min in an empty stomach (Fisher et al., 1982) and can happen 
immediately after administration of liquids (Hellström et al., 2006). The presence of a solid 
(food) component can delay gastric emptying (Fisher et al., 1982). Therefore, in addition to the 
drug being expected to dissolve faster from a crushed than a whole tablet, crushed paracetamol 
administered with 250 mL of water may result in the dispersed drug being cleared immediately 
from the stomach. 
The current study also investigated the effect of co-administering jam with crushed 
paracetamol. In an in vitro study jam delayed dissolution of crushed amlodipine, 
carbamazepine, and warfarin in comparison to whole and crushed tablets (Manrique-Torres et 
al., 2014). In the present in vivo study, crushing and mixing with jam was associated with a Cmax 
that was lower than delivering with water but similar to the whole tablets. The main ingredients 
of jam are fruit puree, sugar, acids, and pectin; the concentration of pectin needed to maintain 
jam consistency is between 0.1 to 0.4% (Endreß and Christensen, 2010). Due to its ability to 
form gels consisting of a cross-linked polymer network, pectin has been investigated for use in 
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sustained release formulations with carboxymethyl cellulose, but in higher concentrations 
(Thakur et al., 1997). The low concentrations of pectin present in jam, along with other 
components such as fruit and sugar, in addition to delivery with 250 mL water, did not cause a 
delay in paracetamol release in vivo.  
Crushed medications mixed with thickened water may be provided to people with dysphagia 
(Burridge et al., 2011). Water thickened to level 900, the thickest level prescribed for dysphagic 
patients in Australia, was associated with a large effect on drug release for all four medications 
tested in vitro and products containing xanthan gum were the worst performers (Manrique-
Torres et al., 2014). A xanthan gum based thickener was used in the present study, and it caused 
Cmax to be significantly lower in comparison to whole tablet. The highly ordered xanthan gum 
network traps drug molecules within it and slows drug release and is used as an excipient in 
sustained release formulations (Talukdar and Kinget, 1995). 
There are some limitations in the present study. Firstly, measurement of paracetamol levels in 
saliva is dependent on the participants removing residual paracetamol after swallowing the dose 
and before the first sample at 5 minutes. Participants rinsed and swallowed 250 mL of water 
and, then brushed their teeth, with spitting out and rinsing, for 4 minutes. This design was based 
on preliminary tests in 3 adults in which 4 minutes of brushing and rinsing resulted in the 
concentration of paracetamol in saliva and capillary blood being very low when measured at 5 
minutes in comparison to the subsequent large increase associated with paracetamol absorption. 
However, variation in brushing techniques could have influenced oral contamination of saliva 
samples and without blood samples it is not possible to assess its role. When paracetamol 
powder dispersed in a nutrient drink was held in the mouth for 1 minute, oral contamination 
was believed to have affected salivary paracetamol measurements and affected reliability of the 
readings for up to 15 minutes (Sanaka et al., 2000). Furthermore, the use of 250 mL of water is 
not representative of what happens in practice for dysphagic patients using jam or thickened 
fluids to take their medicines, and may have altered the clearance from the stomach. Secondly, 
the exact time that each sample was taken was not recorded in the present study, which may 
reduce the accuracy of the PK parameters calculated. However, the sampling schedule was 
attended by the researcher and the participants kept to time well. Additionally, this study was 
conducted on healthy volunteers, so the extension to dysphagic people may be limited because 
both swallowing dynamics and paracetamol PK parameters may be expected to be altered in 
populations with co-morbidities. 
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No significant difference in total exposure to paracetamol (AUC(0-8 h),Saliva) was found, and 
although significant, the alterations in Cmax and tmax were small and unlikely to result in a clinical 
effect for this particular drug. This is in sharp contrast to published in vitro data using the same 
thickener (Manrique-Torres et al., 2014) from which a large and highly significant effect on 
drug absorption might be expected. The push and pull within the oral cavity for the bolus to 
mix with the saliva and to transfer the bolus to the pharynx (Kieser et al., 2011), and the force 
required to swallow and move the bolus through the oesophagus could have altered the viscosity 
of the bolus (Kong and Singh, 2008). This could have influenced the in vivo dissolution and 
absorption of the paracetamol when it was mixed with jam and thickened water. The ability of 
the standard in vitro dissolution test to predict in vivo bioequivalence of crushed tablets when 
mixed with vehicles is called into question. 
4.5 Conclusion 
This study has established that the pharmacokinetics of crushed paracetamol with thickened 
fluids on healthy volunteers did not meet the bioequivalent criteria for Cmax when compared 
with whole tablet (test formulation). Also, tmax was slower when compared with crushed tablet 
in water or jam. While these alterations may not affect clinical efficacy for paracetamol, it may 
be inferred that there is the potential for the co-administration with thickened fluids to have a 
significant clinical effect on medications with a narrow therapeutic index. 
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5 Delivering crushed paracetamol tablets using thickened fluids: can in vitro – in vivo 
correlation (IVIVC) make accurate predictions from dissolution testing? 
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5.1 Introduction 
In vitro dissolution testing has indicated strong effects of gum-based thickeners on drug release 
for four immediate release medications, and drug-dependent restriction in drug release by food 
products including jam (Manrique-Torres et al., 2014). However, crushing and mixing 
paracetamol into jam or water thickened to level 900 with Easythick Advanced resulted in no 
significant difference in total exposure to paracetamol (AUC(0-8 h),Saliva) and small alterations in 
Cmax and tmax when taken by healthy human volunteers (Chapter 4). The ability of the standard 
in vitro dissolution test to predict in vivo bioequivalence of crushed tablets mixed with vehicles 
was explored in this study using in vitro-in vivo correlation (IVIVC). 
IVIVC is a predictive mathematical model describing the relationship between in vitro 
dissolution and in vivo response to the drug that is used extensively for quality analysis and 
batch comparisons (Li et al., 2008). Establishing a correlation between in vitro and in vivo 
studies is also helpful to optimise formulations. IVIVC reduces the number of bioequivalence 
studies performed during product development, scaling-up and post-approval changes. FDA 
guidance recommends four levels of correlation: level A, B, C and Multiple C (FDA, 1997a). 
Level A IVIVC is the highest level of correlation, representing point-to-point correlation 
between in vitro dissolution and in vivo absorption.  
In this study level A IVIVC was established using in vitro dissolution tests and in vivo PK 
profile for whole paracetamol tablets, crushed paracetamol tablets with water, and crushed 
tablets mixed with jam. This IVIVC was then used to predict the in vivo PK profile for crushed 
paracetamol mixed with thickened water using the respective in vitro dissolution data. The 
prediction was then compared with actual in vivo results to determine the accuracy of the IVIVC 
model.  
5.2  Methods 
5.2.1 Drug formulation 
An immediate release formulation of paracetamol (Panadol, Glaxo Smithkline, NSW Australia) 
was delivered using water, a semi-solid food vehicle (jam) and thickened water (Table 5-1). 
Water was thickened using a commercial food thickening agent, Easythick Advanced (Flavour 
Creations, Tennyson, Qld), prepared as directed by the manufacturer at three thickness levels 
indicated for dysphagic patients; mildly thick (Level 150), moderately thick (Level 400) and 
extremely thick (Level 900). The measured quantity of the powder (Table 5-2) was mixed with 
100 mL of water using a stick blender for 3 minutes.  
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Table 5-1: Composition of the vehicles used in this study 
Vehicle Composition 
Water Water (purified) 
Jam Strawberries, pectin, food acids, natural colour, sugar 
Thickened water Water (purified) and Easythick Advanced (maltodextrin, 
xanthan gum, vitamin C, calcium chloride) 
 
Table 5-2: Concentration of the thickeners used to prepare thickened water at each thickness and 
the resulting viscosity (Manrique-Torres et al., 2014). 
Vehicle Thickness Conc 
%(w/v) 
Viscosity 
(cP) 
Easythick 
Advanced 
Level 900 
Level 400 
Level 150 
4.32 
1.70 
0.87 
1250 
414 
176 
 
5.2.2 In vitro dissolution  
Paracetamol tablets (2 x 500 mg) were crushed using a mortar and pestle. The powder obtained 
was transferred into a 30 mL plastic cup previously filled with 15 g of the vehicles (Table 5-1) 
and mixed with the vehicle by hand using a spoon. For comparison, whole tablets (2 x 500 mg) 
delivered with 15 mL water were tested. Dissolution tests were also performed on the vehicles 
without paracetamol as the control. Standard USP dissolution apparatus II (VK7000, Varian, 
Mulgrave, Vic) was used with 900 mL of pH1.2 simulated gastric fluid (SGF) without enzymes 
(British Pharmacopoeia Commision, 2012) as the dissolution media. The temperature was 
maintained at 37ºC, and paddle speed of 50 rpm. The dispersion of the drug in the vehicle was 
placed in the dissolution vessel and 5 mL samples were collected at 1, 3, 5, 10, 15, 20, 30, 40, 
50, 80, 100, 120, and 180 minutes through a stainless steel cannula assembled with full flow 
filter (10 µm, Varian) into 5 mL plastic syringes. SGF (5 mL) was immediately replaced into 
the dissolution vessels at every sampling point. Samples were filtered through 0.45 µm nylon 
membranes (Millipore, Bayswater, Vic, Australia) and absorbance measured at 244 nm using a 
Spectrophotometer Hitachi U-1900, (Scientific Instrument & Optical Sales, Brisbane, Qld). 
Background absorbance was accounted for using the mixers, results for the controls were 
subtracted from the absorbance of the vehicle-containing drug. A standard curve for 
paracetamol in SGF was prepared and used to calculate the concentration of paracetamol in the 
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samples retrieved from the dissolution chambers. Cumulative percentage of the drug dissolved 
was plotted against sampling time. All tests were repeated in triplicate. 
All observed data were recorded in Excel (Microsoft Corporation, Redmond, WA, USA), and 
DDSolver was used to analyse the data (Zhang et al., 2010). Differences in drug dissolution 
between the thickening agents, jam, and crushed tablets were compared to the whole tablet 
using univariate ANOVA (model built from DDSolver). 
5.2.3 In vivo drug release 
The data for the in vivo component of this study is described in Chapter 4. The experimental 
design is summarised here for clarity. Healthy volunteers (n=20), ten male and ten female, were 
recruited for a crossover study. The ages ranged from 24 to 45 years, and body weight was 67.5 
± 11.6 (mean ± SD, range 50 – 95) kg. Participants received 2 x 500 mg paracetamol on four 
occasions separated by a washout period of at least 3 days: whole tablets, crushed tablets, 
crushed tablets mixed with 15 g jam, or crushed tablets mixed with 15 g thickened water (Level 
900). With the medication, subjects used 250 mL of water to rinse their mouths and swallow. 
They then brushed their teeth using an electronic brush for four minutes, spitting out toothpaste 
and rinsings, to remove adsorbent paracetamol from the mouth. Stimulated saliva was collected 
at the following intervals: pre-dose, 5 min, 10 min, 15 min, 20 min, 30 min, 40 min, 50 min, 1 
hour, 1 hour 20 min, 1 hour 40 min, and 2, 3, 4, 6, and 8 hours. Collected samples were 
centrifuged and stored at -80ºC and the paracetamol concentration subsequently measured using 
HPLC. 
Pharmacokinetic parameters were determined using the salivary concentration–time profile, 
and a standard model-independent approach was used. Total area under the curve (AUC) and 
half-life (t1/2) were calculated using linear trapezoidal rule method. Similarly, maximum 
salivary concentration (Cmax) and time maximum for the peak (Tmax) were estimated. The non-
compartmental pharmacokinetic analysis was conducted using Phoenix® WinNonlin® (Build 
6.3.0.395). 
5.2.4 In vitro-in vivo correlation development and validation 
Level A correlation, the point-to-point relationship between in vitro and in vivo data, was 
performed using WinNonlin® IVIVC ToolkitTM. The correlation was built using in vitro 
dissolution data (mean of 3 replicate tests) and in vivo concentration-time data (mean of 20 
individuals) for whole paracetamol tablets, crushed tablets in water, and crushed tablets in jam. 
Development of the IVIVC consisted of the following stages: a) modelling the cumulative in 
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vitro dissolution profile, b) modelling the cumulative in vivo absorption profile of paracetamol 
using the saliva concentration-time data for each formulation and c) modelling the relationship 
between in vitro dissolution and in vivo absorption, and d) using the model to predict salivary 
concentration profiles and associated PK parameters from in vitro dissolution data, and 
comparing these with the observed in vivo salivary concentration-time profile and PK 
parameters. 
A Weibull model was selected for modelling the in vitro dissolution data of the three 
formulations, 
𝑦(𝑡) = 𝑖𝑛𝑡 + (𝐹𝑖𝑛𝑓 − 𝑖𝑛𝑡) ∗ (1 −  𝑒
−[
𝑡
𝑀𝐷𝑇])
 
 
where int is the y-intercept; Finf is the amount released at time infinity; MDT is the mean 
dissolution time and t is the time. Numerical deconvolution was the approach used for 
modelling the in vivo absorption profile. Intravenous infusion concentration-time data for 
paracetamol (supplied by Dr Geraldine A Elliot, Imaginot Pty Ltd, Brisbane, Qld) was used as 
the reference formulation; this was analysed using a compartmental model, and the best fit 
model was selected and used to estimate the unit impulse response (UIR), which describes the 
distribution and elimination phases. Drug input rate was then estimated by numerical 
deconvolution for the three formulations.  
The IVIVC relationship between in vivo drug absorption and in vitro drug release was 
established using linear and nonlinear models and the model with the best fit was selected. 
Differences in in vitro dissolution and in vivo absorption time scales were adjusted using a time-
scaling factor in the correlation model (Levy, 1964, Levy and Hollister, 1965).  
The IVIVC model was validated by determining internal predictability. The model was used to 
predict concentration-time profile and calculate PK parameters (Cmax and AUC(0-8 h),Saliva). The 
predicted PK parameters were compared with PK parameters calculated directly from observed 
in vivo salivary concentration-time data, and prediction errors (%PE) were estimated using the 
formula:  
%𝑃𝐸 =
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 − 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
 𝑋 100 
According to FDA guidelines, the prediction error should not be more than 15% and mean 
absolute prediction error should be less than 10% for each of the formulations (FDA, 1997a). 
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5.2.5 IVIVC predictions for drug delivery using thickened water 
The IVIVC model was used to predict in vivo paracetamol salivary concentrations based on in 
vitro dissolution test data for crushed tablets mixed into water thickened to level 150, 400 and 
900. These predictions were compared with observed data in terms of %PE for the in vivo 
absorption of paracetamol whole tablets to determine whether the model predicts that these 
delivery options are bioequivalent to whole tablets.  
5.2.6 Model accuracy 
Finally, the accuracy of predictions calculated by the IVIVC model was tested for the crushed 
tablets in thickened water level 900 by comparing %PE for the prediction obtained from the 
IVIVC model with the observed in vivo saliva concentration-time profile.  
5.3 Results 
5.3.1 In vitro study 
Paracetamol exhibited very rapid dissolution in SGF whether it was delivered as whole tablets 
or crushed with water (Table 5-3). As complete dissolution was achieved by 30 minutes (Figure 
5-1) these met the FDA criteria for immediate release tablets, which is for 85% of the labelled 
amount to be released within 30 minutes (FDA, 1997b). Crushing paracetamol and mixing it 
with jam or water thickened to level 150 resulted in 90% by 30 minutes, so these also met the 
FDA criteria. However, mixing the crushed tablets with thickened water at Level 400 and Level 
900 resulted in a significant delay in the release of paracetamol in comparison to the other 
treatments (P<0.05), with the 30 minute release being 67% with Level 400 and 29% with Level 
900 (Table 5-3). By the end of three hours, paracetamol release from Level 400 was 97%, but 
it only reached 57% for Level 900 (Figure 5-1). 
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Figure 5-1: Dissolution in simulated gastric fluid of paracetamol (2 x 500 mg) delivered as (a) 
whole tablets or crushed and mixed with water thickened to level 150, 400 and 900, and (b) crushed 
tablets with water or jam. The data shows mean ± standard deviation for 3 replicate tests. 
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Table 5-3: Total release (%) measured in a dissolution test at 15 or 30 minutes (mean ± standard 
deviation; n=3) for paracetamol tablets (2 x 500 mg) delivered whole or crushed and mixed with 
a vehicle. Within each column, different superscript letters indicate significant difference in 
paracetamol release.  
 Paracetamol release (%) 
Formulation 15 mins 30 mins 
Whole tablets 91.6 ± 4.9 a 95.8 ± 2.5 a 
Crushed  
  Water 91.9 ± 6.3 a 97.0 ± 0.7 a 
  Jam 81.1 ± 8.2 a 89.6 ± 7.7 a 
  Thickened water 
    Level 150 73.6 ± 7.3 b 89.8 ± 5.6 a 
    Level 400 49.1 ± 5.8 c 67.3 ± 4.3 b 
    Level 900 17.4 ± 1.4 d 29.1 ± 8.0 c 
 
5.3.2 In vivo study 
Saliva concentration-time profiles for paracetamol following a single dose of 2 x 500 mg whole 
tablets swallowed whole, or crushed and mixed with water, water thickened to level 900, or jam 
are presented in Figure 5-2  as the mean of the 20 participants. The PK parameters, Cmax, tmax, 
and AUC(0-8 h),Saliva (Table 5-4), calculated for the mean concentration-time saliva profiles, were 
used for building the IVIVC model.  
Table 5-4: Mean in vivo values of saliva pharmacokinetic parameters for paracetamol 2 x 500 mg 
delivered as whole tablets, or crushed and mixed with water, water thickened to level 900, or jam 
(n = 20). 
 Whole 
tablets 
Crushed tablets 
Water Thickened water  Jam 
Cmax (µg/mL) 5.73 5.76 3.88 5.72 
AUC(0-8h),Saliva 
(µg/mL*hr) 
16.47 17.14 15.89 15.25 
tmax 0.50 0.33 0.83 0.50 
 
  
91 
 
 
Figure 5-2: Mean salivary paracetamol concentration-time profile after a single dose of 1 g of 
paracetamol in healthy subjects (n = 20) taken as a whole tablet, crushed tablet with water, 
crushed tablet with thickened water (level 900) and crushed tablet with jam. 
5.3.3 In vitro-in vivo correlation development and validation 
A two-compartment model was found to be optimal for modelling the reference formulation, 
the paracetamol IV infusion data, which enabled calculation of the drug unit impulse response 
(UIR) function. This was then used in numerical deconvolution to model the cumulative in vivo 
absorption profile from the observed in vivo salivary paracetamol concentration profile of three 
formulations, whole tablets, crushed tablets with water and crushed tablets with jam (Figure 
5-3). 
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Figure 5-3: Mean fraction of paracetamol absorbed, as obtained using numerical deconvolution, 
after administration of whole tablets, crushed tablets with water, and crushed tablets with jam. 
The IVIVC model was then developed as a level A correlation for the three formulations by the 
plotting the fraction of paracetamol dissolved in vitro with respect to fraction of paracetamol 
absorbed in vivo. Good linear correlation was observed between in vitro and in vivo profiles, 
with r2 values greater than 0.97 (Figure 5-4:).  
The correlation model was evaluated using the model described below, which described the 
relationship between in vivo and in vitro. 
𝐹𝑎𝑏𝑠 =  𝐴𝑏𝑠𝑆𝑐𝑎𝑙𝑒 ∗ 𝐷𝑖𝑠𝑠(𝑇𝑠𝑐𝑎𝑙𝑒 ∗ 𝑇𝑣𝑖𝑣𝑜 − 𝑇𝑠ℎ𝑖𝑓𝑡) 
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Figure 5-4: In vitro-in vivo correlation (IVIVC) model regression plots of fraction absorbed and 
fraction dissolved for (a) whole tablet, (b) crushed tablet with water and (c) crushed tablet with 
jam. For each plot, data collected after the plateau was reached were not included in the 
correlations. 
The correlation model was determined to have acceptable internal predictability based on 
comparison of the IVIVC predictions of salivary concentration-time profile with observed 
salivary concentration-time profiles (Figure 5-5) and PK parameters calculated from the 
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predicted and observed concentration-time profiles (Table 5-5). Average %PE for Cmax and 
AUC(0-8 h),Saliva were less than 10% and individual %PE were less than 15% (Table 5-5), 
therefore meeting the FDA guidelines (FDA, 1997a).  
Table 5-5: Percent prediction errors (%PE) associated with Cmax and AUC(0-8 h),Saliva , with the 
average %PE shown for each parameter followed by details for each formulation. 
Parameters  Formulation  Observed Predicted %PE 
Cmax (µg/mL)    8.99% 
 Whole 5.73 5.95 3.94% 
 Crushed with water 5.76 6.62 14.90% 
 Crushed with jam 5.72 5.25 8.13% 
     
AUC(0-8 h),Saliva 
(µg.h/mL) 
   4.63% 
 Whole 16.46 16.97 3.08% 
 Crushed with water 17.14 16.95 1.12% 
 Crushed with jam 15.24 16.72 9.69% 
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Figure 5-5: Mean observed (symbols) and predicted (line) paracetamol salivary concentration-
time profile of (a) whole tablet, (b) crushed tablet with water, and (c) crushed tablet with jam. 
Observed values are taken from the in vivo data in Figure 5-2, and the predicted lines are derived 
from IVIVC modelling. 
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5.3.4 IVIVC predictions for drug delivery using thickened water 
The IVIVC model was applied to the in vitro dissolution data for crushed tablets mixed with 
water thickened to level 150, 400 and 900 in order to predict in vivo saliva concentration-time 
profiles. The predicted in vivo profile for crushed tablets in thickened water was compared with 
the observed in vivo profile for the whole tablets (Figure 5-6). Both Level 150 and Level 400 
had good agreement with whole tablet in terms of AUC(0-8 h),Saliva with %PE being less than 
15%, but Cmax was high (more than 15%) (Table 5-6). When the thickness increased to level 
900, both AUC(0-8 h),Saliva and Cmax had %PE values that were much greater than 15% indicating 
lack of bioequivalence to the whole tablet. 
Table 5-6: Percent prediction errors (%PE) for Cmax and AUC(0-8 h),Saliva. Predicted values are 
derived from IVIVC using in vitro dissolution data for 2 x 500 mg paracetamol tablets crushed 
and mixed into water thickened to level 150, 400 or 900. Observed values are derive from in vivo 
measurement of salivary paracetamol concentrations following a single oral dose of 2 x 500 mg 
whole tablets. 
Parameters  Formulation  Observed Predicted %PE 
Cmax (µg/mL) Level 150 5.73 4.64 18.85% 
 Level 400 5.73 3.49 38.93% 
 Level 900 5.73 1.51 73.55% 
AUC(0-8 h),Saliva 
(µg.h/mL) 
Level 150 16.47 16.47 0.002% 
 Level 400 16.47 15.78 4.11% 
 Level 900 16.47 9.08 44.82% 
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Figure 5-6: Comparison of predicted and observed salivary paracetamol concentration-time 
profiles. Predicted values are derived from IVIVC using in vitro dissolution data for 2 x 500 mg 
paracetamol tablets crushed and mixed into water thickened to level 150, 400 or 900. Observed 
values are derived from in vivo measurement of salivary paracetamol concentrations following a 
single oral dose of 2 x 500 mg whole tablets. 
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5.3.5 Model accuracy 
The predictions obtained using the IVIVC model could be evaluated for accuracy using the 
treatment involving water thickened to level 900. Comparison of the saliva paracetamol 
concentrations predicted using IVIVC with those observed in vivo (Figure 5-7) indicated a lack 
of similarity. The %PE for both Cmax and AUC(0-8 h),Saliva were more than 15% (Table 5-7) 
indicating poor correlation between predicted and observed values. 
 
 
Figure 5-7: Mean observed (in vivo) and predicted (IVIVC model) paracetamol salivary 
concentration-time profile for a single dose of paracetamol crushed tablets mixed with thickened 
water (Level 900). 
Table 5-7: Percent prediction errors (%PE) associated with Cmax and AUC(0-8 h),Saliva for the 
formulations. 
Parameters  Formulation  Observed Predicted %PE 
Cmax (µg/mL) Level 900 3.87 1.51 60.95% 
AUC(0-8 h),Saliva 
(µg.h/mL) 
Level 900 15.88 9.08 42.81% 
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5.4 Discussion 
The objective of this study was to develop and evaluate a level A IVIVC to be used in predicting 
the in vivo performance of crushed medication with thickened water. Level A correlation 
between the in vitro and in vivo performance of the three formulations used to develop the 
IVIVC model (whole tablet, crushed tablet with water and crushed tablet with jam) had a % PE 
less than 10% and individual %PE is less than 15% indicating that the developed model had 
good agreement between the saliva concentration-time data that was observed in vivo and that 
predicted from in vitro dissolution data.  
The IVIVC model showed poor ability to predict the in vivo saliva concentration-time profile 
produced when crushed paracetamol tablets were mixed with water thickened to level 900. Drug 
release from thickened fluids was severely retarded in vitro, as also happens when medications 
are crushed and mixed into water thickened with other commercial thickeners at similar 
thicknesses (Manrique-Torres et al., 2014). The in vivo drug concentration profile indicated that 
drug release was not retarded as strongly as that predicted. The lack of accuracy in prediction 
for paracetamol release from water thickened to level 900 suggests that the predictions for level 
400 and level 150 are also likely to be inaccurate. 
This study has highlighted that paracetamol dissolution from jam differs considerably than from 
thickened fluids. Jam significantly delayed the dissolution of crushed amlodipine and warfarin 
though not to the same extent as water thickened to level 900 (Manrique et al., 2014). In the 
present study jam did not delay release of crushed paracetamol, which was also the case with 
atenolol and carbamazepine (Manrique et al., 2014). Therefore the barrier to dissolution 
presented by jam was not consistent, and not as extensive as that provided by thickened water 
at level 900. Jam contains pectin, which forms a gel network that may be stronger with the 
presence of fruit pieces (Carbonell et al., 1991) whereas xanthan gum forms a highly ordered 
rigid rod type of conformation of its polymer chains (Stokes, 2012). Manrique et al. (2014) 
found that viscosity is not a good indicator for the propensity of a vehicle to affect drug release, 
as highlighted by the viscosity of the jam (3120 cP) being greater than that of thickened fluid 
(1250 cP) but exerting less of a restriction (Manrique et al. 2014). Other rheological properties 
would need to be considered when looking for a predictor for the effect on dissolution of 
crushed tablets mixed within. 
In vivo administration of solid dosage forms is influenced by a number of oral processing factors 
such as the way the bolus is delivered, tongue pressure pattern, tongue-palate interaction (Steele 
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et al., 2012, Cichero et al., 2000). These mechanical factors could alter the bolus structure as it 
enters the stomach and therefore affect drug release. In vitro dissolution tests involve the sample 
being directly delivered to the dissolution media as a single bolus. The paddle rotation speed of 
50 rpm had little impact on the level 900 thickened water, which remained as a single bolus 
rather than breaking up into multiple smaller droplets. If the bolus is broken into multiple 
droplets before it reaches the stomach as a result of the shear stress associated with swallowing, 
it may be expected that the distance for diffusion is reduced and surface area increased. This 
may be responsible for the higher rate of release of paracetamol from the thickened water than 
predicted by IVIVC using results for simple dissolution tests.  
The composition of the gastric environment is critical for drug dissolution, particularly pH, 
buffer capacity, volume, surface tension, osmolality and viscosity. All these parameters can 
affect disintegration, solubility, drug release and dissolution behaviour. Future studies should 
consider whether adjusting the paddle speed, using biorelevent dissolution media, or delivering 
the thickened fluids using a different technique to manipulate the droplet size may alter 
dissolution in a manner that improves IVIVC prediction. Alternatives to simple dissolution such 
as Dynamic Gastric Model (DGM) and the artificial digestive system TNO TIM-1 should be 
considered. Indeed, IVIVC for paracetamol using TIM-1 was better than the standard USP 
apparatus II (Souliman et al., 2006). Using these models could contribute to a better 
understanding of the physical stress of solid oral dosage forms in the gastric tract. However, 
these devices still have some disadvantages. These are designed for the simulation of food 
digestion and prediction of the bioavailability of nutrients. Hence, the use of these devices are 
limited in pharmaceutical dissolution testing, and the reproducibility of these devices has to be 
validated. Also, the use of DGM and TNO-TIM-1 is associated with high cost and time 
compared with the simple in vitro methods. 
5.5 Conclusion 
Delivering crushed paracetamol tablets using thickened water resulted in a strongly delayed 
dissolution profile in comparison to whole or crushed tablets delivered with water. The attempt 
to develop an IVIVC to predict in vivo absorption using a standard method was not successful, 
and the model could not predict the PK parameters accurately. This may be associated with the 
effect of shear during swallowing on bolus structure not being accounted for by simple 
dissolution tests. More work needs to be done to resolve the issues in predicting the IVIVC 
model. 
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6 General discussion 
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6.1 Section A 
Section A of this thesis investigated the prevalence and potential reasons behind medication 
swallowing problems in a non-dysphagic adult population. A person is more likely to 
experience difficulties swallowing whole tablets and capsules if they have a relatively small 
oral cavity size, increased taste sensation, and/or a memory of previously choking when trying 
to swallow a medication. This information aids the identification of people that might 
experience trouble swallowing medications and therefore be more likely to crush or split their 
tablets and capsules. These results also indicate that medication swallowing problems in non-
dysphagic people may have a physiological basis in some people, i.e. mouth cavity size and 
taste bud density. 
Reflecting on the experimental design of this section leads to an awareness of certain limitations 
and areas that could be improved in future work. Phase 1 of this section investigated 
psychological contributions to medication swallowing issues using an independently completed 
questionnaire. Participants were asked to mention what the particular food item was that they 
choked on, but the specific dosage form that caused choking was not documented and this could 
have helped to determine if their issue was specific to capsules or tablets. Also, the question on 
choking on medications was designed to be answered only by those reporting problems 
swallowing medication, which resulted in a low response rate to the question; a separate 
question that was directed to all participants may have derived some more useful information 
and allowed better statistical analysis for this issue. As a part of the questionnaire, all the 
participants assessed the size of the oral dosage forms and their preferences to swallow the 
capsules/tablets (Table 2-5). However, this study did not assess the shape of the capsules/tablets, 
and an association between perception of shape and swallowing preference has been found 
previously (Overgaard et al., 2001, Liu et al., 2016). To derive more information on the 
perception of tablets and capsule sizes, greater attention to the geometry of the examples 
provided would be required to ensure that width and surface arching were comparable. Also, in 
the questionnaire, gathering more specific information on the type of liquid and food used to 
aid swallowing would have been useful in understanding the behaviour of the participant in 
swallowing medication.  
Phase 2 investigated oral sensory contributions by measuring the gag reflex, oral cavity size, 
taste receptor density, and a questionnaire on food texture perception. Most of the participants 
exhibited a strong gag reflex, but when presented with capsules during the capsule-swallowing 
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task they were able to complete the swallow. An earlier study reported that pharyngeal sensation 
is a better indicator of normal swallowing instead of the gag reflex (Davies et al., 1995) so this 
could be a possible avenue for further investigation. Different areas of the tongue have different 
amounts and types of taste buds present (Arvidson, 1979), and so assessment of other areas of 
the tongue may alter the results obtained. However, it proved to be challenging to obtain high-
quality images of the fungiform papillae on the tongue using blue staining method so any future 
work would need to develop the assay further or use an alternative method such as tasting 
phenylthiocarbamide-infused paper strips (Guo and Reed, 2001). The food neophobia and 
texture questionnaire identified three food items with a crispy texture (muesli or granola bar, 
potato chips and popcorn) that had lower preference ratings for people who experience 
medication swallowing issues, but notes made by some participants made it apparent that the 
questions were difficult for people with certain food allergies or dietary restrictions (e.g. 
vegetarians) to answer fully. Future investigation into sensory contributions to medication 
swallowing difficulties are warranted but the tools used for these investigations should be 
adjusted accordingly. 
Phase 3 assessed oral motor contributions by assessing chewing efficiency. There were many 
limitations to this assessment. The particle size of the jelly snake pieces was evaluated visually; 
using an approach that would allow electronic assessment recommended for any future 
investigation. Chewing efficiency is dependent on multiple factors including the type of 
food(Peyron et al., 2004), so including alternatives to a jelly snake would be appropriate. Many 
participants advised that they felt “awkward and embarrassed” because of being watched while 
they were chewing and then spitting in a bag, which could have influenced the chewing of the 
jelly snake. 
Phase 4 observed the swallowing of medication. Although one-third of participants reported 
that they have difficulties swallowing medications whole and 23% believed that they would not 
be able to swallow a 00 size capsule in the survey, all except four of the participants were able 
to complete the task. There is a clear difference between the results obtained from the 
questionnaire where the participants own perceptions of swallowing medication were assessed, 
and the results obtained from the act of the capsule-swallowing task. One of the possibity could 
be the psychological barrier that could have influenced them to swallow the capsule in the 
presence of speech pathologist. Also, earlier studies have identified that capsules are preffered 
over tablets (Overgaard et al., 2001), a comparison between tablet swallowing and capsule 
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swallowing would give a better understanding on the swallowing issue. This has been the 
limitation of this study and should be considere in the feature study.  
Also, the difference between perceived capacity and actual competency to undertake 
swallowing of a certain size deserves further investigation, particularly with respect to whether 
those people would subsequently have a different perception of their ability to swallow a 
medication of that size. The majority of the participants held an appropriate head position for 
the observed swallowing process, but 60% used less water than is considered to be necessary 
for safe swallowing of medication. It is possible that participant behaviour was altered because 
the swallowing process was being observed and perhaps in a less formal scenario there may be 
increased water usage.  
6.2 Section B 
As shown in Section A, the prevalence of tablet crushing is quite high even in those who have 
no apparent need to crush because they can swallow food and drink and therefore medications 
should not be an issue. Section A also showed that people have a variety of methods, as well as 
crushing, that they use to swallow medications. Crushing and mixing with a vehicle of some 
kind is relatively common amongst otherwise healthy members of the public, but more so 
amongst aging populations and particularly those suffering from dysphagia. Therefore Section 
B of this thesis investigated another important component of medication modification, the in 
vivo and in vitro effects of using thickened fluid to deliver crushed tablets. To our knowledge, 
this is the first-in-human study to understand the effects of thickened water on drug absorption 
in comparison with immediate release tablets. 
In this study, saliva was used to measure the levels of paracetamol. Use of a non-invasive 
method had several advantages over venous sampling, including acceptability, ease of 
collection and convenience. It was previously identified that saliva can be used as an alternative 
to venous sampling (Adithan and Thangam, 1982, Wade et al., 2008, Sanaka et al., 2000), so 
no venous samples were taken in this study.  
In the first part of this section (Chapter 3), the intraindividual variability of a single oral 
paracetamol dose (2 x 500 mg tablets) was evaluated in healthy volunteers on two occasions. 
Cmax and tmax were within the range of values previously reported in the literature. Variation in 
PK parameters was small between individuals but larger within individuals (i.e. between days), 
however there was no significant difference between days in PK parameters when the average 
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value across all 20 participants was taken into account. Therefore although variation clearly 
exists, it was concluded that measurement of paracetamol in saliva following a single oral dose 
is a suitable method to consider factors that could alter paracetamol PK.   
The pharmacokinetics and bioequivalence of immediate release paracetamol whole tablets were 
compared with crushed paracetamol with water, jam and thickened fluid (Chapter 4). No 
differences in AUC(0-8 h),Saliva were observed, but delivering crushed tablets with water or 
thickened fluid was classified as not bioequivalent to whole tablets based on alterations to Cmax 
and tmax. A higher variation was obeserved with tmax across the population and a significant 
difference was observed between whole tablet with crushed with water and crushed with jam. 
Although, tmax is not a good measure of the rate of absorption as the concentration-time curve 
was bell shaped and flat around Cmax, similar to the previous study reported (Rygnestad et al., 
2000).  
The excipient present in the thickener includes xanthan gum. Xanthan gum is commonly a 
component of thickening agents used to manage dysphagia due to their stability over time and 
cost effectiveness (Cichero and Lam, 2014) but it is also used in dosage form design to impart 
delayed release characteristics. Therefore, a delay in drug release associated with the presence 
of xanthan gum is unsurprising. However, although significant, the alterations in Cmax and tmax 
were small and, with no alteration in AUC, would be unlikely to result in a clinically significant 
effect for paracetamol. 
An IVIVC approach was used to predict the in vivo performances of crushed paracetamol with 
thickened water from the respective in vitro dissolution data (Chapter 5). In vitro testing has 
been used in the development phase of formulation development, quality control, and 
bioequivalence tests. The standard pharmacopeial methodology was adopted here so the 
dissolution test should reflect the in vivo dissolution process. Paracetamol exhibited rapid and 
complete dissolution in SGF in less than 30 minutes when delivered as a whole tablet, crushed 
with water, jam or thickened water at Level 150. In contrast, crushed paracetamol with 
thickened water at Level 400 or Level 900 exhibited a limited release under the condition of 
this dissolution test, with only 67% and 29% respectively released in 30 minutes. However, the 
current in vitro dissolution method was unable to simulate in vivo conditions when the drug was 
crushed and mixed with thickened fluid at higher viscosity (Level 400 and Level 900).  
The inability of in vitro dissolution to predict in vivo levels when higher viscosity thickeners 
were used may be a reflection of the simplistic method used to test dissolution. Drug release 
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and absorption could be assessed in a more physiologically relevant environment. However, 
paracetamol is in the Biopharmaceutical Classification Scheme (BCS) as class III and has some 
attributes of the BCS class I (Kalantzi et al., 2006). Its solubility is not pH dependent, and with 
a pKa value of 9.5, altering the pH from that used in this study would not be expected to affect 
the dissolution. However, as xanthan gum has weakly acidic caroxylic acid groups with pKa 
4.5 (Bueno and Petri, 2014), adjusting the pH of the dissolution media may be expected to affect 
its dissolution. Dissolution or mixing of xanthan gum into the dissolution media may be greater 
or faster if pH is raised from that of the acidic stomach to the more neutral lower gastrointestinal 
tract.  
The in vivo drug performances could be simulated using commercial software programs, e.g. 
Gastroplus, STELLA, SimCyp and PKSim to simulate the in vivo behaviour of orally 
administered drugs. Alternatively, more realistic representation of the gastro-intestinal 
environment could be used, such as the dynamic gastric model (DGM) (Wickham et al., 2009) 
and the fed stomach model (FSM) used to represent the stomach, and the TNO gastrointestinal 
model (TIM-1) representing the stomach through to the small intestine (Minekus et al., 1999). 
The major aim of these simulations is to combine many variables that are related to 
gastrointestinal tract physiology and drug absorption process. Future work should optimise in 
vitro dissolution methodology to improve the ability to predict the in vivo drug levels when 
crushed and delivered in thickened fluids.  
One particular area of this study that should be considered carefully in future work is the 
measurement of salivary but not venous drug levels. In preparing the methodology for this 
thesis, several different techniques were tried to reduce contamination of saliva, including: 
 Rinse and swallow 250 mL of water followed by rinse and spit mouthwash 
 Rinse and swallow 250 mL of water followed by brushing for 3 minutes with a manual 
toothbrush with thorough rinsing of the mouth  
 Rinse and swallow 250 mL of water followed by rinse and spit mouthwash followed by 
brushing for 3 minutes using a manual toothbrush with thorough rinsing of the mouth 
 Rinse and swallow 250 mL of water followed by brushing with an electronic toothbrush 
for 4 minutes with thorough rinsing of the mouth 
For these initial tests, conducted with 3 participants, saliva paracetamol was collected at 2 to 15 
minutes after swallowing. Initial salivary paracetamol concentration was measurable when the 
subjects ingested crushed paracetamol with water, mixed with jam and mixed with thickened 
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water. The results indicated that use of mouthwash did not show a difference in paracetamol 
levels in the mouth when compared with the use of manual brushing. However, the use of an 
electric toothbrush reduced saliva contamination with paracetamol to low levels. During these 
preliminary studies, the participants were guided to brush their gums, tongue and teeth and to 
spit out the rinsings.  
For the study, all the participants were given similar clear instructions on brushing techniques, 
i.e., gums, tongue, teeth and the sides of the mouth to be brushed to remove paracetamol. 
However,  participants were allowed to use the sinks in the bathrooms to do the brushing, and 
brushing technique was not observed. From the data obtained, some of the participants had 
slightly raised early measurements and so may have had less efficient brushing technique than 
others. This low level oral and pharyngeal contamination may have altered the apparent PK 
measured, though the results for every participant were checked to ensure that the early 
measurement at five minutes was substantially lower than the subsequent Cmax. In hindsight, it 
would have been appropriate to observe the brushing and provide advice, or to have clearly 
demonstrated the optimal process perhaps in person or via video recording. Furthermore, as 
paracetamol was measured in the mouth even 15 minutes after swallowing immediate release 
tablets and rinsing with 600 mL of water (Sanaka et al., 2000), the collection of plasma would 
have been beneficial to understand the oral contamination, and lack of direct venous blood 
measurement is an important limitation of this study. 
There are other limitations with the experimental design in this study that require consideration 
in future work. Firstly, the use of an absorbent cotton pad and Salivette tubes to collect saliva. 
This was a procedure that has been used previously with paracetamol (Soderstrom et al., 2011) 
and so was adopted for the present study. Theoretically, paracetamol may adhere to the pad, 
which would affect measurements, so in future this possiblity should be addressed. Secondly, 
the 250 ml water was part of the attempt to clean the mouth so that any paracetamol being 
collected in the Salivette tubes could be assumed to be associated with paractamol absorption 
and distribution into the saliva. However, this volume of water may influence results, as 
paracetamol absorption may have been different if only the small quantity of jam or thickened 
fluid was swallowed with the crushed paracetamol. Direct venous blood measurement would 
negate the need to use this volume of water and would allow the experiment to be run in a 
manner that is more akin to the way that the vehicles are used in practice. 
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6.3 Future direction 
Based on the results of this thesis, further studies are warranted to extend this work.  
 It is evident that people find it difficult to swallow tablets and capsules whole are likely 
to try a variety of different techniques to swallow them. These include using devices 
that are available commercially. For example, cups that propel the tablet into the mouth 
(Oralflo, Pilgo), lubricating sprays for the mouth (Pill Glide), and lubricating gels for 
the medication (Swallow Aid, Gloup). These products rarely have any scientific 
evidence to support their use, so a comparative study on these swallowing devices using 
a population who have medication swallowing issues would be valuable. 
 In this study, it was observed 33% of the population had trouble swallowing medications 
and preliminary evidence was found for a link with mouth cavity size, taste sensitivity 
and memory of choking on medication. Future work with this specific population (i.e., 
those having trouble swallowing tablets/capsules) to further test this hypothesis would 
be beneficial in addressing the origin of issues with swallowing medication. It would be 
important to change the method of identification of super tasters using a 6-n-
Propylthiouracl or phenylthiocarbamide paper test instead of taste bud density to avoid 
some of the difficulties with assessment. 
 As the swallowing function of dysphagic patients is different to that of healthy people, 
usually taking longer to complete and leaving residue in the mouth, conducting a 
pharmacokinetic study with these patients could give more relevant data on the effect 
of thickened fluid on drug absorption in this population for comparison with healthy 
subjects. This could use paracetamol, which was chosen in the present study because it 
is widely used and considered to be very safe at standard dose. It would be important to 
not use the additional 250 ml water and instead stay with standard care, and measure 
venous blood levels of paracetamol because oral contamination was believed to have 
affected salivary paracetamol measurements. 
 The effect of thickened fluid on absorption of crushed paracetamol was determined to 
be unlikely to result in a clinically significant effect. It was hypothesised that the effect 
may be clinically significant for a narrow therapeutic index drug. Therefore 
investigation using thickened water with a narrow therapeutic index drug such as 
warfarin could help to understand if the drug reaches its therapeutic levels. 
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 Investigation into more bio-relevant dissolution conditions may be worthwhile to 
improve IVIVC model predictions for thick fluids. If IVIVC could be used, this may 
be used in guiding new product development of thickened fluids to reduce their impact 
on absorption. 
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8 Appendices 
8.1 Appendix I 
 
 
 
 
Determining the prevalence and reasons for medication swallowing difficulties in the 
general population 
Medication and Food Questionnaire 
Date  
Participant Number  
Gender  
(please circle) 
Female Male 
Age              years 
Medication-related questions 
1. Do you take any tablets/capsules on a regular basis? (at least 
weekly) 
Yes No 
 If YES, Please list all medications (including those you buy from a pharmacy or supermarket e.g. vitamins, 
nutritional supplements, herbal or homeopathic medicines): 
 Thinking of the size of these tablets, they are mostly:  
(please circle all that apply)  
Small Medium Large 
 Thinking of the shape of these tablets, they are mostly:  
(please circle all that apply) 
Round Oval Other 
2. Have you ever had trouble swallowing a tablet or capsule or 
other medication? 
Yes No Not sure 
 If YES did you feel like you would choke on it? Yes No Not sure 
 If YES were you just convinced you could not swallow it? Yes No Not sure 
3. Do you currently have trouble swallowing tablets or capsules Yes No Sometimes 
4. Have you ever cut or crushed a medication to make it easier to 
swallow? 
Yes No Sometimes 
     SCHOOL OF PHARMACY 
Pharmacy Australia Centre of Excellence 
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Facsimile (07) 3346 1999  
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5. Has anyone else (e.g. a parent), ever crushed a medication for 
you, to make it easier to swallow? 
Yes No Sometimes 
6. Did you have trouble learning to swallow tablets or capsules? Yes No Not sure 
7. How old were you when you could comfortably swallow a tablet 
or capsule? (approximately) 
I was      years old I still have 
trouble 
8. The following items or manoeuvres help me to swallow tablet/capsules: 
8a. Placing the tablet/capsule at the very back of my mouth Yes No  Sometimes 
8b. Tipping my head back as I swallow the tablet/capsule Yes No Sometimes 
8c. Swallowing the tablet/capsule with a liquid (e.g. water) Yes No Sometimes 
8d. Swallowing the tablet/capsule with food Yes No Sometimes 
8e. Swallowing the tablet/capsule by itself Yes No Sometimes 
8f Other method. Please describe in the space provided. 
9. What is your earliest recollection of swallowing tablets (e.g. how old were you, what was the situation?) 
10. Considering the capsules in row A of the container in front of you, which of them do you feel confident that 
you would be able to swallow whole? 
Circle all that apply: 
 1 2 3 4 5 6 7 
 Please explain your reason for this decision 
11. Considering the tablets in row B of the container in front of you, which of them do you feel confident that 
you would be able to swallow whole? 
Circle all that apply: 
 1 2 3 4 5 6 7 
 Please explain your reason for this decision 
 
12. Considering the tablets in row C of the container in front of you, which of them do you feel confident that 
you would be able to swallow whole? 
Circle all that apply: 
 1 2 3 4 5 6 7 
 Please explain your reason for this decision 
13. Considering the tablets and capsules in row D of the container in front of you, which of them do you feel 
confident that you would be able to swallow whole? 
Circle all that apply: 
 1 2 3 4 5 6 7 
 Please explain your reason for this decision 
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Food related questions 
1. Have you ever had a 
significant choking episode 
on a food item? 
Yes No Not sure 
 If YES, what was the food item? 
How old were you? 
 Consider the following foods.  
Thinking about food TEXTURE (the way it feels in your mouth), please rate your acceptability of the 
following foods by placing a tick in the appropriate column  for each food item listed below.  
  Like 
extremely 
Like 
moderately 
Neither like 
or dislike 
Dislike 
moderately 
Dislike 
extremely 
1 Scrambled eggs      
2 Green string beans      
3 Popcorn      
4 Bread      
5 Cooked red meat (e.g. steak)      
6 Cooked chicken      
7 Nuts      
8 Apple with skin on      
9 Lettuce      
10 Bran or shredded wheat      
11 Marshmallow      
12 Mashed potato      
13 Ice cream wafers      
14 Potato chips (crisps)      
15 Corn      
16 Peas      
17 Grapes       
18 Oysters      
19 Yoghurt or mousse      
20 Cereal with milk      
21 Soup with whole pieces of 
vegetables or meat 
     
22 Muesli or granola bar      
 Please answer the following questions and circle the appropriate response: 
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1. I am constantly trying new and different foods True False 
2. I do not trust new foods True False 
3. If I do not know what is in a food, I won’t try it True False 
4. I like foods from different cultures and countries True False 
5. Food from different cultures and countries looks weird 
(strange or unusual) for me to eat 
True False 
6. At social gatherings I will try a new food True False 
7. I am never afraid to eat things I have never tried before True False 
8. I am very particular (selective, picky, or choosey) 
about the foods I eat 
True False 
9. I will eat almost anything True False 
10. I like going to places that serve food from different 
cultures and countries to my own 
True False 
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8.2 Appendix II 
1. GAG REFLEX ASSESSMENT 
Date:________________________________ Assessor: ___________________________ 
1. Neuro profile (tick if any evidence of the following) 
Gait asymmetry Physical asymmetry Tremor Abnormal voice 
qualities 
Speech or language 
disturbances 
     
 
2. Mallampati classification: Please open your mouth and poke your tongue out as far as you 
can (circle the image that most closely represents the mouth when open at rest) 
 
 
 
 
 
 
Gag reflex:  Mark on the picture where the gag reflex is elicited from - test both sides of the mouth.  
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8.3 Appendix III 
CHEWING TASK 
Date: __________________________ 
Assessor: _____________________ 
Instructions to participant: 
In a moment I am going to ask you to chew this piece of jelly snake and then spit it into this 
bag. We’re going to have a practice first. Please place the jelly snake in your mouth as you 
usually would and chew it until you feel it is ready to be swallowed. At that point, please spit 
it into the bag. There is a glass of water in case you’d like to rinse you mouth. Now that 
you’ve had a practice, we’re going to do the same thing again. 
Procedure: 
1. First attempt is for practice 
2. Second attempt is for scoring 
3. (Additional piece provided in case the first piece is accidentally swallowed) 
SCORING (on second attempt): 
Chewed 
bolus is 
COHESIVE 
(holds 
together) 
Yes No    
Analysis of 
particle size 
ALL 
particles 
are  
very small  
(< 4mm) 
MOST 
particles are 
very small 
(< 4mm) 
ROUGHLY 
EQUAL 
numbers of 
small and 
large particles 
MOST 
particles are 
large  
(> 4mm) 
ALL 
particles 
are large 
(> 4mm) 
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8.4 Appendix IV 
TABLET SWALLOWING TASK 
Instructions: 
1. Provide the participant with a gelatine capsule (filled with 100’s and 1000’s) 
2. Provide a plastic cup with water, but do not draw attention to it or insist that it is used 
3. Ask the person to “swallow the capsule as they normally would” 
4. Note the following: 
Completes task Yes No   
Completes task 
in ONE attempt 
Yes No If no, 
How many 
attempts were 
needed? 
2 
3 
4 
could not 
complete 
Uses water 
provided to 
swallow the 
capsule? 
Yes No If yes,  
Roughly how 
much water is 
used? 
<¼ cup 
¼ cup 
½ cup 
1 cup 
Places capsule at 
FRONT of mouth 
(tongue tip) 
Yes No   
Places capsule at 
MIDDLE of 
tongue 
    
Places capsule at 
BACK of mouth 
Yes No   
Head position 
(circle the 
appropriate head 
position at left) 
Straight ahead 
(neutral)? 
Head extended to 
position tablet 
then straight 
ahead to 
swallow? 
Head forward? Other?? 
 
 
 
 
Other features noted, or comments: 
 
 
  
  
130 
 
8.5 Appendix V 
Comments from participants regarding their preferences to take and avoid solid dosage forms 
Capsules 
Size  
 I think i cannot swallow but i havent tried #7 
 5,6,7 seems very large 
 Familiar size - like antibiotics 
 All are smallish 
 Size 
 size 
 shape possibly easier to swallow (neutral flavour) 
 i dont believe i would be able to swallow 6 and 7 comfortably 
 smooth and easily swallowed shape 
 provided i had some fluid capsules seem to slide down easier 
 With water caps 
 I find the capsule shape easiest to swallow 
 "1 - 5 are ok size  
 6 - 7 are 'big' - I would only take if I could eat a slice of bread" 
 they are small 
 all are medium sized tablets and feel that I can swallow them easily 
 size of tablet 
 I don’t have a problem with swallowing get coated capsules 
 I would swallow all, but 6 & 7 may take a couple of goes 
 plastic coating helps, shape helps 
 smallish and elongated 
 small enough to swallow without feeling like choking think 5 & 7 might get caught in back of throat 
 I wold be confident to this size. I would probably be fine with 6 & & as well but not sure 
 not large - all oval 
 not too big 
 good size to swallow 
 capsule size 
 I have had tablets this size in the past 
 feel comfortable 
 if they need to be taken - I will take them 
 I have swallowed capsules of these sizes before 
 size and rounded shape 
 easy shape not too large 
 6 and 7 may be too long and big for me 
 6 and 7 are possibly too large, but would manage with water. All are smooth (capsule) elongated. 
 Narrow and "plastic" body no perception is easier to swallow. 
 capsule shape, not as dry as other tablets 
 5 is quite a bit larger than the previous 4, but would be ok with water. 6 and 7, I could swallow, but visually they look big (to 
me) and I am not confident I could do it. 
 These capsules are small and thin 
 I do not have any problems swallowing capsules. 
 All are capsules and they look slippery 
 So long as I can chew food 
 Small oval capsules gel coated. 
 I don't have much problem with capsules, as they get slimy and goes easily through 
 They are not too big 
 All a reasonable size i.e. Have done previously. 
 All smooth and reasonably small. 
 All the others ( maybe except 2), look too large. 
 Now/always swallow pills/tablets/capules whole but it may take me a while. 
 Because of the outside coating of tablet makes it easier to swallow. 
 Have done so before 
 I regularly take pills this size or large. 
 small size 
 7 I could but not confident 
 I have tried all these sizes-ok 
 capsules are easier to swallow. 
 1 maybe with food because it is the smallest however usually I would not even attempt it. 
 Have swallowed these sizes before and had no issues 
 Capsules are easier to swallow than other forms (e.g. Tablets) 
 Size ok. 
 Small and narrow. Bad experience with 7 before. 
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 7 looks a little too large to comfortably swallow 
 I find the shape and coating easy to swallow. 
 All of them. The shape of the capsule makes it easy for me to swallow. Not being able to taste it helps too. 
 They are little 
 They are all small enough-not too long. 
 I have previously been able to swallow the biggest in size (7) 
 Capsules easy-have swallowed larger 
 They are much smaller so easier to swallow 
 Smooth surface and with water 
 Need lots of water 5, 6, 7 
 Reasonable size/volume 
 I have problems with capsules 
 Size 
 Small size 
 i consider these all to be of a good size 
 i am used to swallowing tablets and capsules of all size now 
 i dont have trouble swallowing these types of tablets if my gag freflex dosent "kickin" 
 i have used capsules up to size 6 
 i think its a psychological matters, as well as it is small in compare to others 
 with water i expected to be able to swallow even large tablets. Without water i would be hesitant to try and swallow any of the 
tablets/capsules 
 they are all in a reasonable size range 
 the size and the gelatine seems convenient 
 just right size 
 already swallow larger tablets 
 they are capsules so it is easy for me to swallow 
 they are small 
 its small size 
 Have done so previously 
 I don't have trouble swallowing large capsules. 
 Size ok. 
 size 
 Shorter and more slender 
 Smaller than what I take now 
 The size 
 I have had capsules this size in the past 
 Small size and smooth surface 
 I have had similar size tablets to these before with no issues regarding swallowing. 
 I would possibly swallow 5-7 but would need lots of water. 
 Small size 
 The size is suitable for normal adults 
 size 
 I take some as large as 7 regularly 
 Capsule size 
 Small/thin 
 Visually 7 is scary 
 Coated capsules are easier 
 7 is large size 
 No problem with capsules 
 I find gel capsules easier to swallow 
 small size 
 Smaller and number 6 would be ok as it looks slimmer and shorter than 5 or 7 
 They are small and slippery 
 capsules arent too big and they are easily swallowed compared to tabs which at times 'stick' to the back of my mouth 
 capsules easy to swallow 
Texture/colour and other response 
 Gelatine cap and water = slide down throat 
 colour and smaller 
 all ready do it 
 i dont think i'd have a problem with any of them - shape is easy and coating 
 they are capsules and sort of dissolve and because of the shape are easier to swallow 
 I believe that the caps slide easily down my throat 
 encapsulated 
 none are different/large than I currently take 
 The size seems okay and the shape also, however I would only do it with water. 
 capsules are easy for me to swallow with water and they are all normal size 
 sometimes use headache medication in capsule form 
 dont have problems swallowing capsules 
 well practised 
 shape and texture 
 its plastic 
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 I can swallow 
 I can swallow anything with water 
Tablets 
Size 
 Smaller 
 I can Swallow from 1 - 6, #7 could stick at the back of my mouth 
 7 looks too large 
 others are too large 
 Big round flat tablets may turn end-over-end and get lodged. Uncoated tablets (#7) may start disintegrating and not slide 
 size 
 #7 is bigger than a Panadol - not tried 
 seven - shape and size would be difficult to swallow as well as texture (get stuck) 
 6 - 7 much larger 
 i dont believe i would be able to swallow too big for me 
 6 & 7 are quite large so i'd tend to cut them up and then take them - they are also dry looking with no coating 
 not too large #7 upper limit of size 
 Tablet 7 is much larter than 6 and would need some fluid for 7 
 tablet 7 is still quite thin, so I think I could manage 
 7 looks too big! It so round it may get stuck in my throat 
 I would probably try to chew the bigger one 
 just never seen anything that round before 
 comfortable size 
 1 and 2 are bit smaller, feel that they will stuck on my tongue. 7 is too big for me and I want to break into 2 before swallowing 
 size of tablet 
 not sure about #7 too large and round, but should have a go 
 I have swallowed tablets of these sizes successfully. Size 6 may have several tries, size 7 may not work 
 1 - 5 very small no trouble, 6 probably ok. 7 annoyingly large but almose certain ok bout would probable cut it half. 
 smallish 
 all small or std size except #7 while I significantly large and the round shape might scratch off the way down 
 6 & 7 too big to swllow whole 
 I think #7 would feel like it was too big. 
 the shpae of tablet 7 would be difficult to swallow 
 not too big 
 again good size of the tablet 
 size 
 #7 looks too big 
 # 7 Looks too big 
 - not sure about #7 - probably would be able to swallow whole but I would rather not - seems too wide /dry 
 #7 would be difficult because they usually absorbed moisture and stick to the tongue at the back of the throat 
 size 
 # 7 shape looks like it might be difficult, and it looks too dry 
 6 is like the tablet which choked me when I was a child. 7 is too big. 
 7 with difficulty. I find large round tablets require more effort than capsules. 
 6 and 7 are too big. The size tells me "you could swallow this" 
 1-5 small enough in size, would still have to swallow with water 
 From 5, I would probably cut in half with a pill cutter, and 7 I would almost need to cut in 4. 
 small in size 
 No experience in swallowing size 7 tablet but I think I can easily swallow it with water. 
 7 too big-I would feel it in my throat and choke 
 Last one too big they get stuck 
 Smaller dry tablets will be ok. 
 7 is too big and wide 
 7-would cut in half. 
 All ok size and shape. 
 fairly small size. 
 7 looks huge and have not had to swallow a round huge tablet before, I think I may try to break this one up. Tablet 6 I have taken 
that sixe before, but sometimes I have trouble. 
 The largest tablets looks quite large. 
 7 might be a bit of trouble, but doable. 
 small enough 
 7 is quite wide 
 I find them hard to swallow when they are round and very large. 
 As this style of tablet gets larger it tend to get "stuck" going down/swallowing 
 Because of its size and also because of it would probably start to dissolve on your tongue. 
 I'd probably cut 7 in half as it is a wide circle and to be on the safe side otherwise no issues with others 
 Tablet 7 is too large-the powdery feeling makes it harder to swallow than a gloss finish on capsules 
 7 too big 
 Similar to above, smaller and more confident. 
 6 and 7 seem quite big as if they would not fit, I would use water at least for 4 and 5. 
 Round tablets are more difficult to swallow 
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 7 looks a bit big. 
 All of them but I would be thinking about the bitter taste of them the whole time. 
 They are small 
 Small enough to swallow with a liquid 
 Not sure about 7-I normally prefer oval shapes 
 Tablets gritty and largest one may stick 
 size again 
 Only with water B7 is quite large 
 7 just too big 
 7 starting to look a little large 
 6 and 7 are too big, I could do it but not confidentially. 
 size 
 Small size 
 7 would have problem slightly too large 
 again this size is ok 
 tablet 7 may be a bit large, i would probably have it 
 i am used to swallowing tablets and capsules of all size now 
 i dont have trouble swallowing these types of tablets if my gag reflex dosent "kickin" 
 i have used tablets upto size 6 
 with water i expected to be able to swallow even large tablets 
 large round powdery texture difficult to swallow -round paracetamol for me is difficult |buy caplet|| capsules 
 the last tablet is too big. With heaps of water maybe 
 the size and shape (round shape) 
 6,7 getting too big to comfortably swallow (with water) 
 good size tablet 
 smallest 
 I can swallow 
 have taken tablets of this size before 
 Tablet no7 is too big for me to swallow 
 They are small and round to be swallowed easily 
 also for its size 
 Some are (slightly larger) than paracetamol. 
 Size ok 
 I can swallow anything with water 
 size 
 Diameter is smaller 
 I have swallowed same size as 7 would be a challenge would leave it. 
 The size-looks smooth 
 I would swallow 7 if required but I am not confident it would not feel a bit painful on the way down. 
 "1-6-SMALL SIZE 
 7-too wide/big, not comfortable, not certain can swallow it easily" 
 B7 looks big but I would probably be fine to swallow, maybe in half pieces would help as the diameter is really large. 
 "Ditto" as above for 6 and 7. I feel like it would stick to my throat. 
 small size 
 Same as above 
 size 
 "7-looks a little wide 
 Tablet size 
 Might have trouble with 7. Slightly too big and wide. 
 Too big 
 Still scared of No.7. Looks dry 
 The largest looks a little difficult to swallow due to large diameter. 
 Size and shape 
 Seems a comfortable size 
 Round powdery tablets are more difficult to swallow 
 Smaller size 
 6 and 7 are a little larger as they don’t look coated they would get stuck 
 Number 7 is too confronting. It is also not smooth. Although the others are not smooth number 7 is too big. 
 B7 is very big! So I am not sure about it 
 hard to swallow 7 - a big circle shaped tablet 
 too big would split 
Other response 
 7 would need a large glass of water, but all look reasonably easy to swallow. Have no troubles swallowing tablets. 
 With water should be fine 
 Tablets that are large with a high friction surface can give me problems 
 Have done so before 
 2 have taken Panadol in this form + some antibiotics 
 i think its a psychological matters, as well as it is small in compare to others 
 Never had a problem before 
 I would give it a go" 
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Caplets 
Size 
 smaller 
 From 1 - 7; easy to swallow because they are all oval 
 6 and 7 seems very big 
 Others are too large 
 might have trouble with #7 due to longish shape. However if it is coated it should slide ok and not get stuck 
 7 would need a large glass of water, but all look reasonably easy to swallow. Have no troubles swallowing tablets. 
 7 appears too large 
 size and shape 
 i have had no reason to try 6 or 7 
 Seven seems too wide and texture need water with these 
 6 - 7 much larger frighten me 
 I think i would struggle to swallow 6 and 7 
 6 & 7 are quite large so i'd tend to cut them up and then take them - they are also dry looking with no coating 
 not too large #7 upper limit of size 
 With water should be fine 
 Unsure about 7 it's very bulky-rectangular edges etc 
 6 - 7 I think I'd have to cut in 1/2 1st 
 the bigger tablets might stick on the back of my tongue 
 good size 
 size of tablet 
 good shape 
 size 6 may be a bit difficult and to be a couple of tries. Size 7 is a better shape but still difficult 
 1 - 5 no probs 6 probably ok. 7 annoyingly large but almose certain ok bout would probable cut it half. 
 smallish 
 the last two are quite carge and may five difficulty or scratch 
 6 & 7 too big 
 6 & 7 might take a few attempts if they weren't lined up correctly 
 7 might be too large/thick 
 size of the tablet 
 size/shape 
 #6 looks just a little big 
 #6,7 looks big 
 6 & 7 seem rather big and powdery - I would be able to taste them and they would stick to my tongue unlike capsules 
 #7 is large but with water I would be able to swallow it 
 size 
 # 7 shape looks like it might be difficult, and it looks too dry 
 7-not sure sharp edges too thick. 
 size, shape says ok to swallow whole. 5, 6, and 7 says "I need to break them in half". 
 I would prefer oval shaped tablets, easier to swallow. 
 I have often swallowed pill 4 size ( i.e. Panadol), however I do take a little time to get it down-it is not pleasant! 
 small and thin 
 As above 
 As above 
 so long as I have food 1-5 ok. 6 and 7 too big, I would feel it in my throat. 
 6 and 7 too big and 7 the depth. 
 I have a lot of difficulty swallowing big dry tablets. 
 7 is too thivk, I'd rather take 2 smaller tablets 
 6 and 7 cut in to half. 
 ize-shape makes others appear very large. 
 6 and 7 look fat, maybe if they were skinnier-too big as a whole would give them a go but may have to halve. 
 The largest tablet looks too large. 
 7 looks like it could go down at an angle. I don't like that feeling after swallowing where it still feels "stuck". 
 7 again might take a couple of goes 
 small enough 
 7 is too big 
 As this style of tablet gets larger it tends to get "stuck" going down/swallowing. 
 Because of its size and also because it would probably start to dissolve on your tongue. 
 I'd probably put the last two (6 and 7) at the back of my mouth length ways to help it go down in that direction. 
 Tablets 6 and 7 are too huge. The sharp edges make them harder to swallow. 
 6 and 7 too big 
 Again size does matter. I am more confident with smaller ones. 
 6 and 7 seem very big 
 Pretty sure I have taken 6 before. 
 7 is the shape/size of a tablet I have trouble swallowing. 
 No problem swallowing them but would hate to imagine the taste. 
 As above 
 Tablets gritty and largest one may stick even though it is capsule shape 
 size again 
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 I would give them all a go but 6 and 7 would be a bit difficult 
 6 and 7 too big. 
 Same as above 
 Size 
 small size 
 if i had to take them i would 
 the size or shape wold not worry 
 shape seems like it would help even the large sized ones 
 i am used to swallowing tablets and capsules of all size now 
 as above. I would possible need to have a couple of attemts for 6 & 7 
 6 & 7 are too big 
 i believe that smaller the size 
 the last tablet is too big. With heaps of water maybe 
 size 
 6,7 getting too big to comfortably swallow (with water) 
 good size tablet 
 7 I would try carefully, but I think it should be ok 
 size is comparable to tablets I already take 
 6 & 7 are too big for me to swallow 
 The shape of the tablets in row c makes it most difficult to swallow, compared with the round tablets 
 the size 
 size 
 7 looks very large 
 They don't look like they would be a problem. 
 Size 
 I can swallow anything with water 
 size 
 As above 
 The size 
 As these are tablets they do not look as smooth so I am not confident I would like 6 and 7. If prescribed I would try to swallow 
them. 
 "1-5-small 
 6- getting a bit wide and long 
 7- thick and long not comfortable with the idea of swallowing, if tablet was not as thick but same shape length, then it is fine." 
 C7 looks big and maybe hard to break in half due to thickness. Very long and thin and therefore might be okay to swallow. 
 I know I would struggle with number 6 and could not manage. 7-I feel like it would get stuck. 
 small size 
 size 
 Smooth edges, elongated shape-can position in mouth to swallow easily 
 Size 
 I think I could manage this number 7 the thin shape would I think be easier to get down 
 It's massive! 
 Looks uncomfortable to swallow 
 Height and length 
 Large size of 6 and 7 
 Similar size to multivitamin 
 size and texture of 6 and 7 may make it difficult to swallow. 
 Longer tablets are easier to swallow 
 smaller size 
 Large coated tablets are ok to swallow 
 Number 7 again is too confronting compared to 1 to 6. 
 6 & 7 are similar size to my carlic + Ctabs and I have trouble with them at times 
 not sure with #7 
 too big would split 
Other response 
 done it before 
 comfortable size to swallow 
 6 & 7 are much larger. I could manage them with fluid small enough 
 I'll crush 6 and 7 if I have to take them 
 Sometimes have a little trouble with oblong tablets especially non glowy ones 
 I have tried these sizes-the last one would be a bit difficult but OK if enough water 
 Small enough to swallow with a drink 
 I have previously been able to swallow tablets of this size. 
 Concerned gets stuck rather break in half 
 these resemble some of the vitamine E caltrate tablets. I take on regular basis 
 with water i expected to be able to swallow even large tablets 
 caplet shape easier to swallow coating, but the lates is too big 
 itsnot round so I cant swallow it 
 Not as thick 
 reasonable size 
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Mixed Size & Shape 
Size 
 I didnt not have trouble swallowing all of these even #7 
 6,7 seems scary with the liquid 
 good size 
 all large ones are gelatine coated so mixed with water should be fine. 
 7 would need a large glass of water, but all look reasonably easy to swallow. Have no troubles swallowing tablets. 
 7 Appears too large 
 wary of corners on no 5 | no 7 too big 
 i have tried 7 (fish oil) , but with water 
 although 7 is large the texture would make it easier to swallow 
 shape verses size - choked on a 1 type when young i do not like these at all 
 I have tried to swallow a tablet the same size as no 7 and I had trouble swallowing it 
 is a capsule but is quite large - i could possible attempt it but i think i'd have some trouble - if i didnt think about it too long i'd 
probably manage to get it down. 
 not too large #7 upper limit of size shape not an issue 
 No 7 is much larger and would need fluid 
 With waer should be fine 
 I think I would manage 7 because of the smooth surface. 
 Definitely not 7 - I'd ask for another medication 
 #7 just looks too big 
 1 - too thick | 5 - too pointish | 7 - too large 
 feel that they will not stuck on my tongue I like the shape of the tablet 
 oval size easier to swallow 
 the small tablets would be ok, size 5 may be difficult, I have no experience with this shape. Size 7 may be too big. 
 1 - 6 no probs | 7 - plastic helps, prefer not to but I could. 
 odd shape of 5 might cause problem also rough surface might get caught 7 too big 
 #7 would need to be lined up correctly might be ok. 
 7 might be too large/long 
 small size or smooth 
 size of the tablet # 5 not sure havent tried before 
 size/shape 
 I have tried tablets like #7 and it is too big 
 #7 looks big 
 7 seems large but my fish oil tablets are the same size and I can swallow them 
 even though #7 is large it appears to be the type that slides easily when wet. 
 size and shape 
 7 is too long and seems not easy to break. 
 size/surface all compatible. Even though 5's shape is not conclusive to ease of swallowing, the size (small) counter-acts this. 
 The look small enough to swallow and 6 looks clear and jelly/ soft so says "yeo I could swallow you". 
 Number 6 and 7 are very large but the smooth surface makes it easier to swallow with water. 
 Regardless of shape they all look "doable" except for 7 which I would certainly steer clear of. 
 Not sure of size 7 capsule. 
 5 is big and a bad shape. 7 is just too big. 
 So long as I have food. 7 I am familiar with its the same as my multi vitamin. 
 The end one is big but gel coated so you don't get the taste. 
 4 is small in size and 6 is capsulated in gelatinous coat so I can swallow them. 
 The large uncoated tablets/capsules sometimes leave a residue on tongue and throat and outside becomes sticky. 
 1 looks a bit thick, 7 is a bit big but I think I have swallowed something similar. 
 7 may just get it down and lots of water. 
 7 sometimes gag on- long and usually short taste and smells good. 
 2 and 4-6 gel would make it easier. 
 1-6 look small enough, 7 is big but looks like it would slide down easily because of its coating. 
 The first 6 are of a small size and would be easy to swallow. The last one looks like it has a smooth coating. 
 Have done so before. 
 I have a regular supplement of D7 size. 
 The 7 is large but soft. So it should dissolve quickly and ease the discomfort. 
 6 should be ok but not confident, 7 too big. 
 They seem small enough despite the shape. 
 1 is an odd shape, 5 is an odd shape, 7 is too big. 
 Same as above. 
 As 7 is a capsule I'd just toughen it out and force it down if it feels like its stuck. But probably would not be bothered to try and 
cut it up. 
 Tablets 1 and 5 are not an easy shape to swallow. Capsule 7 is too large. 
 7 too big 
 5 seems not to "fit" in terms of shape. 
 size 
 I have had tablet 7 for something in the past and had no problems. 
 As above no problem swallowing the capsules as I would not be able to taste them. The tablets are also fine with the exception 
of 5. The shape looks foreign and I would be hesitant. 
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 They are all reasonable sizes. Not too big. 
 size and shape makes it easier. 
 D1-D5 are small enough and 6 and 7 have smooth surfaces. 
 7-my vitamins are this size its hard but I take one at a time with a lot of liquid. 
 7 too big. 
 Same as above. 
 size 
 small size 
 same reasoning as above 
 i would only be concerned with he brown only 
 i amused to swallowing tablets and capsules of all sizes now 
 as above i would possible have trouble with 7 on occasions 
 i have used experienced with size upto 6 no 7 is very big 
 with water i expected to be able to swallow even large tablets 
 7 caplet although bid has a texture which looks easy to swallow. Others all small enough to swallow easy 
 the last tablet is too big. With heaps of water maybe 
 size and shape ok 1 & 6 
 7 look too big for comfort 
 good size and shape 
 small round and plastic 
 7 never tried something that big before 
 even the largest here is only as big as tablets I take it now and it is coated which makes it easier 
 they are small enough except no 7 to swallow 
 "no 1 and 3 tablets have smooth surface 
 #6 is easy to be swallowed" 
 7 looks very large. 
 Don't look like they would be a problem. 
 I can swallow anything with water 
 Size is smaller and smoother surface on 6 
 As above. I don’t usually have a problem 
 The size-shape ( looks flat) 
 "1-too thick 
 2-4-small 
 3- Initially concerned about the shape with obvious centred split i.e. not smooth 
 4-would rather chew it than swallow due to shape 
 6- Small and smooth 
 7-too large and thick" 
 Smooth coating on D7 makes it easy to swallow although very large size- visually similar to C7. I have had meds equivalent to 
this before. 
 Feel like number 7 would get stuck in throat. 
 Shape and small size. 
 same asbove 
 size 
 They are either small or smooth ( or both). 
 Small size 
 Small rounded edges 
 7 looks easier than other rows but still not confident. 
 Capsules are easier. 
 Easy shape to swallow 
 They are all of a reasonable size except for number 7 
 smaller size 
 d7 is big and again I am not sure 
 unsure #5 due to shape | #7 large but a capsule so a bit easier. 
Other response 
 like candy 
 done it before 
 odd shapes small enough. Largest is gel coated. 
 smallish 
 the triangle is unknown to me and looks like an unsuitable shape 
 small in size 
 They seem pretty much flatter than the rest more confidence with it this way. 
 Small enough to swallow with a drink 
 I have previously been able to swallow tablets of this size. 
 Swallow similar. 
 I have taken medication like these in the past and have not experienced problems 
 Gelatine shell capsule are easy to move around throat 
 I like the colour 
 size and soft texture 
 Size and texture 
 I have had capsules this size before and I know that I can usually swallow them without pain. 
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 Again, the oval shape seems like it would go down well. 
 They are either smooth or small enough to swallow. 
 5 looks chalky and an awkward shape. 
  
 
